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INTRODUCTION AND AIMS 
 
Gastrointestinal (GI) motility is under neuronal and hormonal control.  The cholinergic 
neurones are the most important between the neurones, that release a contractile 
neurotransmitter.  Different types of neurones release other contractile or relaxant 
neurotransmitters.  It is known from studies in the peripheral and central nervous system, that 
the release of acetylcholine from cholinergic nerve endings can be modified via  presynaptic 
auto- and heteroreceptors, whereby the release of acetylcholine can be increased or inhibited.  
In the GI tract, the presynaptic regulation of acetylcholine release has not been studied in a 
systematic way.  Especially the possible presynaptic regulation of GI acetylcholine release by 
the most important relaxant neurotransmitter nitric oxide (NO) has not been clarified.  Some 
studies were performed to investigate this interaction between acetylcholine and NO, but most 
were functional studies measuring smooth muscle contraction as outcome.  These studies do 
not allow to localize the interaction between acetylcholine and another substance with 
certainty at the pre- or postsynaptic level.  To investigate the presynaptic regulation of 
acetylcholine release, a technique measuring acetylcholine release directly must be applied. 
The aim of this thesis was to study the presynaptic regulation of acetylcholine release 
in the porcine and human GI tract.  The first tissue examined was the gastric fundus, where 
cholinergic neurones play a role in the development of the pressure gradient, that pushes 
ingested material to the distal stomach.  This part of the stomach also contains an important 
nitrergic innervation, allowing to concentrate on the possible presynaptic interaction between 
acetylcholine and NO.  The muscarinic autoreceptors, inhibiting acetylcholine release, as well 
as the postsynaptic muscarinic receptors mediating cholinergic contractions were 
pharmacologically characterized.  In view of the interest for gastrokinetic agents, the 
influence of the 5-HT4-receptor agonist prucalopride was investigated.  This agent also 
stimulates colonic motility leading us to evaluate its influence on acetylcholine release in the 
colon. 
Chapter 1 gives a literature survey about the innervation of the GI tract, and the 
neuronal contribution in motility regulation of stomach and colon, the two tissues under 
study.  This chapter also summarizes previous studies with regard to presynaptic modulation 
of acetylcholine release in different parts of the GI tract. 
Chapter 2  gives the results of functional experiments, performed to study the 
cholinergic -nitrergic interaction in circular muscle strips of pig gastric fundus.  The pig was 
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selected as experimental animal as it has been proposed that this animal is a good non-primate 
model for studying human digestive function in view of the similarity of the morphology and 
physiology of the GI tracts (Miller & Ullrey, 1987).  The pig gastric fundus is innervated by 
both excitatory cholinergic and inhibitory non-adrenergic non-cholinergic (NANC) neurones 
(Ohga & Taneike, 1977; Miyazaki et al., 1991), and NO is the most important NANC 
neurotransmitter (Lefebvre et al., 1995).  Although the experiments suggested that NO 
interacted with acetylcholine by functional antagonism at the postsynaptic level, a presynaptic 
effect of NO could not be excluded.  A method was therefore introduced to measure 
acetylcholine release from the cholinergic nerve endings after incubation of the tissue with 
[3H]-choline.  Chapter 3 describes in detail how the experimental conditions were adapted to 
measure [3H]-acetylcholine release in the pig gastric fundus.  This study allowed to determine 
more precisely whether NO interferes with the release of [3H]-acetylcholine from cholinergic 
neurones innervating the circular muscle layer of pig gastric fundus.  As it has been 
demonstrated that presynaptic a 2-adrenoceptors (De Ponti et al., 1996) and muscarinic auto-
receptors (Starke et al., 1989; Grimm et al., 1994) can interfere with acetylcholine release, a 
series of experiments was performed to study whether these receptors are present on the 
cholinergic nerve endings innervating the circular muscle layer of the pig gastric fundus. 
The previous experiments demonstrated the presence of inhibitory muscarinic 
receptors on the cholinergic nerve endings in pig gastric fundus.  In Chapter 4, an attempt 
was made to pharmacologically characterize these presynaptic muscarinic autoreceptors by 
using a series of subtype-preferring muscarinic antagonists.  A second goal was the 
characterization of the postsynaptic muscarinic receptors, responsible for the contraction of 
the tissue by the released acetylcholine after activation of the cholinergic neurones.  Both 
functional and release experiments were used to pharmacologically characterize the 
muscarinic receptors. 
As cholinergic neurones innervate human gastric fundus (Parkman et al., 1999; Tonini 
et al., 2000), it should be possible to measure [3H]-acetylcholine release from cholinergic 
neurones innervating the circular muscle layer of human gastric fundus.  The same protocol as 
used for the pig gastric fundus was used to study the release of [3H]-acetylcholine in human 
proximal stomach; the results are given in Chapter 5.  In human gastric fundus, both NO and 
VIP contribute to NANC relaxations (Tonini et al., 2000), and the influence of NO and VIP 
on [3H]-acetylcholine from cholinergic neurones innervating the circular muscle layer was 
studied.  The presence of a2-adrenoceptors and muscarinic autoreceptors on the cholinergic 
neurones was also investigated.  As it is demonstrated that stimulation of 5-HT4-receptors 
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increases human stomach emptying (Johnson, 1989), the presence of facilitatory 5-HT4-
receptors on the cholinergic nerve endings was studied. 
Because of our interest in 5-HT4-receptors, the human colon was studied in Chapter 6 
as it is known that stimulation of 5-HT4-receptors increases human colonic motility in vivo 
(Emmanuel et al. , 1998; Bouras et al., 1999, 2001), but the precise mechanism of this effect is 
not yet known.  In human colon, 5-HT4-receptors have been demonstrated on circular muscle 
cells, causing relaxation (Prins et al., 2000b) while 5-HT4-receptors are also present on the 
cholinergic nerve endings innervating the longitudinal muscle layer, facilitating cholinergic 
contractions (Prins et al., 2000a).  However, the latter can very probably not explain why 5-
HT4-receptor agonists accelerate human colonic transit as the contraction of the longitudinal 
muscle layer can not provide sufficient force to promote colonic transit.  Facilitatory 5-HT4-
receptors on cholinergic nerve endings innervating the circular muscle layer might explain the 
increase in transit.  For this reason, the presence of stimulatory presynaptic 5-HT4-receptors 
on cholinergic nerve endings innervating the circular muscle layer in human colon was 
investigated, by means of contractility and release experiments. 
Chapter 7 discusses the results, leading to the conclusion. 
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CHAPTER  1 
LITERATURE SURVEY 
 
1.1.  Innervation of the gastrointestinal tract 
 
1.1.1.  General 
 
In humans, the gastrointestinal (GI) tract consists of a 6-9 m long canal, beginning at 
the mouth and ending at the anus, together with the associated organs that empty their 
contents in the tract.  The GI tract consists of the mouth, the oesophagus, the stomach, the 
small intestine (divided in the duodenum, jejunum and ileum), and the large intestine (divided 
in the colon and rectum).  The major physiological processes that occur in the GI tract are 
secretion, digestion, absorption, motility and elimination.  Food enters the mouth where it will 
be reduced in size before moving to the stomach via the oesophagus.  The stomach will store 
the food, mix it with its secretions containing pepsin, ions and water, and grind it until the 
particles are small enough to pass the pylorus and enter the small intestine.  In the small 
intestine, enzymes convert the macromolecules into absorbable material, a process called 
digestion; the products of the digestion will be absorbed across the epithelium of the small 
intestine to enter the blood or lymph.  Finally, undigested food will reach the colon where 
water will be resorbed before the contents leave the body.  During the grinding and mixing, 
motility is important, which is mediated by the smooth muscle layer of the GI tract.  Motility 
is also necessary for the progression of the contents throughout the tract and for eliminating 
the undigested food via the faeces. 
Although the GI tract consists  of different regions, the structure of all these regions is 
quite similar and consists of four layers (Figure 1.1): the inner layer is called the mucosal 
layer and can be divided into the mucosa and the mucosal muscle layer; the second layer is 
the submucosa with the submucosal neuronal plexus or plexus of Meissner; the third layer 
consists of the circular and longitudinal muscle layers and in between the myenteric neuronal 
plexus or plexus of Auerbach.  Finally, the serosa forms the outer layer that surrounds the 
tract. 
The two plexuses control the multiple functions of the GI tract, such as secretion, 
absorption and propulsion, and are known as the enteric nervous system (ENS).  Besides this 
intrinsic control, the GI tract also receives extrinsic input from the central nervous system 
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(CNS) via parasympathetic and sympathetic neurones.  These two control levels are described 
more in detail in the next two sections, and the following reviews concerning the innervation 
of the GI tract form the basis for these sections (Costa & Brookes, 1994; Furness et al. , 1996; 
Goyal & Hirano, 1996; Bennett, 1997; Kunze & Furness, 1999).   
 
1.1.2.  Extrinsic innervation 
 
The parasympathetic and sympathetic nervous system both contain efferent and 
afferent fibers.  Both efferent systems have a bi-neural connection with the effector cells.  The 
preganglionic nerves in both systems are cholinergic, releasing the neurotransmitter 
acetylcholine. 
The parasympathetic nervous system towards the GI tract consists of two nerves: 1) 
the vagal nerve, originating in the medulla oblongata and innervating the major part of the GI 
tract as far as the mid-transverse colon, and 2) the pelvic nerve, originating from the sacral 
cord and innervating the lower part of the colon (Figure 1.2).  About 80-90 % of the 
parasympathetic neurones are afferent, and transmit information from the sensory nerve 
endings in the gut through their cell bodies in the nodose ganglia to the CNS.  Sensory nerve 
 
Figure 1.1  Schematic representation of the different layers of the gastrointestinal tract, and the location of the 
enteric plexuses in whole mounts of intestine.  The serosa is not shown. (Adapted from Furness & Costa, 1987). 
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Figure 1.2   The extrinsic efferent innervation of the gastrointestinal tract.  C.g.: celiac ganglion, S.m.g.: superior 
mesenteric ganglion, I.m.g.: inferior mesenteric ganglion, Pelvic pl. + gg.: pelvic plexus and ganglia, H.n.: 
hypogastric nerve.  (Adapted from Baumgarten, 1982). 
 
endings in the mucosa are sensitive to luminal concentrations of glucose, amino acids or long-
chain fatty acids, others respond to a wide variety of transmitters and mechanical stimuli; 
sensory nerve endings in the muscle layers are sensitive to mechanical distension of the gut.  
In the CNS, the sensory neurones connect to the efferent vagal neurones.  Only 10-20 % of 
the parasympathetic fibers are efferent, innervating the GI tract.  These efferent fibres release 
acetylcholine, and stimulation of these fibers generally activates nicotinic receptors within the 
intrinsic enteric ganglia of the gut.  The classic parasympathetic fibers synapse in this way 
with excitatory cholinergic neurones in the gut wall.  However, it has become clear that vagal 
preganglionic fibers also synapse with non-adrenergic non-cholinergic (NANC) neurones. 
The processes of the efferent sympathetic nervous system, originating in the thoraco-
lumbar part of the spinal cord, run through the paravertebral ganglia, and the preganglionic 
neurones release acetylcholine, activating nicotinic receptors on the neuronal cell bodies in 
the prevertebral ganglia (celiac, superior and inferior mesenteric) (Figure 1.2).  From these 
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cell bodies, postganglionic noradrenergic fibers project to the enteric ganglia via the 
splanchnic nerves, having at least four distinct targets in the gut: 1) they influence 
secretomotor neurones containing vasoactive intestinal polypeptide (VIP); 2) they affect the 
blood supply to the musculature but do not directly innervate the smooth muscle cells, 3) 
except for most sphincter regions where they contract the smooth muscle by a direct effect on 
the muscle; and 4) they reduce GI motility in non-sphincteric regions primarily through 
actions of the noradrenergic axons in the myenteric ganglia, inhibiting the release of 
excitatory neurotransmitters from local nerve terminals e.g. inhibition of acetylcholine release 
from excitatory cholinergic neurones via presynaptic a 2-adrenoceptors on the cholinergic 
nerve endings (see review De Ponti et al., 1996).  Besides this efferent limb, there is also 
transfer of sensory information to the CNS by neurones having their endings in the gut wall 
and their cell bodies in the dorsal root ganglia.  These neurones are nociceptors, sensing high-
intensity mechanical, thermal and chemical stimuli that damage or threaten the tissue. 
 
1.1.3.  Intrinsic innervation 
 
 The ENS is a collection of about 100 million neurones in the GI tract that constitutes 
the “brain of the gut” and can function independently of the CNS, although it communicates 
with the CNS through sympathetic and parasympathetic afferent and efferent neurones (see 
above).  The ENS controls the motility, exocrine and endocrine secretions, and 
microcirculation of the GI tract; it is also involved in regulating immune and inflammatory 
processes. 
In the ENS, the nerve-cell bodies are grouped into small ganglia, that are connected by 
bundles of nerve processes forming two major neuronal plexuses, called the myenteric or 
Auerbach’s plexus and the submucosal or Meissner’s plexus (Figure 1.1).  The myenteric 
plexus extends over the entire length of the gut, regulating GI motility.  The submucosal 
plexus is best developed in the small intestine, where it plays an important part in the control 
of secretion and absorption, although it also innervates the muscularis mucosae, intestinal 
endocrine cells and submucosal blood vessels.  The ganglia and connecting nerve bundles are 
surrounded by a basal lamina, collagen fibrils and enteric glial cells.  Smaller plexuses are 
also found such as the deep muscular plexus, lying deep within the circular muscle layer of 
the intestine (Figure 1.1). 
Four functional types of enteric neurones are described in the ENS: the secretory and 
motor neurones, both having efferent functions, the sensory neurones, also called the 
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‘intrinsic primary afferent neurones’ (IPANs), and the interneurones. The motor neurones, 
IPANS and interneurones are involved in reflexes, including peristalsis, an important reflex 
for the motility in the small and large intestine.  These neurones are connected with each other 
and form a complex system, the ENS.  The sensory endings of the IPANs are present in the 
mucosa, with their cell bodies in the myenteric plexus.  They are sensitive to different stimuli 
like distension, changes in luminal content and 5-hydroxytryptamine (5-HT), and they will 
send information to the myenteric plexus.  Some of the IPANs have their cell bodies in the 
submucosal plexus; stimulation of these IPANs might be involved in controlling the 
transmucosal water and electrolyte transport and local blood flow.  In the myenteric plexus 
the IPANs form connections with longitudinally projecting interneurones, the latter running 
orally or anally and designated as ascending or descending respectively (Figure 1.3).  They 
form multisynaptic pathways and make connections with both motor neurones and other 
interneurones; the latter can explain why enteric reflexes often extend for several centimetres 
along the intestine from a single point of stimulus.  Ascending interneurones contain 
acetylcholine, acting on nicotinic receptors of other interneurones and motor neurones; 
however, the transmitters in the descending interneurones are not yet known.  Finally, the 
motor neurones project to the muscle layers (Figure 1.3).  These neurones are either excitatory 
or inhibitory.  Excitatory motor neurones cause contractions of the muscles orally of their cell 
bodies due to the release of acetylcholine and probably substance P.  On the other hand, 
inhibitory motor neurones cause relaxations of the muscles anally to their cell bodies due to 
the release of nitric oxide (NO), VIP and other inhibitory neurotransmitters; these 
neurotransmitters can be released from the same neuron.  Neurotransmitters might interfere 
with each others release and action.  The axons run circumferentially, following the direction 
of the muscle cells, and as the cells are electrically coupled to each other they influence the 
muscle cells as a group. 
Information from both the excitatory and inhibitory motor neurones is transferred to 
the smooth muscle at least in part via  the interstitial cells of Cajal (ICC), which are 
electrically coupled to the muscle.  ICCs are non-neural cells that serve as pacemakers and are 
responsible for the spontaneous, rhythmic, electrical excitatory activity of GI smooth muscle 
that is referred to as slow waves.  The ICCs are susceptible to both the inhibitory transmitter 
NO, and the excitatory tachykinin transmitters.   
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Figure 1.3  Simplified, in series representation of enteric circuits for motility reflexes.  1: IPAN with cell body 
in the myenteric plexus; 2: ascending cholinergic interneuron; 3: descending interneuron in the local reflex 
pathway; 4: descending interneuron of the migrating motor complex pathway; 5: inhibitory motor neuron; 6: 
excitatory motor neuron; 7: IPAN with cell body in the submucosal plexus; 8: enteroendocrine cell that releases 
an excitant of the mucosal endings of IPANs; LM: longitudinal muscle; MP: myenteric plexus; CM: circular 
muscle; SM: submucosa; Muc: mucosa.  (Adapted drom Kunze & Furness, 1999). 
 
1.1.3.a.  Cholinergic innervation 
 
Cholinergic neurones are found all over the body.  These neurones release the 
neurotransmitter acetylcholine.  Choline, taken up by the cholinergic neurones, is linked to 
acetyl-CoA by the enzyme choline acetyltransferase to form acetylcholine, which will be 
taken up into vesicles until it is released after activation of the neurones.  This acetylcholine 
will have its effect by activation of two different types of receptors: nicotinic and muscarinic 
receptors; the effect of acetylcholine at these receptors is indeed mimicked by nicotine and 
muscarine respectively.  To end the effect of acetylcholine, acetylcholine will be broken down 
into acetate and choline by the enzyme acetylcholinesterase.  Choline will be recovered by the 
cholinergic neurones. 
The preganglionic neurones of the parasympathetic and sympathetic nervous system, 
as mentioned before, and the neurones innervating the skeletal muscle cells release 
acetylcholine.  This acetylcholine will activate nicotinic receptors present at the somata of 
postganglionic neurones and at the end plate of skeletal muscle cells.  These receptors are 
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built up by five subunits (two a, and one b, g and d), around a channel.  After each a -subunit 
is occupied by acetylcholine, the central pore opens, resulting in an increased permeability for 
sodium and potassium ions, and consequently a depolarisation of the effector cell.  The 
nicotinic receptors on the postganglionic neurones can be blocked by hexamethonium. 
Acetylcholine released from cholinergic neurones ending on effector cells interacts 
with muscarinic receptors.  They are amongst others localized on neuronal cell bodies in the 
CNS, on cardiac muscle, on smooth muscle cells and on exocrine glands.  Five different 
muscarinic receptor subtypes have been identified based on studies of molecular structure, in 
vitro binding and function (Buckley et al. , 1989; Dörje et al. , 1991).  All subtypes belong to 
the seven-transmembrane G-protein coupled receptor family (see reviews Grimm et al., 1994; 
Eglen et al., 1996; Caulfield & Birdsall, 1998).  Muscarinic M1, M3 and M5 receptors 
preferentially couple to a membrane-bound phospholipase C via stimulatory Gq/11-protein, 
resulting in the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) and the formation 
of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).  IP3 causes release of calcium 
from intracellular stores, while DAG activates protein kinases (PK), especially PKC and is 
metabolised to arachidonic acid and derivatives.  The M2 and M4 receptors preferentially 
inhibit adenylyl cyclase via activation of inhibitory Gi/o-proteins.  Other minor pathways 
might also be involved.  The muscarinic receptors can be blocked by the non-selective 
antagonist atropine; more selective muscarinic antagonists are also known. 
In the GI tract, the ascending motor neurones and interneurones, as well as most 
intrinsic sensory neurones are cholinergic, but they contain very often, apart from 
acetylcholine, also tachykinins.  These neurones project to the smooth muscle cells and to 
other neurones, and the released acetylcholine stimulates muscarinic receptors, resulting in 
contraction.  At the postsynaptic level, M2 and M3 receptors are present, and although the 
majority of the receptors belong to the M2 subtype, mainly the M3 receptors are detected 
pharmacologically (Eglen et al., 1996; Caulfield & Birdsall, 1998).  M2 receptors become 
more important after stimulation of adenylyl cyclase (Ehlert et al., 1999), or during 
inflammation (Shi & Sarna, 1997, 1999).  The released acetylcholine can also interfere at the 
presynaptic level with its own release and the release of other neurotransmitters.  However, 
the situation at this level is more complex as both stimulatory and inhibitory muscarinic 
receptors can be present (Grimm et al., 1994). 
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1.1.3.b.  Nitrergic innervation 
 
For many years it was believed that acetylcholine and noradrenaline were the only two 
neurotransmitters in the GI tract.  However, since the 1960’s it became evident that other 
neurotransmitters exist, which were indicated as non-adrenergic non-cholinergic (NANC; see 
review Bennett, 1997).  The NANC neurones now represent a large class of neurones which 
can contain contractile neurotransmitters like substance P (Shuttleworth & Keef, 1995), or 
inhibitory neurotransmitters like adenosine triphosphate (ATP; Burnstock, 1972), vasoactive 
intestinal polypeptide (VIP; Fahrenkrug, 1982) or nitric oxide (NO; Sanders & Ward, 1992). 
Inhibitory NANC neurones are recognized in the urogenital, respiratory, 
cardiovascular and GI tract.  The functional significance of the inhibitory NANC neurones in 
the GI tract is important in many physiological and pathophysiological conditions (Goyal & 
Hirano, 1996).  An important portion of the inhibitory NANC neurones in the GI tract use NO 
as their neurotransmitter. 
NO is a small labile molecule, with a half-life of 3 to 50 s.  It is enzymatically formed 
together with L-citrulline from the amino acid L-arginine (Figure 1.4) by the catalytic activ ity 
of a family of iso-enzymes, the NO synthases (NOS).  Three iso-enzymes of NOS, encoded 
by three different genes, have been identified: neuronal NOS (nNOS, bNOS or NOS I), 
inducible NOS (iNOS or NOS II) and endothelial NOS (eNOS or NOS III).  These isoforms 
vary in tissue distribution, transcriptional regulation, cofactor requirements, posttranslational 
modification and function.  All three isoforms need flavin mononucleotide (FMN), flavin 
adenine dinucleotide (FAD), tetrahydrobiopterin (BH4) and protoporphyrin IX haem as well 
as two co-substrates (O2 and NADPH) (Schmidt et al. , 1993).  L-arginine binds to NOS, 
resulting in the oxidation of L-arginine whereby the intermediary L-NG-hydroxyarginine is 
formed, that is further oxidized to form NO and its co-product L-citrulline.  All NOS isoforms 
are inactive until calmodulin binds to them in a process which can be either calcium-
dependent (eNOS and nNOS) or calcium-independent (iNOS).  nNOS and eNOS are 
constitutively expressed, calmodulin-free and inactive.  An increase of the amount of free 
intracellular calcium allows that these two NOS isoforms bind calmodulin and become active.  
nNOS is mostly found in neurones, and the produced NO regulates many functions in the 
CNS; in the peripheral nervous system, NO plays an important role as inhibitory NANC 
neurotransmitter in the GI, respiratory and urogenital tract (Toda et al., 2000).  eNOS was 
first identified in endothelial cells (Pollock et al., 1991), and contributes to the regulation of 
the blood pressure.  iNOS on the other hand is mainly expressed after activation of cells such 
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as macrophages with different cytokines or endotoxins.  iNOS binds calmodulin constitutively 
and is thus constitutively active, independently of the intracellular Ca2+ concentration.  The 
NOS isoforms can be inhibited by L-arginine analogues that stereotypically inactivate NOS 
such as NG-nitro-L-arginine (L-NNA) and its methyl ester (L-NAME). 
 
Figure 1.4  Schematic representation of nitrergic neurotransmission.  Upon an action potential, N-type calcium 
channels open, allowing calcium to enter the neuron.  The increase in intracellular calcium activates NO 
synthase, resulting in production of NO.  NO diffuses into the extracellular space and into nearby effector cells 
such as smooth muscle cells.  NO activates soluble guanylyl cyclase in these cells, resulting in an increase of 
cyclic GMP.  This cyclic GMP activates protein kinase (PK), resulting in a decrease in the intracellular calcium 
concentration and muscle relaxation.  Phosphodiesterases (PDE) stop the relaxation by breaking down cyclic 
GMP.  The transmission process can be blocked by inhibiting the neuronal calcium channels with w-conotoxin 
(w-CgTx), by inhibiting NO synthase with e.g. L-NAME, or by inhibiting guanylyl cyclase with ODQ. 
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The lipophilic molecule NO diffuses outwards into nearby target cells where it binds 
to the haem prosthetic group of soluble guanylyl cyclase and stimulates the intracellular 
accumulation of guanosine 3’5’ cyclic monophosphate (cyclic GMP) from guanosine 5’ 
triphosphate (GTP) (Figure 1.4).  Depending on the cell and tissue type, cyclic GMP regulates 
cyclic GMP-dependent protein kinase, cyclic GMP-regulated phosphodiesterase and cyclic 
GMP-gated ion channels.  Bolotina et al. (1994) also reported a ro le for NO as vasorelaxant 
independently of cyclic GMP by activating directly Ca2+-dependent potassium channels 
causing hyperpolarisation.  When NO is formed in large quantities by iNOS, it can also act 
via other signal transduction pathways than described above, often resulting in a loss of 
function of the cell.  
The main inhibitory neurotransmitter in the GI tract is NO.  In the stomach it is 
involved in the receptive as well as the adaptive relaxation; in the small and large intestine, it 
has been demonstrated that the anally orientated motor neurones contain NO, causing 
relaxation of the gut descending of a propagating bolus.  Although NO is an important 
neurotransmitter in the GI tract, immunohistochemical studies demonstrated that VIP is often 
co-localized with NO in the myenteric plexus innervating the GI tract (Furness et al., 1992; 
Lefebvre et al. , 1995; Tonini et al., 2000), and contractility studies demonstrated that this VIP 
plays a role in NANC relaxations.  However, this does not mean that both transmitters are 
always released together and contribute to the relaxations in a similar extent.  In rat, ferret and 
man stomach, NO initiates and VIP sustains the relaxation (Li & Rand, 1990; Boeckxstaens et 
al., 1992; Grundy et al., 1993; Tonini et al. , 2000); in guinea-pig, cat and pig gastric fundus, 
NO is the main inhibitory NANC transmitter (Lefebvre et al., 1992a, 1995; Barbier & 
Lefebvre, 1993; Desai et al., 1994).  Binding of VIP with its receptor stimulates G-proteins 
that activates adenylyl cyclase, resulting in an increased production of adenosine 3’5’ cyclic 
monophosphate (cyclic AMP) from adenosine 5’ triphosphate (ATP), and consequently 
relaxation of the smooth muscle.  
 
1.2.  Gastrointestinal motility 
 
 This study concentrates on the motility of the stomach and colon.  For this reason, the 
motility of these parts of the GI tract are described more in depth in the next two sections. 
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1.2.1.  Stomach 
  
The stomach is a saclike structure, located in the upper abdomen just below the 
diaphragm; it contains the four layers as described in section 1.1.1.  The stomach starts the 
breakdown of an incoming meal by its secretory and motor responses.  The stomach secretes 
about 3 l of gastric juice daily.  This fluid consists of water, hydrochloric acid, intrinsic factor, 
pepsin and mucin, the main component of mucus which protects the stomach from the effects 
of the acid and pepsin.  Hydrochloric acid creates the acid environment necessary for pepsin 
to begin the breakdown of proteins, and it destroys most of the ingested micro-organisms.  
The motor functions of the stomach include acting as a reservoir for ingested food, grinding 
the food and emptying of the contents into the duodenum at controlled rates.  When 
considering these motor functions, the stomach can be divided into two parts: the proximal 
and distal part (Figure 1.5).  The proximal stomach consists of the fundus and oral one-third 
of the corpus; it shows tonic motility changes and is thought to function mainly as a reservoir 
for the storage of liquids and solids.  It also controls the emptying of liquids into the small 
intestine.  The distal part consists of the remaining corpus, the antrum and the pylorus; it 
shows phasic contractility and is involved in grinding the particles and controlling the 
emptying of solids.  Coordinated actions of these regions with feedback control from the 
small and large intestine regulate emptying of the gastric contents into the duodenum (Kelly, 
1980; Hasler, 1996a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.5  Schematic representation of the different parts of the stomach. 
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The proximal stomach regulates intragastric pressure during gastric filling due to its 
relaxant properties.  During swallowing, the pharynx and oesophagus are distended, activating 
mechanoreceptors.  The information of the mechanoreceptors is transported to the brain stem 
by afferent neurones, which will activate efferent vagal preganglionic fibers, that synapse 
with inhibitory NANC neurones in the gastric wall.  This vago-vagal reflex pathway, 
activating NANC neurones, causes relaxation of the proximal part of the stomach which 
allows the  proximal  stomach to  receive the  food with  minimal  increases in pressure; this is 
called the receptive relaxation (Abrahamsson, 1973, 1986) (Figure 1.6).  When the intake of a 
meal is finished, the oesophago-gastric reflex of the stomach stops as well.  Instead, the 
distension of the stomach, or the localised distension of the distal stomach by the gastric 
contents activates distension receptors, which elicit vago-vagal reflex responses maintaining 
the relaxation of the proximal stomach via  inhibitory NANC neurones, being responsible for 
the long term relaxation, the adaptive relaxation (Abrahamsson, 1973, 1986) (Figure 1.6).  
Besides of efferent fibers ending on inhibitory NANC neurones in the gastric wall, the vagus 
also contains efferent preganglionic fibers synapsing with contractile cholinergic neurones in 
the gastric wall.  However, the vagal efferent supply in the reflex pathway to the stomach 
seems organised in a reciprocal manner at the central level: when the vagal preganglionic 
efferents supplying the intrinsic inhibitory NANC neurones are active as is the case during 
intake of a meal, the discharge in those supplying the intrinsic excitatory cholinergic neurones 
is suppressed; during fasting the opposite is seen (Andrews, 1990).  At the level of the 
stomach, evidence has accumulated that both NO and VIP are involved in NANC relaxation 
(Lefebvre, 1993). 
Mixing and grinding of the gastric content, as well as emptying of the stomach, 
especially of solids, are regulated by the distal stomach.  In the upper part of the distal 
stomach at the greater curvature, a pacemaker generates slow waves.  These slow waves, 
consisting of an initial rapid depolarisation followed by a more prolonged plateau potential, 
propagate in the direction of the small intestine (Hasler, 1996a).  Another pacemaker is 
present in the duodenum.  Under quiescent conditions, the slow waves are not of sufficient 
amplitude to reach the threshold to induce a significant contraction in the distal stomach.  
However, these slow waves can be modified: intake of food causes distension of the proximal 
stomach, activating a vagal fundo-antral reflex pathway with stimulation of cholinergic 
neurones.  These neurones increase the amplitude of the slow waves whereby the plateau 
potential of the depolarisation is prolonged and enhanced so that the threshold to initiate an 
action potential is reached, resulting in circular contractions that propagate over the corpus 
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and antrum towards the pylorus.  These contractions are of variable intensity and duration, 
and solid food induces stronger antral contractions than a similar load of liquids.  The 
contractions propel the gastric content distally.  However, while the ingested food moves to 
the distal antrum, the pylorus closes due to the activation of cholinergic neurones, resulting in 
retropulsion of the mixed bolus into the proximal stomach.  These actions serve to grind and 
mix the luminal contents (Kelly, 1980; Hasler, 1996a).  The movements reduce the food into 
particles small enough to pass the pylorus when the sphincter is open due to activation of 
nitrergic neurones during the short moments just before the antral contractions reach the 
pylorus and the pylorus closes. 
In addition to these reflexes which occur during the fed period, the GI tract exhibits 
between two meals cyclic changes of activity that pass along the tract from the stomach to the 
terminal ileum.  These interdigestive patterns, known as migrating motor complexes (MMC), 
 
 
Figure 1.6  Schematic representation of the vagal innervation of the smooth muscle cells in the proximal 
stomach.  Shown are the reflex mechanisms producing gastric receptive and adaptive relaxation via the vagal 
non-adrenergic relaxatory fibres to the stomach. 
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clear the stomach of undigested debris and sloughed epithelial cells.  The MMC consists of 
three phases: phase I is a period of motor quiescence, which is followed by a phase II with 
increasing but irregular contractions.  Phase III is a period of intense, rhythmic, luminally 
occlusive contractions that mostly begin in the corpus at the pacemaker and propagate 
unimpeded to the pylorus, although it sometimes even starts in the distal duodenum.  These 
contractions are highly propagative.  During phase III, the pylorus is open to allow easy 
clearing of the stomach.  There is evidence that the gastric phase III activity is induced by 
motilin, while the extrinsic innervation only modulates MMC activity.  Sometimes a phase IV 
is described, a brief period of less intense activity from phase III to phase I.  This 
interdigestive pattern disappears soon after a meal is taken, to be replaced by the fed pattern 
activity described above (Hasler, 1996a). 
During both the fed and interdigestive periods, a entero-gastric reflex pathway 
modulates the emptying of the stomach, mostly resulting in a delay in gastric emptying or a 
prolonged MMC. 
 
1.2.2.  Colon  
 
In humans, ingesta from the small intestine enter the large intestine through the 
ileocaecal junction, a sphincter preventing the reflux of material from the colon to the 
terminal ileum.  The large intestine consists of the caecum, colon and rectum.  The caecum is 
the first part that receives the food particles.  The colon, 91 – 125 cm long, can be divided into 
four regions: the ascending, transverse, descending and sigmoid colon (Figure 1.7 A.).  The 
caecum, ascending and transverse colon and the rectosigmoid area act as a reservoir, while the 
descending colon acts as a conduit.  Although the same layers are present in the colon as in 
the other regions of the GI tract, the organisation is slightly different: the colon possesses a 
circumferential circular muscle layer with on top three thin layers of longitudinal muscle, the 
taenia coli (Figure 1.7 B).  Contractions of the circular muscle that narrow the lumen, together 
with longitudinal contractions that shorten the length of the colon give rise to colonic haustra 
(Figure 1.7 A and B).  The rectum, 15 – 20 cm long, contains circumferential longitudinal and 
circular muscle layers as in the other regions of the GI tract.  The major functions of the colon 
are extraction of water, digestion of certain meal residues and processing of faeces for 
controlled expulsion.  The large intestine contains, in contrast to the other parts of the GI 
tract, large amounts of bacteria, that metabolise unabsorbed nutrients in the ascending and 
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Figure 1.7  A. Schematic representation of the different regions of the large intestine.  B.  Schematic 
representation of the different layers of the colon.  The enteric plexuses are not shown.  (Adapted from Junqueira 
et al., 1993). 
 
transverse colon.  The bacteria also produce vitamin K, a crucial factor for coagulation.  
These products will be absorbed by the colon, together with about 6 l water daily to make the 
stool solid.  To recover that large amount of water, the faecal material may not propagate to 
fast to allow enough time for absorption.  Indeed, if stool moves too quickly, not enough 
water is absorbed, resulting in diarrhea; however, when the motility of the colon is too low, 
the colon can absorb too much water, resulting in hard stool and constipation (Camilleri & 
Ford, 1998).  Colonic motility must thus be well regulated by the combined actions of several 
distinct motor patterns and their corresponding myoelectrical complexes. 
The circular muscle layer is the most important one with regard to colonic motility.  
Three different motor patterns can be recognized in the colon: local contractions, peristaltic 
reflexes and giant migrating contractions (GMCs).  
Local contractions, originating from pacemakers in the submucosal and myenteric 
border located throughout the whole length of the colon, will mix the faecal material to 
promote extraction of water; the faeces hereby only propagate for short distances in an oral or 
aboral direction. 
At the same time, peristaltic reflexes press the faecal material aborally to the left side 
of the colon, particularly to the rectosigmoid, to store it before it will be removed.  The 
peristaltic reflex originates from IPANs, with their cell bodies in the myenteric plexus, that 
are activated by distension and changes in luminal content.  These neurones activate 
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interneurones and ascending contractile cholinergic neurones and descending inhibitory 
NANC neurones.  However, a retroperistaltic transit pattern from the pacemaker area in the 
transverse colon into the ascending colon has been observed, slowing down the propagation 
of the faecal matter and increasing the absorption.  This results in a transit of one to two days.  
Faeces are stored for the longest period in the rectosigmoid, supporting its role as a reservoir.  
Rectal motor complexes facilitate the storage of the colonic content that reaches the rectum, 
probably by pressing the content together.  These contractions occur about 16 times a day, 
and do not propagate.  During these complexes, no anal relaxations are observed, consistent 
with a role in maintenance of faecal continence.  In contrast to the upper GI tract, there is no 
organised interdigestive, cyclical MMC in the human colon (Hasler, 1996b). 
Ingesta from the small intestine as well as the slow propagation of the faecal contents 
causes a large distension of the proximal colon, inducing GMCs, which propagate aborally 
from the proximal colon to the distal colon and evoke mass movements of faeces.  These 
GMCs are generated by myenteric pacemakers, and thus propagate in motor patterns distinct 
from the peristaltic reflex (Hasler, 1996b).  During the first three to four years of life, the 
number of GMCs progressively decreases from three or four per day until an average of two 
GMCs per day is reached, which remains constant until the frequency in the elderly 
population decreases significantly (Hillemeier, 1995).  Meal ingestion is an important 
stimulus to increase motor activity in the colon via the cholinergic neural pathway of a 
gastrocolonic response.  This is sometimes followed by mass movements and defecation.  No 
GMCs occur during periods of sleep, while the other colonic motor activities are infrequent.  
However, motor activity increases soon after awakening, often leading to defecation. 
The GMCs bring an important mass of faeces into the rectum, resulting in a sudden 
distension of the rectum.  Mechanosensitive enteric neurones register the distension and 
activate a rectoanal inhibitory reflex (Hillemeier, 1995; Hasler, 1996b).  The reflex decreases 
the pressure of the internal anal sphincter due to stimulation of inhibitory NANC neurones 
with release of NO and VIP.  Normally the pressure of this sphincter is sufficient to prevent 
accidental loss of faecal material.  However, the pressure of the external anal sphincter 
increases with the distension of the rectum, preventing that the faeces can leave the body after 
the internal anal sphincter opens, unless it is convenient.  The mechanoreceptors also transmit 
the message to the CNS to register that it is time for defecation.  In order to allow defecation, 
the individual must voluntarily relax the external anal sphincter and associated skeletal 
muscle structures and increase abdominal pressure. 
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1.3.  Presynaptic modulation of cholinergic neurotransmission 
 
Under quiescent conditions and certainly upon stimulation, cholinergic neurones 
release acetylcholine acting at the postsynaptic level on muscarinic or nicotinic receptors.  
The released acetylcholine can also interact at the presynaptic level whereby acetylcholine 
modifies its own release via  autoreceptors or the release of other neurotransmitters via  
heteroreceptors.  On the other hand, other neurotransmitters may facilitate or inhibit the 
release of acetylcholine, mostly via stimulation of receptors on the cholinergic nerve endings; 
NO is able to influence the release of acetylcholine without binding on a receptor.  This 
section focuses on the modulatio n of acetylcholine release via  autoreceptors and 
heteroreceptors on cholinergic nerve endings modulating GI motility. 
 
1.3.1.  Presynaptic modulation via muscarinic receptors 
 
Although a lot of evidence exists that muscarinic receptors are present on the 
cholinergic nerve endings innervating the GI smooth muscle, regulating the release of 
acetylcholine, mainly via inhibition, few studies characterised the subtype of presynaptic 
muscarinic autoreceptor(s).  This is probably due to the lack of very selective muscarinic 
agonists and antagonists.  For this reason, a series of subtype-preferring muscarinic receptor 
antagonists have to be tested, and their affinity at the muscarinic receptors have to be 
compared with affinity values obtained from binding studies for the muscarinic receptor 
subtypes.  Muscarinic subtype preferring antagonists exist (Eglen et al., 1996; Caulfield & 
Birdsall, 1998) such as the non-selective antagonist atropine, the M1-preferring antagonist 
pirenzepine, the M2-preferring antagonists AF-DX 116 and methoctramine, the M3-preferring 
antagonists 4-DAMP and p-F-HHSiD, and the very selective M4-receptor antagonist MT-3 
(Adem & Karlsson, 1997).  In guinea-pig longitudinal muscle-myenteric plexus (LMMP) 
preparations of the ileum, presynaptic muscarinic M3 receptors inhibit while presynaptic M1 
receptors enhance acetylcholine release (Soejima et al., 1993).  On the contrary, presynaptic 
inhibitory muscarinic M1 receptors are present on the cholinergic nerve endings innervating 
the circular smooth muscle of the guinea-pig ileum (Dietrich & Kilbinger, 1995), indicating 
that in the same region of a given species, both stimulatory and inhibitory muscarinic M1 
receptors can be present depending on the muscle layer studied.  In the guinea-pig stomach, it 
has been demonstrated that presynaptic muscarinic M1 and M2 receptors inhibit [
3H]-
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acetylcholine release (Ogishima et al., 2000).  In canine LMMP preparations, a binding study 
demonstrated the presence of presynaptic M3 receptors, although the presence of another 
presynaptic muscarinic subtype could not be excluded (Kostka et al. , 1989). 
 
1.3.2.  Presynaptic modulation via a2-adrenoceptors 
 
As mentioned before, the noradrenergic neurones of the sympathetic nervous system 
generally do not innervate the smooth muscle cells directly, but have their effect indirectly by 
influencing the release of other neurotransmitters, including the release of acetylcholine.  Two 
main adrenergic receptor types have been identified, and these are further divided into 
subclasses, leading to a1-, a 2-, b1-, b2- and b3-adrenoceptors.  Selective adrenoceptor agonists 
and antagonists are used to study the effect of the sympathetic nervous system on the release 
of acetylcholine, and which type of adrenoceptor is involved.  Phentolamine, a selective a-
adrenoceptor antagonist, is used to demonstrated the presence of a-adrenoceptors.  However, 
more selective a2-adrenoceptor agonists and antagonists exist nowadays, discriminating 
between a1- and a2-adrenoceptors; selective a 2-adrenoceptor agonists are clonidine and UK-
14,304, while yohimbine and rauwolscine are selective a2-adrenoceptor antagonists.  When 
noradrenaline inhibits the release of acetylcholine, it does so by acting on presynaptic 
inhibitory a2-adrenoceptors on the cholinergic nerve endings.  Activation of these 
adrenoceptors stimulates Gi-proteins.  This Gi-protein inhibits adenylyl cyclase, resulting in a 
decrease in cyclic AMP synthesis and a decreased calcium influx via blockade of the N-type 
calcium channels; the a2-adrenoceptors can also directly open potassium channels.  These two 
mechanisms result in a reduced transmitter release via hyperpolarisation. 
Many studies, both contractility and release studies, demonstrated the presence of 
inhibitory a2-adrenoceptors on the cholinergic neurones innervating the guinea-pig ileum (e.g. 
Funk et al., 1995; Colucci et al., 1998) and distal colon (Marcoli et al. , 1989; Giaroni et al. , 
1999).  Contractility experiments suggested the presence of presynaptic inhibitory a2-
adrenoceptors on the cholinergic neurones innervating the circular muscle from the human 
distal oesophageal body (Tøttrup et al. , 1990); in human taenia coli, there is some evidence 
that presynaptic a-adrenoceptors are present inhibiting the release of acetylcholine (Del Tacca 
et al., 1970), however, it is not yet known with certainty whether these are a2-adrenoceptors.  
At the level of the stomach, it has also been demonstrated that noradrenaline reduces the 
release of acetylcholine.  In vivo experiments showed that stimulation of noradrenergic 
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neurones inhibited contractions in the cat stomach induced by stimulation of vagal cholinergic 
neurones (Jansson and Martinson, 1966; Jansson and Lisander, 1969).  In vitro, a2-
adrenoceptors have been shown to be present on postganglionic cholinergic neurones in the 
canine and rat gastric fundus (Lefebvre et al., 1984; Verplanken et al., 1984; MacDonald et 
al., 1990); there is also evidence that presynaptic a2-adrenoceptors are present on the intrinsic 
cholinergic neurones of guinea-pig gastric corpus and antrum (Schemann, 1991; Tack and 
Wood, 1992). 
 
1.3.3.  Presynaptic modulation via 5-HT4-receptors 
 
In the GI tract, 5-hydroxytryptamine (5-HT) is present in high concentrations in the 
enterochromaffin cells (ECs) of the epithelium, although some serotonergic neurones are also 
present (Racké et al. , 1991, 1996).  The luminal content is separated from the afferent nerve 
endings by the mucosal epithelium.  Luminal chemicals or increased intraluminal pressure 
cause the release of 5-HT from ECs.  The released 5-HT might act as an essential intermediate 
in reflexes initiated from the mucosa whereby 5-HT is thought to stimulate the IPANs to 
trigger the peristaltic reflex via  stimulation of 5-HT-receptors.  Seven different 5-HT-receptor 
classes have been identified, and some of these can be further divided into subclasses, 
including 5-HT1A-, 5-HT1B-,  5-HT1D-, 5-ht1E-, 5-ht1F-, 5-HT2A-,  5-HT2B-, 5-HT2C-,  5-HT3-,  5-
HT4-, 5-ht5A-, 5-ht5B-, 5-HT6- and 5-HT7-receptors (Hoyer et al., 1994; Gerhardt & van 
Heerikhuizen, 1997).  When the genes for certain 5-HT-receptors are cloned, but there 
function is not yet known, then these receptors are indicated as 5-ht-receptors.  Stimulation of 
some of these receptors influences GI motility.  For instance, 5-HT3-receptor antagonists were 
shown to moderately accelerate gastric emptying in man (Akkermans et al., 1988), delay 
colonic transit in humans (Houghton et al., 2000) and lengthen the MMC time interval in rat 
small intestine (Lördal & Hellstrom, 1999) suggesting that 5-HT3-receptors play a stimulatory 
or inhibitory role in the control of GI motility, depending on the region of the GI tract. 
An important 5-HT-receptor in the GI tract is the 5-HT4-receptor, described for the 
first time in mouse embryo colliculi neurones (Dumuis et al., 1988).  5-HT4-receptors are 
positively linked with adenylyl cyclase, increasing the concentration of cyclic AMP (Hoyer et 
al., 1994; Gerhardt & van Heerikhuizen, 1997).  Both selective 5-HT4-receptor agonists, e.g. 
prucalopride (Briejer et al., 2001), and antagonists, e.g. SB204070 (Wardle et al., 1994) and 
GR113808 (Gale et al., 1994), are available.  These two antagonists are very potent and 
selective (Ford & Clarke, 1993), especially GR113808 that lacks antagonist affinity at other 
 38
5-HT-receptor subtypes, except at the 5-HT3-receptor although the affinity is much lower than 
at the 5-HT4-receptor (Gale et al., 1994).  In the GI tract, 5-HT4-receptors can have a clearly 
distinct location and function.  Muscular 5-HT4-receptors are responsible for the relaxation of 
smooth muscle cells.  Relaxant 5-HT4-receptors are demonstrated on the circular muscle cells 
of canine rectum (Prins et al., 1999), human colon (Tam et al., 1994, 1995; McLean & 
Coupar, 1996; Prins et al., 2000b) and rat oesophagus and ileum (Baxter et al., 1991; 
Tuladhar et al. , 1996).  Other 5-HT4-receptors are located on cholinergic neurones, increasing 
the release of acetylcholine.  In the stomach, facilitatory 5-HT4-receptors on cholinergic 
neurones have been demonstrated in guinea-pig and rat (Buchheit & Bult, 1994; Amemiya et 
al., 1996; Matsuyama et al. , 1996), whereby a recent study suggests a regional distribution of 
neuronal 5-HT4-receptors in the guinea-pig stomach, 5-HT4-receptors being present in the 
corpus and antrum but absent in the fundus (Takada et al., 1999).  It might be expected that an 
increased release of acetylcholine due to stimulation of 5-HT4-receptors increases gastric 
emptying; indeed, in vivo cisapride and prucalopride, two 5-HT4-receptor agonists, 
accelerated human stomach emptying (Johnson, 1989; Bouras et al., 2001), although in an 
earlier study, Bouras and colleagues (1999) did not find any evidence that stimulation of 5-
HT4-receptors accelerates human gastric emptying. 
Facilitatory 5-HT4-receptors have also been demonstrated on cholinergic neurones 
innervating the longitudinal muscle layer of guinea-pig, human and canine colon (Elswood et 
al., 1991; Prins et al., 2000a), but not on cholinergic neurones innervating the circular muscle 
layer, where 5-HT4-receptors are located on the smooth muscle cells, causing relaxation (Tam 
et al., 1994, 1995; McLean & Coupar, 1996; Prins et al., 2000b).  In vivo, prucalopride 
stimulates colonic transit both in healthy people and patients with constipation (Emmanuel et 
al., 1998; Bouras et al., 1999, 2001).  This is difficult to explain as the relaxant 5-HT4-
receptors on the circular muscle would predict a decrease in colonic transit, and the increased 
contractility of the longitudinal muscle due to the stimulation of the 5-HT4-receptors on the 
cholinergic neurones is not expected to induce sufficient force to increase transit.  The precise 
mechanism of stimulation of colonic transit by 5-HT4-receptors is thus not known yet. 
 
1.3.4.  Interaction between the cholinergic and nitrergic innervation 
 
Many GI smooth muscle cells are innervated by both cholinergic and nitrergic 
neurones.  The cholinergic neurones release the neurotransmitter acetylcholine, that contracts 
the muscle cells by activating postsynaptic muscarinic receptors.  Nitrergic neurones release 
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the relaxant NO.  It can thus be expected that NO and acetylcholine will counteract each other 
at the postsynaptic level by functional antagonism.  It is therefore difficult to determine in 
functional studies measuring smooth muscle activity whether NO also inhibits presynaptically 
the release of acetylcholine from the cholinergic nerve endings.  Therefore, it is important to 
measure the release of acetylcholine directly.  The spontaneous and stimulated release of 
acetylcholine from cholinergic neurones of tissues can be measured in the presence of a 
acetylcholinesterase inhibitor, preventing the breakdown of acetylcholine.  Since the amount 
of acetylcholine released in the organ bath is too low to measure as such, it is necessary to 
concentrate the samples by lyophilization, before it is possible to analyse them by 
chromatography (e.g. Soejima et al. , 1993; Shen & Mitchelson, 2001).  Therefore, most often 
tissues are incubated with [3H]-choline to allow the cholinergic neurones to synthesise [3H]-
acetylcholine.  Without concentrating the samples, the released radioactivity upon neuronal 
activation can easily be measured and the different radioactive components released can be 
separated by HPLC to determine to what extent [3H]-acetylcholine accounts for the 
radioactivity released. 
In guinea-pig, mouse and canine small intestine, NOS inhibitors were shown to 
increase the electrically -evoked [3H]-acetylcholine release without interfering with the basal 
release (Hryhorenko et al., 1994; Kilbinger & Wolf, 1994; Kilbinger, 1996; Mang et al., 
2000).  NO donors, however, were shown to increase basal release but to inhibit the 
electrically-evoked release of [3H]-acetylcholine in guinea-pig ileum (Wiklund et al., 1993; 
Hebeib  & Kilbinger, 1996) and to inhibit electrically-evoked [3H]-acetylcholine release in 
mouse ileum (Mang et al., 2000).  The effect of NO on basal and electrically-induced release 
of acetylcholine is probably mediated via activation of soluble guanylyl cyclase.  Indeed, 
ODQ, a selective inhibitor of NO-sensitive soluble guanylyl cyclase (Garthwaite et al., 1995), 
prevented the stimulatory effect of NO donors on basal [3H]-acetylcholine release in guinea-
pig ileum (Hebeib & Kilbinger, 1996), suggesting that NO stimulates basal acetylcholine 
release from myenteric neurones through activation of guanylyl cyclase.  ODQ facilitated 
electrically-induced release of [3H]-acetylcholine in guinea-pig ileum, an effect that was 
prevented by NOS inhibitors (Hebeiss & Kilbinger, 1998), suggesting that endogenous NO 
activates soluble guanylyl cyclase, leading to inhibition of acetylcholine release.  YC-1, a 
NO-independent activator of soluble guanylyl cyclase (Wu et al., 1995), indeed inhibited the 
electrically-induced [3H]-acetylcholine release in guinea-pig ileum (Hebeiss & Kilbinger, 
1998).  Also in mouse ileum, ODQ stimulated electrically -evoked [3H]-acetylcholine release 
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(Mang et al., 2000).  These results indicate that NO interferes with acetylcholine release via  
soluble guanylyl cyclase. 
In other GI tissues however, no evidence was found that NO interferes with 
acetylcholine release.  In guinea-pig taenia coli, the release of [3H]-acetylcholine was 
unaffected by either a NOS inhibitor or a NO donor (Ward et al., 1996), arguing against a 
presynaptic effect of NO on acetylcholine release.  Also in canine proximal colon and 
opossum lower oesophageal sphincter, no evidence was found in favour of a presynaptic 
action of NO on cholinergic nerve endings (Cellek & Moncada, 1997; Rae et al., 1998), 
indicating that NO might only interfere with cholinergic neurotransmission by functional 
antagonism at the postsynaptic level.   
At the level of the stomach, functional experiments suggested that NO inhibits 
acetylcholine release from cholinergic neurones.  NOS inhibitors were shown to enhance 
electrically-induced cholinergic contractions in smooth muscle strips of the rat and rabbit 
gastric fundus (Lefebvre et al., 1992b; Baccari et al., 1993, 1994) and contractions of the 
rabbit stomach, induced by vagal stimulation in vivo  (Iversen et al., 1997).  An in vivo 
experiment in dog gastric fundus suggested that NO inhibits presynaptically acetylcholine 
release from cholinergic nerve endings as the NOS inhibitor L-NNA increased fundic tone, an 
effect that was prevented by prior atropine administration (Paterson et al., 2000).  However, 
these functional experiments cannot exclude that NO solely interferes with cholinergic 
contractions by functional antagonism of acetylcholine at the level of the muscle cells.  In 
guinea-pig gastric fundus, conflicting results were found as Sotirov and colleagues (1999) 
described that L-NNA inhibited electrically-induced [3H]-acetylcholine release, indicating 
that NO facilitates acetylcholine release.  Milenov & Kalfin (1996), however, could not find 
evidence for a nitrergic modulation of acetylcholine release in guinea-pig gastric fundus as L-
NAME was without effect on [3H]-acetylcholine release.   
As mentioned before, VIP is often co-released with NO, and activation of presynaptic 
VIP-receptors on cholinergic neurones might inhibit the release of acetylcholine from the 
cholinergic nerve endings.  A functional study showed that VIP inhibits cholinergic 
contractions in rabbit stomach (Baccari et al., 1994) but this effect of VIP on the cholinergic 
contractions can be due to functional antagonism.  In guinea-pig stomach, VIP inhibited the 
electrically-evoked cholinergic contractions as well as the release of [3H]-acetylcholine 
(Milenov et al., 1991); in LMMP preparations of guinea-pig ileum, VIP and pituitary 
adenylate cyclase-activating polypeptide (PACAP), the latter belonging to the VIP family, 
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increased basal and inhibited electrically -induced [3H]-acetylcholine release (Katsoulis et al., 
1993). 
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CHAPTER  2 
INVESTIGATION OF THE INTERACTION BETWEEN 
CHOLINERGIC AND NITRERGIC NEUROTRANSMISSION IN THE 
PIG GASTRIC FUNDUS 
 
2.1 Summary 
 
The interaction between the cholinergic and nitrergic innervation was investigated in circular 
muscle strips of the pig gastric fundus.  In physiological salt solution containing 4x10-6 M 
guanethidine, electrical field stimulation (EFS; 40 V, 0.5 ms, 0.5 - 32 Hz, 10 s at 4 min 
intervals) induced small transient relaxations at 0.5 - 4 Hz, and large frequency-dependent 
contractions, sometimes followed by off-relaxations, at 8 - 32 Hz.  In the presence of L-NG-
nitroarginine methyl ester (L-NAME; 3x10-4 M) or physostigmine (10-6 M), relaxations were 
reversed into contractions and contractions were enhanced.  Physostigmine added to L-
NAME further enhanced contractions, while addition of L-NAME to physostigmine had no 
additional effect.  Off-relaxations were enhanced in the presence of L-NAME and 
physostigmine.  L-NAME and physostigmine consistently increased basal tone.  Tissues 
contracted by 5-hydroxytryptamine or by acetylcholine responded to EFS in a similar way as 
in basal conditions and L-NAME reversed the relaxations at the lower stimulation frequencies 
into contractions and enhanced the contractions at the higher stimulation frequencies.  Off-
relaxations in the presence of L-NAME were partially reduced by a-chymotrypsin (10 U    
ml-1).  In the absence of physostigmine, the concentration-response curve to exogenous 
acetylcholine was not influenced by L-NAME.  Contractions of the same amplitude induced 
by EFS at 4 Hz and by exogenous acetylcholine were either decreased or enhanced to the 
same extent by sodium nitroprusside (SNP; 10-5 M), depending upon the degree of relaxation 
by SNP.  These experiments suggest that endogenous nitric oxide interferes with cholinergic 
neurotransmission in the pig gastric fundus by functional antagonism at the postjunctional 
level.  The interaction is independent of the degree of contraction. 
 
2.2. Introduction 
 
The gastric fundus is innervated both by excitatory cholinergic neurones and by      
non-adrenergic non-cholinergic (NANC) inhibitory neurones, the latter being the final 
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effectors of the vagally mediated gastric receptive relaxation (Abrahamsson, 1986).  Both 
vasoactive intestinal polypeptide (VIP) and nitric oxide (NO) have been proposed as NANC 
neurotransmitters in the proximal part of the stomach (Lefebvre, 1993).  Whereas in species 
such as the rat and the ferret, NO is mainly involved in short-lasting relaxations and in 
initiating sustained relaxations (Li & Rand, 1990; D’Amato et al., 1992; Grundy et al., 1993), 
in other species such as the guinea-pig it is also the predominant neurotransmitter during 
sustained relaxation (Lefebvre et al., 1992a; Desai et al., 1994).  The vagal preganglionic 
efferent fibers to the stomach seem centrally organised in a reciprocal manner: when the 
efferents supplying the intramural cholinergic neurones are active, the discharge in those 
supplying the intramural inhibitory NANC neurones is suppressed, and vice versa (Andrews, 
1990).  Besides this central interaction between the two pathways, interaction might also 
occur between the nitrergic and cholinergic system at the level of the stomach.  NO synthase 
inhibitors were shown to enhance electrically-induced cholinergic contractions in smooth 
muscle strips of the rat, guinea-pig and rabbit gastric fundus (Lefebvre et al., 1992b; Baccari 
et al., 1993; Milenov & Kalfin, 1996) and contractions of the rabbit stomach, induced by 
vagal stimulation in vivo (Iversen et al., 1997).  In the guinea-pig small intestine, NO donors 
were shown to increase the basal release but to inhibit the electrically-induced release of [3H]-
acetylcholine (Hebeib & Kilbinger, 1996). 
The pig is a good non-primate model for studying human digestive function in view of 
the similarity of the morphology and physiology of the gastrointestinal tracts (Miller & 
Ullrey, 1987).  The pig gastric fundus is innervated by excitatory cholinergic and inhibitory 
NANC neurones (Ohga & Taneike, 1977; Miyazaki et al., 1991) and NO is a major 
contributor to NANC relaxation (Lefebvre et al., 1995).  The aim of this study in the pig 
gastric fundus was to investigate the interaction between the cholinergic and nitrergic 
innervation. 
 
2.3. Methods 
 
2.3.1. Tissue preparation 
 
Experiments were carried out on isolated circular smooth muscle strips of the pig 
gastric fundus.  The stomach was removed from healthy castrated male pigs, slaughtered at a 
local abattoir, and transported to the laboratory in ice-chilled physiological salt solution 
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(PSS).  After the mucosa was removed, strips of approximately 1.5 cm in length and 0.3 cm in 
width were cut in the direction of the circular muscle, with a maximum of eight strips from 
one pig gastric fundus.  All strips were used the same day.  Strips were mounted vertically 
between two platinum plate electrodes under a load of 2 g in 20 ml organ baths containing 20 
ml of PSS (mM: 112 NaCl, 4.7 KCl, 1.2 MgCl2, 1.2 KH2PO4, 2.5 CaCl2, 11.5 glucose and 25 
NaHCO3), maintained at 37°C and gassed with carbogen.  Guanethidine (4x10-6 M) was 
present in the medium throughout all experiments.  The mechanical activity of the 
preparations was recorded via isotonic transducers (T3, Palmer Bioscience, U.S.A.) on a 
recorder (FWR 3701 Graphtec Linearcorder or MC6625 Graphtec Multicorder, Japan).  
Electrical field stimulation (EFS) was applied by means of a S88 stimulator (Grass, U.S.A.).  
The tissues were allowed to equilibrate for 90 min with rinsing every 15 min before starting 
the experiment. 
 
2.3.2. Evaluation of the cholinergic-nitrergic interaction 
 
In all these experiments, strips were first maximally contracted with 80 mM KCl, 
followed by rinsing every 10 min during 30 min.  EFS was applied to the tissues (40 V, 0.5 
ms, 10 s trains, 0.5 - 32 Hz, with an interval of 4 min).  Two, or in some experiments three, 
frequency-response curves were obtained with an interval of at least 1 h in between.  The 
tissues were incubated in the presence of agents for 30 min.  The responses in parallel time 
control experiments were reproducible unless otherwise stated. 
A first set of experiments was performed to study the effect of L-NG-nitroarginine 
methyl ester (L-NAME), physostigmine, and their combination on the electrically -induced 
responses.  Three frequency-response curves were obtained in two parallel tissues.  
Physostigmine (10-6 M) or L-NAME (3x10-4 M) was added before the second curve.  Before 
the third curve, L-NAME was added to the medium containing physostigmine, and 
physostigmine to the medium containing L-NAME.  To study the influence of tetrodotoxin 
(TTX; 3x10-6 M), atropine (10-6 M) and hexamethonium (5x10-4 M), two frequency-response 
curves were obtained before and after addition of these agents.  This was done in three 
conditions: PSS only containing guanethidine as in all experiments, and PSS where in 
addition to guanethidine L-NAME (3x10-4 M) or L-NAME (3x10-4 M) plus physostigmine 
(10-6 M) were present from the beginning of the experiment.  The influence of TTX was also 
studied in tissues, only stimulated at 16 and 32 Hz. 
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As EFS induced off-relaxations at the higher frequencies of stimulation, that were 
even enhanced in the presence of L-NAME, the influence of 10 U ml-1 a-chymotrypsin was 
studied on these off-relaxations in the presence of L-NAME.  As a -chymotrypsin induced a 
pronounced contraction, the off-relaxations were also evaluated in parallel tissues, contracted 
to the same extent by use of 5-hydroxytryptamine (5-HT). 
As it has been shown that the cholinergic-nitrergic interaction can be influenced by the 
degree of contraction of the tissues and by the contractile agent used (Baccari et al., 1997), 
frequency-response curves were also obtained in tissues contracted with 5-HT or 
acetylcholine.  In a first set, after the maximal contraction with KCl and rinsing, the tissues 
were contracted with 3x10-7 M 5-HT and, once a stable plateau was obtained, electrically 
stimulated (40 V, 0.5 ms, 10 s, 0.5 - 32 Hz at 4 min interval).  This cycle was repeated twice.  
L-NAME (3x10-4 M) or atropine (10-6 M) was added before the second cycle.  Before the 
third cycle, atropine was added to the medium already containing L-NAME and L-NAME to 
the medium containing atropine.  In a second set, tissues were contracted with acetylcholine 
in a concentration to mimic the contraction amplitude obtained with 3x10-7 M 5-HT in the 
previous set.  In these conditions, the influence of 3x10-4 M L-NAME was studied on the 
electrically-induced responses. 
Cumulative concentration-response curves to acetylcholine (10-9 - 3x10-4 M) were 
obtained before and after (30 min) addition of 5x10-4 M hexamethonium and 3x10-4 M L-
NAME.  The interval between the two curves was at least 1 h 30 min.  The influence of L-
NAME on exogenous acetylcholine was also studied in the continuous presence of 10-6 M 
physostigmine. 
To study the influence of sodium nitroprusside (SNP) on contractions induced by EFS 
and exogenous acetylcholine, the following protocol was used.  L-NAME (3x10-4 M) was 
present throughout the experiment.  Tissues were stimulated three times (40 V, 0.5 ms, 4 Hz, 
10 s, 4 min interval); after rinsing, acetylcholine was administered in increasing 
concentrations to select the concentration, inducing a similar contraction amplitude as EFS at 
4 Hz.  After another rinsing interval, this concentration was repeated.  After further rinsing, 
six parallel tissues received SNP (10-5 M; 4 strips) or its solvent (2 strips).  In three of the 
SNP-treated tissues, acetylcholine was administered when the maximal relaxation by SNP 
was reached or 20 or 40 min later respectively.  The control solvent-treated tissue was 
contracted three times with acetylcholine, with rinsing in between, at moments corresponding 
to the administration of acetylcholine in the three parallel strips.  In the fourth SNP-treated 
tissue, EFS was applied 15 times at 4 Hz (10 s) with 4 min intervals, starting when the 
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maximal relaxation by SNP was reached.  The control solvent-treated tissue was stimulated at 
the same moments as the SNP-treated tissues. 
 
2.3.3. Data analysis 
 
Experimental data are expressed as means ± s.e.mean and n  refers to the number of the 
tissues from different animals.  All results are expressed as percentage of the maximal KCl-
induced contraction.  When the response during electrical stimulation was not monophasic, 
the amplitude of the first phase is taken into account.  Off-relaxations are measured from the 
tone level present before the start of the stimulation until maximal relaxation.  Results within 
the same tissues were compared by the paired t-test or by ANOVA followed by a t-test 
corrected for multiple comparisons (Bonferroni procedure) when more than two responses 
had to be compared; results in different groups of tissues were compared by the unpaired t-
test.  P values of less than 0.05 were considered statistically significant. 
 
2.3.4. Drugs used 
 
Acetylcholine chloride, atropine sulphate, guanethidine sulphate, L-NG-nitroarginine 
methyl ester and sodium nitroprusside were obtained from Sigma (St. Louis, U.S.A.), 5-
hydroxytryptamine creatinine monosulphate from Janssen Chimica (Geel, Belgium), 
physostigmini salicylas from Federa (Brussels, Belgium), tetrodotoxin from Alomone labs 
(Jerusalem, Israel) and from Sigma. 
Drugs were dissolved and diluted with distilled water.  Stock solutions of 10-3 M TTX 
were kept frozen at -20°C and dilutions were made the day of the experiment. 
 
2.4. Results 
 
The tone of the tissues decreased during the first 30 min of the equilibration period, 
after which tone tended to increase during the course of the experiment.  In control tissues, the 
responses to three consecutive frequency-response curves (40 V, 0.5 ms, 0.5 - 32 Hz, 10 s, 4 
min interval) were reproducible (n = 14).  EFS induced small transient relaxations at the 
lowest frequencies (0.5 - 4 Hz).  After the 10 s period of stimulation, tone returned to the pre-
stimulation level at a slower rate than it had declined.  Occasionally, the relaxation was 
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preceded by a very small contraction.  Stimulation at the highest frequencies (8 - 32 Hz) 
induced large fast frequency-dependent contractions (Figure 2.1A and 2.2A,B).  After 
stimulation, tone declined as quickly as it had risen and sometimes, it decreased to a lower 
level than present before stimulation.  These decreases of tone will be indicated as off-
relaxations. 
 
2.4.1. Influence of L-NAME and physostigmine on the electrically-induced responses 
 
The administration of 3x10-4 M L-NAME induced an increase in resting tone of the 
tissues (31 ± 5 %, n = 14).  L-NAME (3x10-4 M) reversed the relaxations at the lowest 
stimulation frequencies into contractions (for example, at 2 Hz the relaxation of 7 ± 3 % 
changed to a contraction of 24 ± 7 %).  At the higher stimulation frequencies (8 - 32 Hz), L-
NAME enhanced the contractions, although the increase only reached significance at 8 Hz 
(Figure 2.1B and 2.2A). At the frequencies 4 - 32 Hz, the contractions were followed by off- 
 
Figure 2.1  Representative traces from 1 tissue showing the responses to EFS (40 V, 0.5 ms, 0.5 - 32 Hz) with 
10 s trains before (A) and after addition of 3x10-4 M L-NAME (B) and 10-6 M physostigmine in the continuous 
presence of L-NAME (C).  KCl indicates the addition of 80 mM KCl, R indicates rinsing.  Upon rinsing after the 
second trace, L-NAME was added again.  During the incubation with L-NAME and physostigmine, the paper 
speed was reduced 2.5 fold.  
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relaxations, with a maximum at 16 Hz (Figure 2.2C).  The less pronounced off-relaxation by 
stimulation at 32 Hz is probably due to the decreased tone level by the preceding off-
relaxations.  When physostigmine (10-6 M) was added to the medium already containing L-
NAME, the tone further increased by 9 ± 4 % (n = 14).  In the presence of L-NAME and 
physostigmine the contractions at the lowest stimulation frequencies further increased, and 
this was significant at 1 and 2 Hz.  Also, after stimulation, tone declined at a slower rate than 
it had increased.  In the presence of both substances, the contractions at all frequencies were 
significantly enhanced compared to responses in the absence of any drug (Figure 2.1C and 
2.2A).  The off-relaxations further increased , reaching significance at 2 and 4 Hz.  At the 
stimulation frequencies 2 - 16 Hz the off-relaxations were significantly enhanced compared to 
off-relaxations in the absence of both drugs (Figure 2.2C) (n = 14 for all observations).  
In a parallel set of tissues, the order of administration of physostigmine and L-NAME 
was reversed.  The addition of physostigmine (10-6 M) increased the tone by 20 ± 5 % (n = 
14).  In the presence of physostigmine, contractions occurred at the frequencies tissues 
responded to EFS with relaxation in its absence, and the contractions at higher frequencies 
were significantly potentiated (Figure 2.2B); the off-relaxations were enhanced (Figure 2.2D).  
Addition of L-NAME (3x10-4 M) to tissues already incubated with physostigmine increased 
tone by 54 ± 7 % (n = 14); this increase was more pronounced than when L-NAME was 
administered before adding physostigmine in the first series (P  < 0.01).  L-NAME had no 
additional effect on the electrically-induced responses compared to those in the presence of 
physostigmine alone (Figure 2.2B,D). 
 
2.4.2. Influence of hexamethonium, atropine and TTX on the electrically-induced responses 
 
Hexamethonium (5x10-4 M), atropine (10-6 M) and TTX (3x10-6 M) did not influence 
the basal tone in the three conditions tested.  Hexamethonium had no influence on the 
responses to EFS in any of the conditions examined. 
In medium containing guanethidine, atropine prevented the contractions at the higher 
stimulation frequencies and frequency-dependent relaxations occurred  over the whole 
frequency range, except at 32 Hz where the relaxation amplitude decreased (Figure 2.3A).  No 
off-relaxations occurred in the presence of atropine.  In medium with guanethidine and L-
NAME, EFS induced frequency-dependent contractions.  In the presence of atropine, tissues 
responded with frequency-dependent relaxations at the stimulation frequencies 0.5 - 4 Hz 
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(Figure 2.3C).  At the frequencies 8 - 32 Hz, the responses to EFS became very variable 
(contraction followed by relaxation, n = 3; relaxation, partial recovery of tone, sustained 
relaxation, n = 2; pure relaxation, n = 1).  In medium with guanethidine, physostigmine and L-
NAME, atropine abolished the contractile responses at 0.5 - 4 Hz, while the contractions at 8 - 
32 Hz were significantly reduced (Figure 2.3E).  In the presence of atropine, off-relaxations 
were significantly reduced at 8 Hz, equal at 16 Hz and significantly increased at 32 Hz. 
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Figure 2.2  Mean ± s.e.mean (n = 14) frequency-response curves for the primary responses (A,B) and off-
relaxations (C,D) to EFS (40 V, 0.5 ms, 0.5 - 32 Hz) with 10 s trains in circular muscle strips of the pig gastric 
fundus.  Responses were obtained (A,C) in the absence and presence of 3x10-4 M L-NAME, and of 3x10-4 M L-
NAME plus 10-6 M physostigmine; and (B,D) in the absence and presence of 10-6 M physostigmine, and of 10-6 
M physostigmine plus 3x10-4 M L-NAME.  The X-axis shows the frequency on a log-2-scale.  * P < 0.05; ** P  
< 0.01: Significantly different from the response before addition of L-NAME (A) or physostigmine (B,D).  + P  < 
0.05; ++ P  < 0.01: Significantly different from the response in the presence of L-NAME (A,C).  #  P  < 0.05; ##  P  
< 0.01: Significantly different from the response in the absence of L-NAME and physostigmine (A - D). 
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Figure 2.3  Mean ±  s.e.mean frequency-response curves for the primary responses to EFS (40 V, 0.5 ms, 0.5 - 32 
Hz) with 10 s trains in circular muscle strips of the pig gastric fundus.  The medium contained 4x10-6 M 
guanethidine (A,B) (n = 6); 4x10-6 M guanethidine and 3x10-4 M L-NAME (C,D) (n = 6); 4x10-6 M 
guanethidine, 3x10-4 M L-NAME and 10-6 M physostigmine (E,F) (n = 8).  Responses were obtained in the 
absence and presence of 10-6 M atropine (A,C,E) and in the absence and presence of 3x10-6 M TTX (B,D,F).  In 
C, the responses at the frequencies 8 - 32 Hz in the presence of atropine became very complex and inconsistent 
and are described in the text. The X-axis shows the frequency on a log-2-scale.  * P < 0.05; ** P < 0.01: 
Significantly different from the response before addition of atropine (A,C,E) or TTX (B,D,F). 
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In the three conditions tested, TTX nearly abolished the responses at the frequencies 
up to 4 Hz.  However, at the higher frequencies, small contractions still occurred (Figure 
2.3B,D and F).  This was not due to the long incubation time of TTX before stimulation at 16 
and 32 Hz was performed, as the TTX-resistant contractions were also observed in tissues 
only stimulated at 16 and 32 Hz (n = 4, results not shown).  
 
2.4.3. Influence of a-chymotrypsin on off-relaxations 
 
As described previously, off-relaxations were maintained in the presence of L-NAME, 
suggesting that they are not nitrergic in origin.  To study if they were peptidergic, the 
influence of the peptidase a-chymotrypsin (10 U ml-1) was studied on the off-relaxations in a 
medium containing 3x10-4 M L-NAME.  In two parallel strips, one frequency-response curve 
was applied.  When a-chymotrypsin was added, it induced a 51 ± 6 % (n  =  8) increase in 
basal tone.  To mimic this increase, 5-HT was added to parallel strips to cause a similar 
increase in tone (51 ± 7 %, n  = 8).  Off-relaxations in the presence of a-chymotrypsin were 
reduced at all frequencies applied, except at 32 Hz, compared with tissues contracted with 5-
HT (3 ± 1, 8 ± 3, 19 ± 4, 26 ± 4 and 19 ± 5 % at 2, 4, 8, 16 and 32 Hz in tissues contracted 
with 5-HT, n  = 8; 0, 3 ± 1, 8 ± 2 [P < 0.05], 15 ± 2 [P < 0.05] and 17 ± 3 % in the presence of 
a-chymotrypsin, n = 8). 
 
2.4.4. In fluence of L-NAME and atropine on electrically-induced responses in contracted 
tissues  
 
Representative experiments of tissues contracted with 5-HT are shown in Figure 2.4.  
Addition to the bath medium of 3x10-7 M 5-HT induced stable contraction plateaus (57 ± 4 % 
of the maximal KCl-induced contraction, n  = 24).  Following rinsing, tone did not fully return 
to its original level.  The contraction induced by the second and third administration of 5-HT 
attained 85 ± 6 % and 64 ± 6 % (n = 6), respectively, of the first contraction with 5-HT. 
When EFS (40 V, 0.5 ms, 0.5 - 32 Hz, 10 s at 4 min intervals) was applied during the 
first contraction plateau, fast relaxations occurred at the stimulation frequencies 0.5 - 4 or 8 
Hz (Figure 2.4A,D).  Relaxations were larger than when tissues were not contracted (see 
Figure 2.1A).  At the frequencies 16 and 32 Hz, frequency-dependent contractions 
consistently occurred (Figure 2.4A,D), and they were followed by off-relaxations.  
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Administration of L-NAME (3x10-4 M) before the second administration of 5-HT increased 
resting tone by 28 ± 8 % (n = 6).  L-NAME unmasked frequency-dependent contractions at 
the frequencies tissues responded to EFS with relaxation in its absence, and the contractions 
at higher frequencies were enhanced (Figure 2.4B).  Contractions were followed by off-
relaxations, already appearing at 0.5 Hz.  When atropine (10-6 M) was added to the medium 
already containing L-NAME, tone was not further changed.  Atropine completely abolished 
contractions: small relaxations at all frequencies, except at 32 Hz, occurred.  At 32 Hz small 
contractions occurred, followed by off-relaxations (Figure 2.4C). 
 
Figure 2.4  Representative traces from two tissues of the same animal showing the responses to EFS (40 V, 0.5 
ms, 0.5 - 32 Hz) with 10 s trains when tissues were contracted by 3x10-7 M 5-HT.  The responses in one tissue 
are shown before addition (A) and after addition of 3x10-4 M L-NAME (B), and of 3x10-4 M L-NAME plus 10-6 
M atropine (C).  In the second tissue, responses are shown before (D) and after addition of 10-6 M atropine (E), 
and of 10-6 M atropine plus 3x10-4 M L-NAME (F). 
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When the influence of atropine (10-6 M) was studied first, large frequency-dependent 
relaxations were obtained, followed by an off-contraction (Figure 2.4E).  When L-NAME 
(3x10-4 M) was administered to strips that previously received atropine, basal tone rose by 23 
± 5 % (n = 6), and the relaxations were reduced (Figure 2.4F); the responses were similar as 
when atropine was added after L-NAME (see Figure 2.4C). 
When tissues were contracted by acetylcholine, added at a concentration to mimic the 
contraction amplitude caused by 3x10-7 M 5-HT, tissues reached a stable contraction plateau.  
Following rinsing, the resting tone was not completely regained.  The contraction induced by 
the second addition of acetylcholine attained 77 ± 7 % of the first contraction by acetylcholine 
(n = 16).  The response to EFS and the influence there upon of 3x10-4 M L-NAME was the 
same as when tissues were contracted with 5-HT (n  = 8, results not shown). 
 
2.4.5. Influence of hexamethonium and L-NAME on the contractions by exogenous 
acetylcholine 
 
Administration of acetylcholine (10-9 - 3x10-4 M) induced sustained concentration-
dependent contractions.  In the presence of physostigmine, the concentration-response curve 
of acetylcholine was shifted to the left (EC50: 2.8 ± 1.0 x 10-6 M in the absence and 6.5 ± 1.3 x 
10-8 M in the presence of physostigmine; n = 12, P  < 0.01). 
In the absence of physostigmine, the contractions by acetylcholine were reproducible 
in control tissues.  The responses were not influenced by 5x10-4 M hexamethonium (n = 4) 
nor by 3x10-4 M L-NAME, that increased basal tone by 26 ± 6 % (n  = 6). 
In the presence of physostigmine, the contractions by acetylcholine were not fully 
reproducible as the responses to 3x10-8 till 3x10-7 M acetylcholine were significantly reduced 
upon a second administration in the control tissues (P < 0.05; n = 6).  L-NAME (3x10-4 M) 
reduced the contractions significantly (P  < 0.01) from 3x10-8 M acetylcholine onwards.  The 
decrease of the maximal response to acetylcholine (from 112 ± 5 to 66 ± 8 %, n  = 6) 
mimicked the increase in basal tone occurring after the addition of L-NAME (49 ± 4 %, n = 
6). 
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2.4.6. Influence of SNP on electrically and acetylcholine-induced contractions 
 
To study the influence of exogenous NO, the effect of 10-5 M SNP was investigated in 
medium containing 3x10-4 M L-NAME.  The solvent of SNP, added after obtaining the initial 
responses to electrical stimulation at 4 Hz and to acetylcholine, had no effect on basal tone.  
When the tissues were stimulated 15 times at 4 Hz at 4 min intervals, the responses were 
decreased as compared to that obtained before the addition of solvent (66 ± 18 % at the first 
stimulation, 50 ± 20 % at the 15th stimulation, n = 7).  The decrease was significant (P  < 0.05) 
at the 14th and 15th stimulation.  The responses to electrical stimulation in the presence of SNP 
depended upon the degree of relaxation induced by SNP.  In three tissues out of seven, SNP 
decreased the basal tone by 56 ± 11 %.  The contractile response to the first and second 
stimulation at 4 Hz after reaching the maximal relaxation by SNP, was significantly decreased 
to 41 ± 3 % and 65 ± 2 %, respectively, as compared to the response before addition of SNP; 
the contraction amplitude then progressively increased during the following stimulations and 
was no longer significantly different from the response before SNP.  In the four other tissues, 
SNP decreased the basal tone by 113 ± 7 % and the response to the first till sixth stimulation 
at 4 Hz (162 ± 11, 234 ± 16, 266 ± 26, 296 ± 44, 313 ± 59 and 312 ± 64 %) was significantly 
increased in comparison to the response before SNP (P  < 0.05 except for the 2nd and 3rd 
stimulation where P < 0.01).  
In control tissues, the responses to the three additions of acetylcholine in the presence 
of the solvent of SNP were reproducible (Figure 2.5A).  The responses to acetylcholine in the 
presence of SNP were again dependent on the degree of relaxation induced by SNP.  In the 
tissues of three animals out of seven, SNP decreased the basal tone by 58 - 67 %.  When 
acetylcholine was administered immediately when the maximal relaxation by SNP was 
reached, the response was significantly decreased to 23 ± 13 % (P  < 0.05, unpaired t-test, n  = 
3; Figure 2.5B).  When acetylcholine was administered 20 or 40 min after reaching the 
maximal relaxation by SNP, the amplitude of the contraction was not significantly different 
from that before addition of SNP (n = 3 for both; Figure 2.5C and D, respectively).  In the 
tissues of four other animals, SNP decreased the tone by 106 - 118 %.  In this case, the 
response to acetylcholine tended to be more pronounced than before administration of SNP: 
151 ± 28 %, 191 ± 23 % (P < 0.05) and 222 ± 42 % at 0, 20 and 40 min, respectively, after 
reaching the maximal relaxation by SNP. 
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Figure 2.5  Representative traces from four tissues of the same animal showing the effect of acetylcholine (ACh) 
administered before and 0 (B), 20 (C) or 40 (D) min after the SNP-induced relaxation attained maximum.  The 
solvent was added to the control tissue (A), which was contracted by acetylcholine at time points corresponding 
with the three other tissues.  R indicates rinsing. 
 
2.5. Discussion 
 
The aim of this study was to investigate the interaction of the nitrergic and cholinergic 
innervation in the pig gastric fundus, by investigation of the responses to electrical field 
stimulation in the presence of guanethidine to exclude adrenergic influences.  The responses 
studied were due to activation of postganglionic neurones, as the nicotinic receptor antagonist 
hexamethonium had no influence and the sodium channel blocker TTX abolished them except 
 
 66
for a small contractile response with stimulation at 16 and 32 Hz.  At these frequencies, some 
direct smooth muscle cell activation might thus contribute to the responses.  Alternatively, 
some transmitter release not involving conducted action potentials might occur at the nerve 
endings. 
The inhibition of the relaxant responses by the NO synthase inhibitor L-NAME and of 
the contractile responses by the muscarinic antagonist atropine confirm that the principle 
neurotransmitters involved are the relaxant NO and the contractile acetylcholine (Miyazaki et 
al., 1991; Lefebvre et al., 1995).  It has been suggested that L-NAME is able to antagonise 
muscarinic receptors (Buxton et al., 1993) but the opposite effect of L-NAME versus atropine 
in the pig gastric fundus clearly illustrates that this is not the case in this tissue.  Both 
transmitters are released at all stimulation frequencies, but the nitrergic contribution is 
dominant at the lower frequencies of stimulation, while the cholinergic contribution is 
dominant at the highest frequencies, corresponding to what has been observed in the opossum 
lower oesophageal sphincter (Cellek & Moncada, 1997).  Upon concomitant release, NO and 
acetylcholine functionally antagonise each other.  It has also been shown that NO is able to 
modulate cholinergic responses by prejunctional inhibition of acetylcholine release in the 
guinea-pig ileum (Wiklund et al., 1993; Kilbinger & Wolf, 1994; Hebeib & Kilbinger, 1996), 
canine ileum (Hryhorenko et al., 1994) and rat trachea (Sekizawa et al., 1993).  Two lines of 
results in the pig gastric fundus suggest that the potentiating effect of L-NAME on the 
electrically-induced contractions reflects only functional antagonism of acetylcholine by NO.  
First, the effect of L-NAME was studied on contractions by exogenous acetylcholine.  The 
latter are related to activation of muscarinic receptors as hexamethonium had no influence; 
some degree of activation of neurones via ganglionic nicotinic receptors is thus excluded.  In 
the absence of physostigmine, the acetylcholine-induced contractions were not influenced by 
L-NAME, excluding a  non-specific potentiating effect of L-NAME on acetylcholine-induced 
contractions.  The cholinesterase inhibitor physostigmine potentiated the contractions to 
acetylcholine as expected in view of the previously demonstrated presence of cholinesterase 
in the tissue (Miyazaki et al.; 1991).  In the presence of physostigmine, L-NAME even 
reduced the responses to the higher concentrations of acetylcholine but this is probably related 
to the pronounced increase in tone by L-NAME in these conditions.  Second, the influence of 
exogenous NO (SNP) was studied on electrically and acetylcholine-induced contractions.  
The influence of SNP on the responses was clearly dependent on the degree of relaxation 
induced by SNP as no inhibition of the cholinergic contractions was observed in tissues that 
showed a pronounced relaxation to SNP.  However, in tissues moderately relaxing to SNP, 
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the cholinergic contractions were inhibited but the inhibition of the acetylcholine-induced 
responses was as pronounced as that of the electrically-induced ones and showed the same 
recuperation with time.  In case of a prejunctional effect, a more pronounced inhibition of the 
electrically-induced contractions is expected.  The conclusion that the interaction between NO 
and acetylcholine in the pig gastric fundus is only localized at the postjunctional level 
corresponds with what was shown in the opossum lower oesophageal sphincter (Cellek & 
Moncada, 1997), the guinea-pig gastric fundus (Milenov & Kalfin, 1996), the guinea-pig 
trachea (Brave et al., 1991) and human airways (Ward et al., 1993) and illustrates that the 
type of interaction depends on the species and tissue. 
The augmentation of the electrically-induced contractions upon NO synthase 
inhibition with L-NAME was not maximal as the contractions were further increased by 
cholinesterase inhibition with physostigmine.  However, in the presence of physostigmine, the 
contractile response at each frequency seems maximal as the further addition of L-NAME had 
no influence even at the lower frequencies where NO is predominant in the absence of 
inhibitors.  Thus NO seems not to be able to counteract acetylcholine when the breakdown of 
the latter is inhibited.  Alternatively, the pronounced increase in tone by administration of L-
NAME in the presence of physostigmine might mask the potentiating effect of L-NAME in 
the presence of physostigmine.  A final possibility is that acetylcholine also counteracts the 
nitrergic innervation at a prejunctional level.  Inhibition of the breakdown of acetylcholine 
might then lead to a nearly complete prejunctional inhibition of NO release so that the 
addition of L-NAME has no influence.  Prejunctional inhibition of nitrergic nerves via  
muscarinic receptors has been proposed in the rat anococcygeus (Li and Rand, 1989) and  in 
monkey ciliary arteries (Toda et al. , 1998). 
In rabbit gastric corpus, the cholinergic-nitrergic interaction can be influenced by the 
degree of contraction of the tissues and by the contractile agent used (Baccari et al. , 1997).  In 
basal conditions, tissues responded to EFS (2 - 16 Hz) with contractions, that were enhanced 
by NO synthase inhibitors and abolished by atropine (Baccari et al., 1993).  When tone was 
increased by substance P or prostaglandin F2a, EFS induced relaxations, that were reversed 
into contractions by NG-nitro-L-arginine (L-NOARG).  However, in the presence of high 
concentrations of the muscarinic antagonists scopolamine or atropine, L-NOARG had no 
influence on the EFS-induced relaxations.  When tone was increased by carbachol, the EFS-
induced relaxations became progressively less sensitive to L-NOARG corresponding with the 
degree of contraction (Baccari et al., 1997).  These phenomena were not observed in the pig 
gastric fundus.  When tissues were contracted by 5-HT and acetylcholine, the same pattern of 
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electrically-induced responses was observed as in basal conditions, i.e. relaxations at low 
frequencies (with increased amplitude as the relaxant effect of NO can become more manifest 
at increased tone) and contractions at the higher frequencies, and L-NAME reversed the 
relaxations into contractions.  As tested upon contraction with 5-HT, L-NAME was able to 
almost abolish the relaxations in the presence of atropine.  Thus, in the pig gastric fundus, the 
cholinergic -nitrergic interaction does not depend upon the degree of contraction and the 
contractile agent. 
L-NAME consistently increased the tone of the tissues.  We previously observed 
(Lefebvre et al., 1995) that this effect is partially  prevented by L-arginine, suggesting that it is 
related to suppression of NO synthesis and that a tonic nitrergic inhibition is present.  Also 
physostigmine increased basal tone, suggesting that some tonic acetylcholine release is 
present.  Apparently, the amount of acetylcholine when cholinesterase is not inhibited is not 
sufficient to contribute to the tone of the tissues as atropine has no influence.  As TTX did not 
influence the tone of the tissues, tonic release of NO and acetylcholine via action potential 
conduction seems excluded but some leakage out of the nitrergic and cholinergic nerves 
might occur.  L-NAME increased basal tone significantly more in the presence of 
physostigmine.  In the porcine ileum, L-NOARG had no influence in basal conditions but it 
increased phasic activity dramatically in the presence of neostigmine (Fernández et al., 1998).  
It was suggested that basal release of NO is poor but is strongly enhanced in the presence of 
significant levels of acetylcholine. 
In the presence of atropine, only relaxations occurred at all stimulation frequencies, 
but in the concomitant presence of L-NAME small contractions sometimes occurred at the 
higher stimulation frequencies.  This probably reflects the higher levels of acetylcholine 
overcoming the muscarinic receptor antagonism, when acetylcholine is no longer functionally 
antagonised by NO.  This is also suggested by the further increase of these contractions in the 
presence of physostigmine.  In the presence of atropine and L-NAME, small relaxations were 
obtained by electrical field stimulation, suggesting the possibility of release of another non-
nitrergic inhibitory neurotransmitter.  This was still more evident from the occurrence of the 
off-relaxations that were not prevented by L-NAME.  The off-relaxations were potentiated by 
physostigmine and inhibited by atropine, suggesting that cholinergic activation is required to 
observe them.  This might imply that the cholinergic contraction induces a rebound activation 
of inhibitory neurones.  As the off-relaxations were partially reduced by the peptidase a-
chymotrypsin, a peptide seems to be involved.  A candidate is VIP, as double-labelling for 
NOS and VIP showed that both substances co-exist in a major part of the intrinsic nitrergic 
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neurones in the myentericus plexus (Lefebvre et al., 1995).  The contractile effect of a-
chymotrypsin per se, that we had observed before in the absence of L-NAME (Lefebvre et al. , 
1995) was also observed in this study in the presence of L-NAME, which itself increased the 
tone.  A contractile effect of a-chymotrypsin has also been described in the rat gastric fundus 
(Gilfoil & Kelly, 1966) and most probably reflects a non-specific action and not cleavage of a 
continuously leaking inhibitory peptide.  Even in the presence of L-NAME and a-
chymotrypsin, some degree of off-relaxation was maintained.  This might be related to 
penetration problems of a-chymotrypsin into the tissue or to a third non-peptide transmitter.  
In longitudinal muscle strips of the pig gastric fundus, ATP seems not involved (Ohga & 
Taneike, 1977). 
In conclusion, our results show that endogenous NO is able to markedly interfere with 
cholinergic neurotransmission in the pig gastric fundus most probably by functional 
antagonism of acetylcholine at the level of the smooth muscle cells. 
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CHAPTER  3 
INFLUENCE OF NITRIC OXIDE DONORS AND OF THE a2-AGONIST 
UK-14,304 ON ACETYLCHOLINE RELEASE IN THE PIG GASTRIC 
FUNDUS 
 
3.1.  Summary 
 
This study in circular muscle strips of the pig gastric fundus aimed to measure the release of 
acetylcholine directly and to investigate whether NO and a2-adrenoceptor agonists can 
modulate acetylcholine release from cholinergic neurones.  After incubation of the tissues 
with [3H]-choline, basal and electrically induced release of tritium and [3H]-acetylcholine was 
analysed in a medium containing physostigmine (10-5 M) as well as atropine (10-6 M).  The 
NO synthase inhibitor L-NG-nitroarginine methyl ester (3x10-4 M), and the NO donors sodium 
nitroprusside (10-5 M) and 3-morpholino-sydnonimine (10-5 M) did not influence the basal 
release nor the electrically evoked release, indicating that NO does not modify [3H]-
acetylcholine release.  The a2-adrenoceptor agonist UK-14,304 (10
-5 M) significantly 
inhibited the electrically evoked release of [3H]-acetylcholine, and this effect was prevented 
by the a2-adrenoceptor antagonist rauwolscine (2x10-6 M), suggesting that presynaptic a2-
adrenoceptors are present on cholinergic neurones of the pig gastric fundus. 
 
3.2.  Introduction 
 
The stomach is innervated by excitatory cholinergic neurones, by non-adrenergic non-
cholinergic (NANC) inhibitory neurones, the latter being the final effectors of the vagally 
mediated gastric receptive relaxation (Abrahamsson, 1986) and by sympathetic noradrenergic 
fibers, whose cell bodies are localized in the celiac ganglion (Baumgarten, 1982).  Nitric 
oxide (NO) has been proposed as an important inhibitory NANC neurotransmitter in the 
proximal part of the stomach (Li & Rand, 1990; Boeckxstaens et al, 1991; Desai et al. , 1991; 
Grundy et al., 1994; Meulemans et al, 1995).  In addition to its direct inhibitory effect on 
smooth muscle cells, NO might also decrease gastric motility by inhibiting the release of the 
excitatory neurotransmitter acetylcholine.  In the guinea-pig ileum, NO donors decreased 
electrically induced acetylcholine release (Hebeib & Kilbinger, 1996), while NO synthase 
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inhibitors increased acetylcholine release in the guinea-pig and canine ileum (Kilbinger & 
Wolf, 1994 ; Hryhorenko et al. , 1994), suggesting that endogenous NO reduces acetylcholine 
release.  A similar mechanism might occur at the level of the stomach, as electrically induced 
cholinergic contractions were enhanced by NO synthase inhibitors in smooth muscle strips of 
the rat and rabbit gastric fundus (Lefebvre et al., 1992; Baccari et al., 1993).  The majority of 
noradrenergic fibers, innervating the gastrointestinal tract, end on intrinsic enteric neurones 
rather than on smooth muscle cells (Jacobowitz, 1965) and exert their effect by modulating 
the activity of the intrinsic neurones.  In general, noradrenergic activity inhibits non-
sphincteric gastrointestinal smooth muscle by inhibition of acetylcholine release from 
intrinsic excitatory cholinergic motor neurones via a2-adrenoceptors (Furness & Costa, 1987; 
McIntyre & Thompson, 1992).  This has also been shown at the level of the stomach; in vivo, 
stimulation of noradrenergic nerves supplying the cat stomach inhibited contractions induced 
by stimulation of the vagal cholinergic nerves (Jansson & Martinson, 1966; Jansson & 
Lisander, 1969) and in vitro, a2- or a2-like adrenoceptors have been shown to be present on 
postganglionic cholinergic  neurones in the dog and rat gastric fundus (Lefebvre et al., 1984; 
Verplanken et al. , 1984). 
The pig is a good non-primate model for studying human digestive function in view of 
the similarity of the morphology and physiology of the gastrointestinal tracts (Miller & 
Ullrey, 1987).  The pig gastric fundus is innervated by excitatory cholinergic, sympathetic 
noradrenergic and inhibitory NANC neurones (Ohga & Taneike, 1977; Miyazaki et al., 1991) 
and NO is a major neurotransmitter of these NANC neurones (Lefebvre et al., 1995).  We 
recently studied the interaction between the cholinergic and nitrergic innervation in pig gastric 
fundus strips by measuring contractile activity; our results suggested that NO and 
acetylcholine functionally antagonise each other at the postjunctional level although 
prejunctional interaction could not be excluded (Leclere & Lefebvre, 1998).  The aim of this 
study in the pig gastric fundus was to measure acetylcholine release directly and to investigate 
the influence of NO donors, NO synthase inhibition and stimulation of a2-adrenoceptors on 
the electrically induced acetylcholine release. 
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3.3.  Methods 
 
3.3.1.  Tissue preparation  
 
Experiments were carried out on isolated circular smooth muscle strips of the pig 
gastric fundus.  The stomach was removed from healthy castrated male pigs, slaughtered at a 
local abattoir, and transported to the laboratory in ice-chilled physiological salt solution 
(PSS).  After the mucosa was removed, full thickness strips of approximately 1.5 cm in length 
and 0.3 cm in width (weight: 160 ± 5 mg; n = 92) were cut in the direction of the circular 
muscle.  All strips were used the same day.  Strips were mounted vertically between two 
platinum wire electrodes (40 mm x 0.5 mm) under a load of 2 g in 2 ml organ baths 
containing PSS (composition in mM: 112 NaCl, 4.7 KCl, 1.2 MgCl2, 1.2 KH2PO4, 2.5 CaCl2, 
11.5 glucose, 25 NaHCO3, 0.0015 choline and 0.057 ascorbic acid), maintained at 37°C and 
gassed with carbogen (95% O2 / 5% CO2).  Guanethidine (4x10
-6 M) was present in the 
medium throughout all experiments, unless otherwise stated.  Electrical field stimulation 
(EFS) was applied by means of a stimulator (S88 Grass, USA).  
 
3.3.2.  Experimental protocol 
 
During a 60 min equilibration period, the tissues were superfused at a rate of 2 ml/min, 
using a peristaltic pump (Gilson Minipuls, France).  During the last 20 min the strips were 
subjected to continuous EFS (1 ms monophasic square wave pulses, 0.5 Hz, 40 V).  After this 
equilibration period, superfusion was stopped and the preparations were incubated for 30 min 
with [3H]-choline (5 µCi/ml) during which the tissues were stimulated electrically (40 V; 2 
Hz; 1 ms) in order to label their cholinergic transmitter stores.  In preliminary experiments, 
performed in the presence of 10-5 M physostigmine, it had been found that when frequencies 
of less than 1 Hz were applied during the incubation period with [3H]-choline, no 
acetylcholine release could be detected; from 2 Hz onwards the percentage of acetylcholine 
formed reached  its maximum. 
After the labelling procedure, the strips were superfused (2 ml/min) for 90 min with 
PSS to remove loosely bound radioactivity.  From now on the PSS contained in addition 10-5 
M hemicholinium-3 to prevent the re-uptake of choline, and, unless otherwise stated, 10-5 M 
physostigmine to prevent the hydrolysis of acetylcholine and 10-6 M atropine to prevent the 
auto-inhibition of acetylcholine release. 
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After the washout period, the content of the organ bath (2 ml) was collected each 3 
min.  1 ml of the samples was mixed with 4 ml of the scintillator containing solution Ultima 
Gold (Canberra Packard, USA).  The strips were stimulated twice for 2 min (S1 and S2; 40 V, 
1 ms, 4 Hz).  S1 started 13 min (5th sample), and S2 79 min (27th sample) after the end of the 
washout period.  Drugs were added 37 min (15th sample) before S2, except for the a2-
adrenoceptor agonist, UK-14,304, which was added 4 min (26th sample) before S2 (unless 
otherwise stated) and for tetrodotoxin (TTX), w -conotoxin and calcium-free medium which 
were added or installed 34 min (16th sample) before S2, and they remained present until the 
end of the experiment.  At the end of the experiment, tissues were blotted and weighed. 
 
3.3.3.  Measurement of radioactivity and separation by HPLC of radioactive compounds 
 
Radioactivity of all samples was measured by liquid scintillation counting (Packard 
Tri-Carb 2100 TR, Canberra Packard, USA).  External standardization was used to correct for 
counting efficiency.  Electrical stimulation induced an increase in tritium overflow, in 
samples 5 up to 13 (for S1) and 27 up to 35 (for S2).  The stimulation-induced increase in 
tritium overflow was calculated by subtracting basal tritium overflow.  Basal tritium overflow 
during the period of enhanced tritium overflow was calculated by fitting a regression line 
through the values of the 4 samples just before stimulation and the values of the 4 samples 
starting from where overflow had returned to basal values after stimulation. 
The amount of [3H]-acetylcholine, [3H]-choline and [3H]-phosphorylcholine in the 
samples were analysed by reverse phase HPLC (Bischoff Chromatography, Germany; 
Hyperchrome-HPLC-column, 250 x 4.6 mm, prepacked with HYPERSIL – ODS 5.0 µm), as 
previously described (Wessler & Werhand, 1990).  A 0.1 M phosphate buffer (pH 4.7) was 
used, containing methanol (8 vol %) and tetramethylammonium (0.2 mM).  The flow was 0.5 
ml/min and the effluent was collected in one min fractions.  To estimate the retention times 
for each compound, the standards of [14C]-acetylcholine, [14C]-choline and [14C]-
phosphorylcholine were used (see Figure 3.1A and B).  
HPLC was performed on 1 basal fraction before S1 and S2 (sample 3 before S1 and 
sample 25 before S2), and on the fraction with the highest radioactivity after stimulation 
(sample 5 and 27).  100 µl of the sample was injected into the HPLC; 27 fractions were 
collected, and they were mixed with 2.5 ml of Ultima Gold.  Fractions 7 to 12 contained the 
peaks of phosphorylcholine and choline and were taken together to calculate the amount of 
phosphorylcholine and choline, as both peaks could not be separated completely with the 
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phosphate buffer we used.  Fractions 15 to 25 were summed to calculate the amount of 
acetylcholine.  The real amount of choline plus phosphorylcholine and of acetylcholine was 
calculated by subtracting the background counting.  Background counting was calculated by 
fitting a regression line through the values of the first 5 fractions and fractions 26 and 27.  
Finally, the percentage of acetylcholine in each sample was calculated. 
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Figure 3.1  Separation of radiolabelled choline, acetylcholine and phosphorylcholine by reverse phase HPLC 
followed by liquid scintillation spectrometry.  A. Radiochromatogram obtained after the injection of a solution 
that contained 125 dpm [14C]-phosphorylcholine or 1200 dpm [14C]-acetylcholine.  B. Radiochromatogram 
obtained after the injection of a solution that contained 300 dpm [14C]-choline or 1200 dpm [14C]-acetylcholine.  
100 µl of each solution was injected into the HPLC, and every min 500 µl was collected. 
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3.3.4.  Drugs and radiochemicals 
 
3-morpholino-sydnonimine (gift by Therabel), L-ascorbic acid, atropine sulphate, 
choline chloride, guanethidine sulphate, L-NG-nitroarginine methyl ester and sodium  
nitroprusside were obtained from Sigma (St. Louis, USA), hemicholinium-3-bromide from 
RBI (USA), methanol from Lab-Scan (Dublin, Ireland), phentolamine mesilate from Novartis 
Pharma (Basel, Swiss), physostigmine salicylate from Federa (Brussels, Belgium), 
rauwolscine hydrochloride from Carl Roth KG (Karlsruhe, Germany), tetramethylammonium 
chloride from Merck-Schuchardt (Hohenbrunn, Germany), tetrodotoxin and w -conotoxin-
GVIA from Alomone labs (Jerusalem, Israel) and UK-14,304 tartrate (5-bromo-6-[-2-
imidazolin-2-ylamino]-quinoxaline) (gift by Pfizer, Sandwich, England). 
Radiochemicals: acetylcholine iodide [acetyl 1-14C] (2.0 GBq/mmol) from American 
Radiolabeled Chemicals (ARC) (St. Louis, USA), [methyl-3H]-choline chloride (2775 
GBq/mmol) and [methyl-14C]-choline chloride (2.0 GBq/mmol) from NEN (Boston, USA) 
and phosphoryl [methyl-14C] choline, ammonium salt (2.07 GBq/mmol) from Amersham 
(Buckinghamshire, England). 
Drugs were dissolved and diluted with distilled water.  Stock solutions of 10-3 M TTX 
were kept frozen at –20°C and dilutions were made the day of the experiment. 
 
3.3.5.  Data analysis 
 
The ratios S2/S1 for total radioactivity (TR) and for tritiated acetylcholine were 
calculated.  Experimental data are expressed as means ± s.e.mean and n  refers to the number 
of tissues.  Results were compared by the unpaired t-test or by ANOVA followed by a t-test 
corrected for multiple comparisons (Bonferroni procedure) when more than two responses 
had to be compared.  P values of less than 0.05 were considered statistically significant.  
 
3.4.  Results  
 
3.4.1.  Control experiments 
 
Optimal incubation conditions were determined by evaluating tritium release induced 
by field stimulation at 40 V, 4 Hz, 1 ms for 2 min after incubation with 3H-choline for 30 min. 
First, tissues were stimulated in PSS only containing guanethidine (4x10-6 M) and 
hemicholinium-3 (10-5 M) (n  = 4).  A clearcut increase in total radioactivity (TR) followed the 
 79
stimulation, and 15 to 27 min were required after stimulation to re-establish the basal release 
of tritium.  The response during the second  stimulation  was  smaller,  yielding  a S2/S1 ratio 
for  TR  of  0.63  (Table 3.1).  However, no acetylcholine was detected upon HPLC analysis, 
most probably due to the breakdown of acetylcholine by acetylcholinesterase.  For this 
reason, a second set of experiments was performed in the presence of the acetylcholinesterase 
inhibitor physostigmine (10-5 M).  The S2/S1 ratio for TR was lower than in the absence of the 
drug, although without reaching significance (n  = 6; Table 3.1).  However, HPLC now 
indicated the presence of acetylcholine in the samples upon stimulation with an S2/S1 ratio of 
0.56 (Table 3.1).  In the presence of physostigmine, the amount of TR released during S1     
(109 559 ± 10 550 dpm per g tissue; n = 6) tended to be lower in comparison with that in the 
absence of the drug (190 578 ±  59 819 dpm per g tissue; n  = 4; P > 0.05).  This might 
illustrate a more pronounced auto-inhibition of release by acetylcholine, that is less broken 
down in the presence of physostigmine.  When atropine was present together with 
physostigmine, the amount of TR released during stimulation tended to be higher (249 560 ± 
37 428 dpm per g tissue; n  = 10) and the S2/S1 ratio for TR was 0.69.  The ratio for 
acetylcholine was 1.08 (Table 3.1) and from now on, these conditions were used in further 
experiments. 
The mean resting efflux of TR before S1 (sample 3) in PSS containing guanethidine, 
hemicholinium-3, physostigmine and atropine was 20 540 ± 1 613 dpm per g tissue (n = 34).  
There was a progressive moderate decline in the basal efflux throughout the experiment 
(Figure 3.2A).  The mean value of the resting efflux of TR before the second stimulation 
(sample 25), expressed in relation to that in sample 3 was 0.58 ± 0.02 (n = 34).  The recovery 
of radioactivity by HPLC was complete for samples 3 and 25, containing basal efflux (99 ± 4 
%; n = 34), while it was 91 ± 2 % (n = 34) for the samples obtained during stimulation 
(samples 5 and 27).  For samples 3 and 25, 6 ± 2 % of TR was acetylcholine (n  = 34), while 
this increased to 52 ± 2 % for samples during stimulation (n = 34).  During stimulation 
(samples 5 and 27), there was a 2.5 ± 0.1-fold increase in the amount of [3H]-
phosphorylcholine and [3H]-choline released compared to basal release (P < 0.01; n = 34; 
Figure 3.2B and C), while there was a 1 076 ± 386-fold increase in the amount of [3H]-
acetylcholine released compared to basal release (P  < 0.01; n = 34; Figure 3.2B and C).  
TTX (3x10-6 M; n  = 4), w -conotoxin -GVIA (10-6 M; n = 3) or removal of extracellular 
calcium (n  = 3) did not influence basal release of TR, but they nearly abolished the 
electrically-evoked tritium release as compared with control (P < 0.01).  In control tissues (n  
= 4), the S2/S1 ratio for release of TR was 0.75 ± 0.03.  After superfusion with TTX,  
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w -conotoxin or calcium free medium, the S2/S1 ratios were respectively 0.07 ± 0.03, 0.07 ± 
0.04 and 0.17 ± 0.06.  Acetylcholine was not determined in these experiments. 
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Figure 3.2  Influence of electrical field stimulation on the release of total radioactivity (TR) and [3H]-
acetylcholine from the pig gastric fundus.  A.  TR outflow from pig gastric fundus preparations preincubated 
with [3H]-choline.  The abscissa starts at the end of the washout period.  Tissues were stimulated twice (S1 and 
S2: 40 V, 1 ms, 4 Hz, 2 min), and the superfusate (2 ml) was collected in 3 min fractions.  B.  HPLC-separation 
of the radioactive outflow before (sample 3) and during (sample 5) S1.  C.  HPLC-separation of the radioactive 
outflow before (sample 25) and during (sample 27) S2.  100 µl of the samples were injected into the HPLC, and 
every min 500 µl was collected.  For details about the peaks, see Figure 3.1.  Results are given as mean ± 
s.e.mean (n = 34). 
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Table 3.1  Ratio (S2/S1) of the efflux of total radioactivity and [
3H]-acetylcholine induced by two periods of 
stimulation in different experimental conditions 
 
Drugs present throughout experiment  TR n  ACh n 
None  0.63 ± 0.04 4  n.d. 2 
Physostigmine (10-5 M)  0.46 ± 0.05 6  0.56 ± 0.32 5 
Physostigmine (10-5 M) + atropine (10-6 M)  0.69 ± 0.03* 10  1.08 ± 0.18 10 
 
After incubation with [3H]-choline and washout, tissues were stimulated twice (S1 and S2: 40 V, 1 ms, 4 Hz, 2 
min) with an interval of 66 min, and the superfusate (2 ml) was collected every 3 min.  TR: total radioactivity; 
ACh: [3H]-acetylcholine; n.d.: not detectable.  * P < 0.05: Significantly different from strips where only 
physostigmine was present throughout the experiment.   
 
3.4.2.  The effects of a NO synthase inhibitor and NO donors 
 
The NO synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME, 3x10-4 M) did 
not influence basal release of TR (n = 6).  When L-NAME was added before the second 
stimulation, neither the electrically evoked increase of TR released nor the release of 
acetylcholine were changed.  In control tissues, the S2/S1 ratios for release of TR and 
acetylcholine were 0.72 ± 0.01 and 0.75 ± 0.03 respectively, while in the presence of L-
NAME the ratios were 0.68 ± 0.06 and 0.69 ± 0.06 (n = 6).  
The NO donors, sodium nitroprusside (SNP, 10-5 M; n = 6) and 3-morpholino-
sydnonimine (SIN-1, 10-5 M; n  = 6), did not affect basal release of TR or the electrically-
evoked increase in release of TR or acetylcholine (Table 3.2).  
 
3.4.3.  The effects of UK-14,304 and a-adrenoceptor antagonists 
 
The selective a2-adrenoceptor agonist UK-14,304 (10-5 M), added 4 min before the 
second stimulation period, did not alter the basal efflux of TR.  However, UK-14,304 
significantly reduced the amount of TR and acetylcholine released upon electrical stimulation 
  
Table 3.2  Influence of NO donors on the ratio (S2/S1) of the efflux of total radioactivity and [
3H]-acetylcholine 
induced by two periods of stimulation 
 
Drugs added before S 2  TR  ACh 
None  0.71 ± 0.04  0.66 ± 0.07 
SNP (10-5 M)  0.79 ± 0.04  0.76 ± 0.04 
None  0.71 ± 0.03  0.74 ± 0.05 
SIN-1 (10-5 M)  0.75 ± 0.02  0.72 ± 0.09 
 
After incubation with [3H]-choline and washout, tissues were stimulated twice (S1 and S2: 40 V, 1 ms, 4 Hz, 2 
min) and the superfusate (2 ml) was collected every 3 min.  Sodium nitroprusside (SNP, 10-5 M) and 3-
morpholino sydnonimine (SIN-1, 10-5 M) were added 37 min before S2.  TR: total radioactivity; ACh: [
3H]-
acetylcholine.  Mean ± s.e.mean (n = 6). 
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Figure 3.3  Effects of UK-14,304 (UK) and UK-14,304 in the presence of rauwolscine (rauw) or phentolamine 
(phent) on the electrically evoked release of total radioactivity (TR) and [3H]-acetylcholine from preparations of 
pig gastric fundus preincubated with [3H]-choline.  Tissues were stimulated twice (S1 and S2, 40 V, 1 ms, 4 Hz, 2 
min);  rauwolscine (2x10-6 M) and phentolamine (10-5 M) were added 37 min and UK-14,304 (10-5 M) 4 min 
before S2.  The electrical evoked efflux by S2 is expressed as a ratio of that by S1.  Each column represents the 
mean ± s.e.mean (n = 6).  * P < 0.05: Significantly different from control. 
 
(n = 6; Figure 3.3).  When the incubation time for UK-14,304 was increased to 37 min, the 
inhibition of the release of TR by UK-14,304 was not significantly increased compared to  
incubation during 4 min (S2/S1 ratios for TR: 0.70 ± 0.03 for control and 0.48 ± 0.04 for UK-
14,304; P < 0.01; n = 5).  The a2-adrenoceptor antagonist rauwolscine (2x10-6 M; n = 6) and 
the non-selective a -adrenoceptor antagonist phentolamine (10-5 M; n  = 6) did not alter the 
basal efflux of TR.  Rauwolscine prevented the inhibition of the electrically evoked release of 
TR and acetylcholine by UK-14,304 (Figure 3.3) while phentolamine was not able to 
counteract the effect of UK-14,304 on the amount of TR and acetylcholine released (Figure 
3.3). 
To study if endogenous noradrenaline is able to inhibit the release of acetylcholine via  
a2-adrenoceptors, a series of experiments was done in the absence of guanethidine.  In the 
absence of guanethidine, the mean basal release of TR before the first stimulation (sample 3) 
was 21 830 ± 2 655 dpm per g tissue (n  = 6), which is not significantly different from the 
basal release in the presence of guanethidine.  The increase in TR released after stimulation 
(204 520 ± 31 459 dpm per g tissue; n  = 6) was also not significantly different from that in the 
presence of guanethidine (values in the presence of guanethidine: see control experiments).  
The S2/S1 ratios for TR and acetylcholine were 0.70 ± 0.02 and 0.71 ± 0.07 respectively for 
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control strips (n = 6).  When rauwolscine (2x10-6 M) was added between the two stimulation 
periods, the S2/S1 ratio for TR released was 0.71 ± 0.03 and that for acetylcholine was 0.75 ± 
0.10 (n  = 6).  
 
3.5.  Discussion 
 
3.5.1.  Control experiments 
 
This study investigated the interaction of the nitrergic and sympathetic nerves with 
cholinergic transmission in the pig gastric fundus.  Experiments were conducted on 
preparations which had been incubated with [3H]-choline to incorporate [3H]-acetylcholine 
into the cholinergic transmitter stores. 
Separation of the samples with HPLC offers the possibility to separate on the one hand 
[3H]-phosphorylcholine and [3H]-choline, and on the other [3H]-acetylcholine with a recovery 
rate of roughly 100 %.  This is particularly interesting when only small amounts of 
acetylcholine are present.  Because of the very small variation in the recovery rate (the 
s.e.mean on the recovery was maximally 4 %, see above), there is no need to correct every 
individual sample for the recovery rate by using an internal standard. 
Incubation of the pig gastric fundus with [3H]-choline resulted in the synthesis of [3H]-
acetylcholine in the nerve terminals, which was released by field stimulation.  However, the 
synthesis of [3H]-acetylcholine depended on the stimulation frequency during labelling. When 
frequencies of less than 1 Hz were used during labelling, as is done to label guinea-pig ileum 
and colon (see e.g. Szerb, 1975; 1976; Marcoli et al., 1989; Wiklund et al., 1993; Hebeiss & 
Kilbinger, 1998), no [3H]-acetylcholine could be detected with HPLC, even in the presence of 
physostigmine.  However, the amount of newly synthesised acetylcholine and the subsequent 
release of [3H]-acetylcholine increased considerably when the stimulation frequency during 
labelling was increased from 1 to 4 Hz, and a maximum percentage of [3H]-acetylcholine was 
reached if the tissue was stimulated during labelling at 2 Hz.  This frequency-dependent 
labelling was also found in the myenteric plexus of the rat (Wessler & Werhand, 1990).  The 
need for electrical stimulation during labelling suggests a low degree of spontaneous neuronal 
activity with a slow spontaneous exchange of newly -synthesised [3H]-acetylcholine against 
unlabelled acetylcholine.  This is confirmed by the observation that tetrodotoxin had no effect 
on basal efflux of TR and was also suggested in functional experiments were TTX did not 
influence the tone of the tissues (Leclere & Lefebvre, 1998).  In contrast, in the guinea-pig 
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myenteric plexus large amounts of [3H]-acetylcholine were synthesised even when the 
labelling period was carried out in the absence of electrical stimulation, suggesting a high 
degree of spontaneous neuronal activity as also demonstrated by the decrease in the basal 
release of acetylcholine with TTX (Szerb, 1975). 
Field-stimulated release of TR was prevented by TTX or by the removal of 
extracellular calcium, indicating a neuronal release, as it is depending on, respectively, the 
opening of sodium channels, and the presence of calcium in the external medium.  The 
calcium enters the cholinergic nerves via N-type calcium channels as w -conotoxin-GVIA, a 
N-type calcium channel blocker, abolished the electrically evoked release of TR.  [3H]-
choline and / or [3H]-phosphorylcholine may be released by leakage from the nerve terminals 
as basal release was not influenced in the presence of these drugs. 
Acetylcholine could only be detected when the acetylcholinesterase inhibitor 
physostigmine was present.  In the presence of physostigmine, the stimulation-evoked 
outflow of TR tended to be lower than in its absence.  Similarly, in the guinea-pig myenteric 
plexus physostigmine concentration-dependently depressed the release of TR (Kilbinger & 
Wessler, 1980).  This might be due to an increase in the muscarinic inhibitory feedback, when 
the breakdown of acetylcholine is inhibited.  This is indeed corroborated by the observation 
that the stimulation-evoked release of TR increased when the muscarinic antagonist atropine 
was present with physostigmine from the beginning of the experiments and that (results not 
shown) the ratio S2/S1 was significantly increased compared to control strips, when 10-6 M 
atropine was added between S1 and S2.  The presence of muscarinic autoreceptors is in 
agreement with the current concept that presynaptic muscarinic receptors inhibit the release of 
acetylcholine from peripheral ends of parasympathetic nerve fibres in tissues of different 
species (see Starke et al., 1989).  As it was our aim to systematically analyse the amount of 
[3H]-acetylcholine in the TR released, further experiments were performed in the presence of 
physostigmine and atropine.  To determine the amount of [3H]-acetylcholine released, the 
combination of a muscarinic antagonist and an acetylcholinesterase inhibitor was used in 
several studies (Wessler & Werhand, 1990; Wessler et al., 1990; 1991); other authors, 
however, only used an acetylcholinesterase inhibitor (Hebeib & Kilbinger, 1996; 1998; 
Hryhorenko et al., 1994).  This suggests that the degree of muscarinic auto -inhibition can 
differ from species to species and upon the experimental conditions. 
Electrical stimulation caused, in addition to the release of [3H]-acetylcholine, a 
moderate increase in the outflow of [3H]-phosphorylcholine and [3H]-choline, i.e. the 
stimulated increase in TR was not due to the release of [3H]-acetylcholine alone.  This is in 
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contrast with results in the guinea-pig and rat myenteric plexus, where electrical stimulation 
only caused an increase in [3H]-acetylcholine release (Hebeib  & Kilbinger, 1996; Wessler & 
Werhand, 1990).  [3H]-phosphorylcholine can be formed via two pathways: 1) [3H]-choline is 
not only a substrate for choline acetyltransferase to form acetylcholine, but also for choline-
kinase to form [3H]-phosphorylcholine which will be converted to [3H]-
cytidylyldiphosphocholine, which is further synthesised to [3H]-phosphatidylcholine (Stryer, 
1988); 2) [3H]-phosphorylcholine can be liberated via the breakdown of [3H]-
phosphatidylcholine (Pelech & Vance, 1989).  In canine ileum, transmural stimulation also 
caused an enhanced outflow of [3H]-phosphorylcholine (Hryhorenko et al., 1994).  This also 
occurred in rat and guinea-pig trachea after field stimulation, however, after preganglionic 
stimulation of the parasympathetic nerves, the stimulated increase in tritium outflow was 
exclusively caused by an enhanced release of [3H]-acetylcholine (Wessler et al., 1990; 1991).  
As removal of the epithelium reduced the amount of [3H]-phosphorylcholine liberated in 
response to field stimulation, Wessler et al. (1991) concluded that the electrical field injures 
epithelial cells with the subsequent liberation of [3H]-phosphorylcholine from the outer leaflet 
of the cell membrane.  As the mucosa was removed from the pig gastric fundus in our 
experiments, the source of the [3H]-phosphorylcholine cannot be the epithelial cells.  The 
increase in release of [3H]-choline after electrical stimulation is probably due to the presence 
of [3H]-choline in the vesicles after labelling, although we can not exclude that it is formed 
via breakdown of [3H]-phosphorylcholine and [3H]-phosphatidylcholine.  However, as the 
S2/S1 ratio for [3H]-acetylcholine was systematically similar to that for TR released, it will no 
longer be necessary to separate all radioactive components in future experiments as the results 
of TR reflect those of [3H]-acetylcholine. 
 
3.5.2.  The effects of a NO synthase inhibitor and NO donors 
 
We demonstrated before that blockade of NO synthase increased basal tone and that 
endogenous NO interferes with cholinergic neurotransmission in the pig gastric fundus, 
probably by functional antagonism of acetylcholine at the level of the smooth muscle cells 
(Leclere & Lefebvre, 1998).  Many authors have reported that NO can also act presynaptically 
on cholinergic nerves to enhance the basal release of acetylcholine and to inhibit the 
electrically evoked release of acetylcholine (see review Kilbinger, 1996).  As it is not possible 
to determine with certainty the site(s) of action of NO (i.e. pre- vs. postsynaptic) from 
functional experiments, the effects of a NO synthase inhibitor and NO donors on 
 86
[3H]-acetylcholine release in the pig gastric fundus were now determined.  Blockade of NO 
synthase with L-NAME, or addition of NO donors, in concentrations shown in our lab to 
induce maximal relaxation of circular muscle strips of the pig gastric fundus, did not 
significantly affect basal release of TR or electrically-evoked overflow of TR and [3H]-
acetylcholine, suggesting that NO does not enhance basal acetylcholine release or suppress 
electrically-evoked release of acetylcholine in the pig gastric fundus.  This is in agreement 
with the findings of others who reported that NO donors and NO synthase inhibitors do not 
modify [3H]-acetylcholine release in either tracheal or intestinal preparations (Brave et al, 
1991; Ward et al., 1993; Ward et al, 1996; Milenov & Kalfin, 1996; Rae et al., 1998).  Still, in 
view of the circular direction of the strips, it cannot be excluded that acetylcholine release 
from longitudinally directed interneurones and / or sensory neurones is not fully assessed; 
modulation of acetylcholine released by NO might still be present at this level. 
 
3.5.3.  The effects of UK-14,304 and a-adrenoceptor antagonists 
 
Several investigators have reported that presynaptic inhibitory a2-adrenoceptors are 
present on cholinergic nerves in various gastrointestinal tissues and in other tissues (see 
review: De Ponti et al. , 1996 and introduction).  In this study, the a2-adrenoceptor agonist 
UK-14,304 significantly reduced the stimulation-induced efflux of TR and [3H]-acetylcholine 
in the pig gastric fundus.  The reduction was smaller than in other species, where the 
depression of release with 10-5 M UK-14,304 was about 50 % or more (e.g. Wessler et al., 
1987).  This was not due to the short incubation time of UK-14,304 as increasing the 
incubation time to 37 min did not increase the degree of inhibition of TR release by UK-
14,304.  The inhibition of the stimulated overflow produced by UK-14,304 was completely 
antagonised by rauwolscine, a selective a2-adrenoceptor antagonist, indicating that 
cholinergic nerves of the pig gastric fundus are also endowed with a2-adrenoceptors, causing 
inhibition of transmitter acetylcholine release.  We have no explanation why phentolamine, a 
non-selective a-adrenoceptor antagonist, did not counteract the inhibitory action of UK-
14,304.  To study whether endogenous noradrenaline is able to inhibit acetylcholine release 
via the presynaptic a2-adrenoceptors on the cholinergic neurones, experiments were 
performed in the absence of guanethidine.  Both basal and electrically-evoked release were 
not lower compared to the release in the presence of guanethidine, suggesting that in pig 
gastric fundus sympathetic nerves do not modulate the release of acetylcholine via  the 
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inhibitory a2-adrenoceptors within the experimental conditions and / or that electrical field 
stimulation does not lead to the release of noradrenaline.  This was confirmed when 
rauwolscine was added between S1 and S2; it was without effect on the electrically-evoked 
release of TR and [3H]-acetylcholine while an increase is expected if endogenous 
noradrenaline were inhibiting acetylcholine release via the presynaptic a2-adrenoceptors.  
Also in the guinea-pig ileum and rat trachea (Alberts & Stjärne, 1982; Fabiani et al., 1997), 
no evidence to suggest that endogenous noradrenaline influences acetylcholine release was 
obtained. 
In conclusion, the data provided by this study indicate that measurement of tritium 
release after incubation with [3H]-choline can be used for measurement of endogenous 
acetylcholine output in response to cholinergic neuron stimulation in the pig gastric fundus.  
The method allowed to suggest the presence of presynaptic muscarinic and a2-adrenoceptors 
on the cholinergic neurones.  No evidence for the modulation of acetylcholine release by NO 
was obtained. 
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CHAPTER  4 
 
  CHARACTERISATION OF PRE- AND POSTSYNAPTIC 
MUSCARINIC RECEPTORS IN CIRCULAR MUSCLE OF PIG 
GASTRIC FUNDUS 
 
4.1.  Summary 
 
This study investigated the subtype of muscarinic receptors on the cholinergic neurones and 
smooth muscle in the circular muscle of the pig gastric fundus.  Muscarinic antagonists, 
except MT-3, concentration-dependently inhibited the contractions induced by a given 
concentration of acetylcholine.  Concentration-response curves by acetylcholine were shifted 
rightwards in a parallel manner without depression of the maximum by the muscarinic 
antagonists, except by MT-3 that induced a leftward shift.  Correlation of the pIC50 and pA2 
values with published pK i values for the five muscarinic receptor subtypes suggests that the 
muscarinic receptors on pig gastric fundus circular muscle belong to the M3 subtype.  
Electrically-evoked contractions (40 V, 4 Hz, 0.25 ms, 2 min) were concentration-
dependently inhibited by the muscarinic antagonists except for methoctramine and AF-DX 
116, that increased the amplitude of the electrically -induced contractions in lower 
concentrations.  MT-3 tended to increase the electrically-induced contractions.  The 
antagonists, except MT-3, concentration-dependently increased the electrically -induced 
tritium outflow (40 V, 4 Hz, 0.25 ms, 2 min) after incubation of the tissues with [3H]-choline.  
MT-3 (3x10-8 and 10-7 M) decreased the electrically-induced tritium release.  Correlation of 
the pIC50 values with published pKi values for the different muscarinic receptor subtypes 
yielded a significant and comparable correlation for M1,  M3,  M4 and M5 receptors.  These 
results suggest that the postsynaptic receptors in circular muscle of the pig gastric fundus 
belong to the M3 subtype.  However, the presynaptic receptor could not be clearly defined, 
although it does certainly not belong to the M2 subtype. 
 
4.2.  Introduction 
 
In circular muscle strips of the pig gastric fundus, contractions induced by electrical 
field stimulation (EFS) are blocked by atropine (Leclere & Lefebvre, 1998), while the 
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electrically-evoked release of acetylcholine in the same tissue is enhanced by atropine 
(Leclere & Lefebvre, 2001), indicating the presence of respectively postsynaptic muscular 
muscarinic receptors and presynaptic inhibitory muscarinic auto-receptors on the cholinergic 
neurones of the pig gastric fundus.  However, the type of muscarinic receptor(s) involved in 
the pig gastric fundus has not yet been characterised.  Five different muscarinic receptor 
subtypes have been identified based on studies of molecular structure, in vitro binding and 
function (Buckley et al., 1989; Dörje et al., 1991).  All subtypes belong to the seven-
transmembrane G-protein coupled receptor family (see reviews Grimm et al., 1994; Eglen et 
al., 1996; Caulfield & Birdsall, 1998).  In most tissues, including the gastrointestinal tract, 
mainly M3 receptors can be detected to function pharmacologically at the postsynaptic level 
(Eglen et al., 1996; Caulfield & Birdsall, 1998).  With regard to the presynaptic level, the 
situation is more complex as both stimulatory and inhibitory muscarinic auto -receptors can be 
present, and only a limited number of experiments have been reported in the gastrointestinal 
tract.  In guinea-pig longitudinal muscle myenteric plexus (LMMP) preparations, it has been 
shown that presynaptic muscarinic M3 receptors inhibit while muscarinic M1 receptors 
enhance acetylcholine release (Soejima et al. , 1993).  However, in circular smooth muscle of 
the guinea-pig ileum, the presynaptic inhibitory muscarinic receptors belong to the M1 
subtype (Dietrich & Kilbinger, 1995).  In the guinea-pig stomach, there is evidence that 
acetylcholine release is inhibited by muscarinic M1 and M2 receptors (Ogishima et al., 2000).  
In canine LMMP preparations, a binding study demonstrated that presynaptic muscarinic 
receptors belong to the M3 subtype, although this technique could not exclude the presence of 
another presynaptic subtype (Kostka et al., 1989).  Prejunctional stimulatory and inhibitory 
muscarinic receptors have also been demonstrated in other tissues, especially in the 
respiratory tract and urinary bladder (see reviews Grimm et al., 1994; Somogyi & de Groat, 
1999). 
By use of functional and release experiments, the present study had two objectives:  
First, to characterise the muscular muscarinic receptor, responsible for the contraction by 
muscarinic agonists of the smooth muscle cells in the pig gastric fundus.  Second, to 
characterise the muscarinic receptor(s) present on the cholinergic nerves, inhibiting the 
release of acetylcholine. 
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4.3.  Methods 
 
4.3.1.  Tissue preparation  
 
Experiments were carried out on isolated circular smooth muscle strips of the pig 
gastric fundus.  The stomach was removed from healthy castrated male pigs, slaughtered at a 
local abattoir, and transported to the laboratory in ice-chilled physiological salt solution 
(PSS).  After the mucosa was removed, strips of approximately 1.5 cm in length and 0.3 cm in 
width were cut in the direction of the circular muscle except in one series of experiments 
when strips were cut in the direction of the longitudinal muscle.  In one series, circular muscle 
strips were prepared after removal of the longitudinal muscle layer and the myenteric plexus.  
All strips were used within 24 hours.  When tissues were used the next day, they were stored 
in fresh PSS at 4°C.  Strips were mounted vertically between two platinum plate electrodes 
(30 x 6 x 0.1 mm) in 20 ml organ baths (functional experiments) or between two platinum 
wire electrodes (45 x 0.5 mm) in 2 ml organ baths (functional or release experiments) under a 
load of 2 g, containing PSS (mM: 112 NaCl, 4.7 KCl, 1.2 MgCl2, 1.2 KH2PO4, 2.5 CaCl2, 
11.5 glucose and 25 NaHCO3), maintained at 37°C and gassed with carbogen.  The PSS 
contained guanethidine (4x10-6 M) to avoid noradrenergic influences, L-NG-nitroarginine 
methyl ester (L-NAME, 3x10-4 M) to prevent relaxations due to nitric oxide, and, as the basal 
tonus increases during the course of the experiment (Leclere & Lefebvre, 1998), 
indomethacin (10-5 M) to prevent this increase.  The mechanical activity of the preparations 
was recorded via isotonic transducers (T3, Palmer Bioscience, U.S.A.) on a recorder (FWR 
3701 Graphtec Linearcorder or MC6625 Graphtec Multicorder, Japan or Ankersmit, The 
Netherlands).  Electrical field stimulation (EFS) was applied by means of a S88 stimulator 
(Grass, U.S.A.). 
 
4.3.2.  Functional experiments 
 
The tissues were allowed to equilibrate for 90 min with rinsing every 15 min before 
starting the experiment.  After the equilibration period, strips were first maximally contracted 
with 80 mM KCl, followed by rinsing every 10 min during 30 min. 
In a first set of experiments, muscarinic antagonists were tested versus electrically and 
acetylcholine-induced contractions.  After equilibration and KCl treatment, EFS (40 V, 0.25 
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ms, 4 Hz during 2 min) was applied, contracting the tissues.  Three to five consecutive 
electrical stimulations at 10 min intervals were required before contractions remained stab le.  
When the response of muscarinic antagonists versus exogenous acetylcholine was studied, a 
cumulative concentration-response curve for acetylcholine was performed after the electrical 
stimulations, to determine the concentration of acetylcholine inducing a contraction of similar 
amplitude as that induced by EFS (3x10-7 to 10-5 M).  Tissues were then re-exposed to this 
concentration of acetylcholine.  After contraction to EFS or exogenous acetylcholine, tissues 
were washed to re-establish the basal tone level.  To study the influence of tetrodotoxin (TTX; 
3x10-6 M), hexamethonium (5x10-4 M) and atropine (10-6 M) on the electrically-evoked 
contractions and on the contractions by exogenous acetylcholine, they were added for 30 min 
before tissues were stimulated again with either EFS or exogenous acetylcholine.  To study 
the influence of muscarinic antagonists, EFS or addition of acetylcholine was repeated at 45 
min intervals and increasing concentrations of muscarinic antagonists or solvent were added 
30 min before EFS or acetylcholine addition.  The response before the first addition of 
antagonist was used as control response (S1). 
In a second set of experiments, muscarinic antagonists were tested versus cumulative 
concentration-response curves of acetylcholine in order to determine pA2 values for the 
postsynaptic muscarinic receptors.  After the equilibration period and KCl treatment, tissues 
were exposed to 10-6 M of acetylcholine to test their viability and responsiveness.  After 
washing until basal tone level was re-established, cumulative concentration-response curves 
to acetylcholine (3x10-8 – 10-2 M) were constructed using half-logarithmic dosing increments 
of acetylcholine.  After construction of the first concentration-response curve, the preparation 
was washed for 45 min, until the tension returned to baseline.  A muscarinic antagonist was 
then incubated for 30 min before the second concentration-response curve was obtained.  This 
cycle was repeated four times with increasing concentrations of antagonist.  Parallel control 
experiments without antagonist were performed under identical conditions.  In another series 
of experiments, cumulative concentration-response curves to acetylcholine (3x10-8 – 10-3 M) 
or KCl (5x10-3 – 8x10-2 M) were constructed.  After construction of the first concentration-
response curve, the preparation was washed for 45 min, until the tension returned to baseline.  
The M4-selective antagonist MT-3 was then incubated for 30 min before the second 
concentration-response curve to acetylcholine or KCl was obtained.  Parallel control 
experiments without antagonist were performed under identical conditions.  The control 
experiments allowed for any correction to be made for changes in sensitivity to acetylcholine 
or KCl. 
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4.3.3.  Release experiments 
 
Strips, weighing 148 ± 5 mg (n = 82), were mounted vertically between two platinum 
wire electrodes in 2 ml organ baths containing PSS.  The PSS contained in addition to the 
composition mentioned under Tissue preparation 1.5x10-6 M choline and 5.7x10-5 M ascorbic 
acid.  Baths were maintained at 37 °C and gassed with carbogen.  The tissues were superfused 
at a rate of 2 ml/min using a peristaltic pump (Gilson Minipuls, France) during 60 min.  The 
strips were subjected to continuous EFS (40 V, 1 ms, 0.5 Hz) during the last 20 min.  After 
the equilibration period, superfusion was stopped and the preparations were incubated for 30 
min with [3H]-choline (5 µCi/ml) during which the tissues were stimulated electrically (40 V, 
1 ms, 2 Hz) in order to label their cholinergic transmitter stores. 
After the labelling procedure, the strips were superfused (2 ml/min) for 90 min with 
PSS to remove loosely bound radioactivity.  From now on the PSS contained in addition 10-5 
M hemicholinium-3 to prevent the re-uptake of choline.  After the washout period, strips were 
no longer superfused but the content of the organ bath, filled with 1 ml, was collected and 
replaced each 3 min.  A total of 75 samples was collected.  0.5 ml of the samples was mixed 
with 2 ml of the scintillator containing solution Ultima Gold (Canberra Packard, U.S.A.).  The 
strips were stimulated five times for 2 min, except in one series of experiments with MT-3 
when strips were only stimulated four times (S1 - S5; 40 V, 0.25 ms, 4 Hz), at 10 min (S1, 4th 
sample), 58 min (S2, 20th sample), 106 min (S3, 36th sample), 154 min (S4, 52nd sample), and 
202 min (S5, 68th sample) after the end of the washout period.  Muscarinic antagonists were 
added in increasing concentrations 30 min before S2 - S5, and they remained present until the 
next concentration was added, or until the end of the experiment.  At the end of the 
experiment, tissues were blotted and weighed. 
Radioactivity of all samples was measured by liquid scintillation counting (Packard 
Tri-Carb 2100 TR, Canberra Packard, U.S.A.), and external standardization was used to 
correct for counting efficiency.  Electrical stimulation induced an increase in tritium overflow, 
not only during stimulation, but also in three samples following that with stimulation.  The 
stimulation-induced increase in tritium overflow was calculated from the difference between 
the total tritium release during stimulation plus the following three samples, and the 
calculated basal tritium overflow.  Basal tritium overflow during the period of enhanced 
tritium overflow was calculated by fitting a regression line through the values of the three 
samples just before stimulation and the values of the three samples starting from where basal 
release was re-established. 
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4.3.4.  Data analysis 
 
Experimental data are expressed as means ± s.e.mean and n  refers to the number of the 
tissues from different animals.  For both functional and release experiments, concentration-
response curves for the muscarinic antagonists were constructed by expressing the ratio Sn/S1 
in the presence of an antagonist as a percentage of the equivalent ratio obtained in parallel 
tissues in the absence of antagonists.  The concentrations which produced half-maximal 
inhibition of contractions or facilitation of tritium release (IC 50) were calculated by linear 
interpolation from individual concentration-response curves.  Statistical significance (P < 
0.05) was assessed by the paired and unpaired t-test. 
In experiments to determine the pA2 values, the second till fifth concentration-
response curves to acetylcholine were expressed as percentage of the maximal contraction in 
the first concentration-response curve.  The EC50 was calculated for each curve and the dose 
ratios (DR) were calculated as (EC50)n/(EC50)1.  As a moderate rightward shift of the 
concentration-response curves to acetylcholine occurred in control tissues, the DR in the 
presence of antagonist was corrected for this change by dividing the DR for tissues in the 
presence of antagonists by the DR obtained in parallel control tissues.  Finally, the log (DR-1) 
was expressed as a function of log [antagonist], and the pA2 value was calculated according to 
Arunlakshana & Schild (1959).  The slope of the Schild plot was considered to be not 
different from unity when the 95% confidence interval for the slope includes 1.0.  Then, pKB 
values were obtained from plots constrained to a slope of 1.0. 
Pearson correlation coefficients (r) and associated P-values were calculated using the 
program GraphPad Prism, version 3.0, for the relationship of binding affinity data generated 
at the five human recombinant muscarinic receptors with our potency and affinity data. 
 
4.3.5.  Drugs used 
 
Acetylcholine chloride, atropine sulphate, choline chloride, dimethylsulfoxide 
(DMSO), guanethidine sulphate, indomethacin and L-NG-nitroarginine methyl ester (L-
NAME) were obtained from Sigma (St. Louis, MO, U.S.A.), hemicholinium-3-bromide, p-
fluoro-hexahydro -sila-difenidol hydrochloride (p-F-HHSiD), methoctramine 4 hydrochloride 
and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) were obtained from RBI 
(Natick, U.S.A.), (11-[[2-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11-dihydro-6H-
pyrido[2,3b] [1,4]-benzodiazepine-6-one) (AF-DX 116) was obtained from Karl Thomae 
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GmbH (Biberach, Germany), pirenzepine dihydrochloride from Boehringer Ingelheim 
(Brussels, Belgium), [methyl-3H]-choline chloride (2775 GBq/mmol) from NEN (Boston, 
U.S.A.), hexamethonium chloride from Federa (Brussels, Belgium) and mamba toxin-3 (MT-
3) and tetrodotoxin (TTX) from Alomone labs (Jerusalem, Israel).  
Drugs were dissolved and diluted with distilled water, except for 4-DAMP and AF-
DX 116 which were dissolved in DMSO before dilution with distilled water.  Stock solutions 
of 10-3 M TTX, 10-2 M of atropine, pirenzepine, methoctramine and p-F-HHSiD were kept 
frozen at –20°C and 10-6 M MT-3 was kept at 4°C.  Dilutions were made the day of the 
experiment. 
 
4.4.  Results  
 
4.4.1.  General observations 
 
Tissues responded to EFS (40 V, 0.25 ms, 4 Hz, 2 min) in the presence of L-NAME 
(3x10-4 M) with a biphasic contraction.  Fast contractions occurred in all tissues stimulated, 
but the initial contraction was sometimes followed by a small decrease of tone and a more 
sustained contraction whereof the amplitude was smaller than that of the initial phasic 
contraction; in other tissues the initial contraction was very shortly stopped before the 
contraction gradually increased to an amplitude higher than the initial contraction.  When 
ending the electrical stimulation, tone declined as quickly as it had risen.  The highest 
amplitude of the electrically-induced contractions was measured.  After 3 to 5 electrical 
stimulations, the contraction amplitude was stable.  Addition of exogenous acetylcholine 
(range 3x10-7 M till 10-5 M) caused monophasic reproducible contractions. 
In control tissues of the release experiments, the release of tritium before S1 (sample 3) 
was 660 ± 50 Bq per g tissue (n = 14).  The amount of tritium released due to S1 (samples 5, 
6, 7 and 8) above calculated basal release (2 590 ± 180 Bq per g tissue) was 2 700 ± 520 Bq 
per g tissue (n = 14).  The outflow evoked by S2, S3, S4 and S5 was 0.80 ± 0.02, 0.65 ± 0.02, 
0.54 ± 0.02 and 0.43 ± 0.02, respectively (n = 14) of that caused by S1.  In the experiments 
with AF-DX 116 and 4-DAMP, where parallel control tissues received dilutions of the solvent 
DMSO, these values were not significantly different from values of control tissues receiving 
aqua as solvent. 
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4.4.2.  Effect of muscarinic receptor antagonists on acetylcholine-induced contractions and 
on electrically-induced tritium outflow and contractions 
 
Contractions induced by a fixed concentration of acetylcholine were not influenced by 
TTX (3x10-6 M) and hexamethonium (5x10-4 M), while atropine (10-6 M) completely blocked  
the contractions, indicating that acetylcholine causes contraction by stimulation of 
postsynaptic muscular muscarinic receptors, and thus the effect on the contractions by 
muscarinic antagonists is solely at the postsynaptic level.  As shown in Figure 4.1A and 4.2, 
atropine, pirenzepine, AF-DX 116, 4-DAMP and p-F-HHSiD inhibited the acetylcholine-
induced contractions at all concentrations tested, while methoctramine inhibited the 
acetylcholine-induced contractions only significantly from 10-5 M upwards (n = 6; P  < 0.05; 
Figure 4.2C).  MT-3 (3x10-11 – 10-8 M) did not influence the acetylcholine-induced 
contractions (n  = 6; data not shown).  The negative logarithms of the postsynaptic IC 50 values 
of the antagonists, determined versus acetylcholine, are given in Table 4.1.  The rank order of 
potency of the antagonists at postsynaptic level was: atropine = 4-DAMP > p-F-HHSiD > 
pirenzepine > AF-DX 116 > methoctramine. 
In release studies, the electrically -evoked tritium outflow was abolished by TTX, w -
conotoxin-GVIA or removal of extracellular calcium, and contains a consistent amount of 
acetylcholine as determined by HPLC (Leclere & Lefebvre, 2001), indicating that electrical 
stimulation activates cholinergic neurones releasing acetylcholine.  This acetylcholine inhibits 
its own release by activation of presynaptic muscarinic receptors on the cholinergic neurones 
(Leclere & Lefebvre, 2001), and changes in electrically -induced tritium release by muscarinic 
antagonists are only related to interference with these presynaptic muscarinic receptors on 
these cholinergic neurones.  None of the muscarinic antagonists affected the basal outflow of 
tritium, while all antagonists, except MT-3, increased concentration-dependently the 
electrically-evoked tritium outflow (Figure 4.2).  Methoctramine and p-F-HHSiD showed 
bell-shaped concentration-response curves.  MT-3 (3x10-11 – 10-8 M) did not influence the 
electrically-induced tritium release (n  = 6; data not shown).  However, higher concentrations 
of MT-3 decreased the electrically-induced release (10-8 M: 101 ± 2%;  3x10-8 M: 87 ± 2% (P 
< 0.01); 10-7 M: 81 ± 3% (P < 0.01) (n = 6)).  The negative logarithms of the presynaptic IC50 
values of the antagonists are given in Table 4.1.  The rank order of potency of the antagonists 
at presynaptic level was: 4-DAMP > atropine > pirenzepine ³ p-F-HHSiD > AF-DX 116 > 
methoctramine.  As acetylcholine release from cholinergic nerve endings towards the 
longitudinal muscle layer might contribute to the tritium measured in the whole tissue strips, a 
 101
small series of experiments measuring tritium release was performed in the absence of the 
longitudinal muscle layer and myenteric plexus so that only the tritium release of nerve 
endings in the circular muscle layer was evaluated (n  = 4; data not shown).  The amount of 
tritium released was too low for obtaining reproducible results. 
The electrically-induced contractions were completely blocked by atropine (10-6 M) 
and TTX (3x10-6 M), while hexamethonium (5x10-4 M) was without effect, indicating the 
activation of postganglionic cholinergic neurones during EFS.  The released acetylcholine 
 
Figure 4.1  Representative traces showing the contractions to exogenous acetylcholine (3x10-7 M) (A) and 
electrical field stimulation (B) in the presence of solvent or increasing concentrations of AF-DX 116.  AF-DX 
116 was incubated for 30 min before tissues were stimulated. 
 A 
B 
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causes contraction by stimulating postsynaptic muscular muscarinic receptors but this 
contraction will be influenced by the effect of the released acetylcholine on its own release by 
stimulation of presynaptic muscarinic receptors on the cholinergic neurones.  Antagonists 
tested versus the electrically -evoked contractions can thus interfere with the response at both 
pre- and postsynaptic muscarinic receptors.  The results are shown in Figure 4.2 and the pIC50 
values are given in Table 4.1.  Pirenzepine and 4-DAMP concentration-dependently inhibited 
the contractions induced by EFS and the concentration-response curve paralleled that versus 
the acetylcholine-induced contractions.  In contrast, lower concentrations of methoctramine 
and AF-DX 116 (Figure 4.1B) increased the amplitude of the electrically -induced 
contractions, while higher concentrations decreased it.  Although atropine and p-F-HHSiD did 
not enhance the electrically-induced contractions, the concentration-response curve versus 
these contractions was moderately (atropine) to markedly (p-F-HHSiD) shifted to the right in 
comparison with that versus acetylcholine-induced contractions.  MT-3 (3x10-11 – 10-8 M) did 
not influence the electrically -induced contractions (n = 6; data not shown).  However, higher 
concentrations tended to increase the electrically-induced contractions (10-8 M: 100 ± 4%; 
3x10-8 M: 101 ± 6%; 10-7 M: 108 ± 7% (n  = 4)). 
The effect of pirenzepine was also studied on electrically - and acetylcholine-induced 
contractions in strips cut in the longitudinal direction so that the contractions were due to 
longitudinal smooth muscle activity.  In these tissues, the pIC50 value of pirenzepine versus 
electrically-induced contractions (6.55 ± 0.13; n = 4) was significantly larger than that versus 
acetylcholine-induced contractions (6.06 ± 0.12; n  = 4; P < 0.05). 
 
Table 4.1 Comparison between pre- and postsynaptic potencies (pIC50) of muscarinic antagonists in circular 
muscle strips of the pig gastric fundus 
 
Antagonist 1pIC 50 pre n 
2pIC50 post n 
3pIC 50 (EFS) n 
Atropine 8.12 ± 0.18 6 8.48 ± 0.11 8 8.10 ± 0.12+ 8 
Pirenzepine 7.09 ± 0.05 6 6.37 ± 0.12*** 8 6.35 ± 0.06***  8 
AF-DX116 6.65 ± 0.32 6 5.69 ± 0.08** 8 5.03 ± 0.08*** ,+++ 8 
Methoctramine 6.43 ± 0.14 7 5.19 ± 0.14*** 6 4.72 ± 0.07*** ,++ 8 
4-DAMP 8.25 ± 0.04 6 8.48 ± 0.08* 8 8.54 ± 0.07** 8 
p-F-HHSiD 7.03 ± 0.30 6 6.85 ± 0.13 8 6.09 ± 0.11**,+++ 7 
 
The pIC50 values are mean ± s.e.mean.  1: Assessed versus EFS-induced tritium release; 2: Assessed versus 
acetylcholine-induced contraction; and 3: Assessed versus EFS-induced contraction.  *,**,***: P  < 0.05, 0.01, 
0.001.  Significantly different from pIC50 pre.  +,++,+++: P < 0.05, 0.01, 0.001.  Significantly different from  
pIC50 post. 
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Figure 4.2  Mean ± s.e.mean (n = 6 to 8) of the effect of muscarinic antagonists on tritium outflow (tritium) 
induced by electrical stimulation and smooth muscle contraction evoked by either electrical field stimulation 
(EFS) (40 V, 0.25 ms, 4 Hz, 2 min) or exogenous acetylcholine (ACh) in the circular muscle of pig gastric 
fundus strips.  The ratio of the response in the presence of antagonist versus the control response before addition 
of antagonist (Sn/S1) was expressed as % of the same ratio in parallel control tissues receiving the solvent of the 
antagonist.  *,**,***: P  < 0.05, 0.01, 0.001: Significantly different from the value in the absence of antagonist (= 
100 %). 
 
4.4.3. Postsynaptic affinities of muscarinic receptor antagonists versus acetylcholine 
 
Acetylcholine caused concentration-dependent contractions with an EC50 of 2.05 ± 
0.41x10-6 M (n  = 40), and the maximal contraction was 111 ± 1% as percentage of the KCl 
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(80 mM)-induced contraction (n = 40).  Except for MT-3 (3x10-10 – 10-8 M; n = 2), parallel 
rightward shifts of the concentration-response curves to acetylcholine, without depression of 
the maximum response, were obtained with the muscarinic antagonists (atropine: 3x10-9 –   
10-7 M, n = 6; pirenzepine: 10-7 – 3x10-6 M, n  = 6; AF-DX 116: 10-6 – 3x10-5 M, n = 6; 
methoctramine: 3x10-6 – 3x10-5 M, n  = 8; 4-DAMP:  10-9 – 3x10-8 M, n = 8 (Figure 4.3A); p-
F-HHSiD : 10-7 – 3x10-6 M, n  = 8 (Figure 4.3B)).  In two out of eight tissues, methoctramine 
(3x10-6 – 3x10-5 M) produced no significant parallel rightward shift of the concentration-
response curve.  The Schild plot was therefore performed on the basis of the results in the six 
tissues where methoctramine was active.  Schild regression analysis was linear with a slope 
not significantly different from unity for atropine, pirenzepine, 4-DAMP and p-F-HHSiD 
(Table 4.2).  The rank order of antagonist affinities was 4-DAMP > atropine > p-F-HHSiD > 
pirenzepine > AF-DX 116 > methoctramine. 
 MT-3 (10-7 M; n = 4) caused a parallel leftward shift of the concentration-response 
curve to acetylcholine, without depression of the maximum response.  The pEC50 of 
acetylcholine in the control strips was 5.54 ± 0.19, while this was 6.25 ± 0.18 in the presence 
of MT-3 (P < 0.05).  However, MT-3 (10-7; n = 4) had no effect on the concentration-response 
curve to KCl.  The pEC50 of the control strips was 1.67 ± 0.04, while this was 1.75 ± 0.02 in 
the presence of MT-3. 
 
4.5. Discussion 
 
In this study we describe the pharmacological profile of muscarinic receptor(s) 
involved in the control of acetylcholine release and smooth muscle contraction of the circular  
 
Table 4.2  Postsynaptic affinity values of muscarinic antagonists at receptors mediating contraction of circular 
muscle strips of the pig gastric fundus in response to acetylcholine 
 
Antagonist pA2 Slope pKB n 
Atropine 8.94 ± 0.07 0.87 ± 0.07 8.79 ± 0.04 6 
Pirenzepine 6.76 ± 0.19 0.98 ± 0.15 6.70 ± 0.09 6 
AF-DX116 5.96 ± 0.12 0.71 ± 0.07  6 
Methoctramine 5.55 ± 0.25 0.20 ± 0.09  6 
4-DAMP 9.09 ± 0.16 1.05 ± 0.09 9.13 ± 0.05 8 
p-F-HHSiD 7.13 ± 0.13 0.94 ± 0.12 7.01 ± 0.08 8 
 
Values are means ± s.e.mean.  The antagonist action of each antagonist was estimated by Schild plot analysis, 
and pA2 values and the slope of the linear regression were calculated.  When the 95 % confidence limits of the 
slope included the value 1.0, the line slope was considered to be not significantly different from unity, and pKB 
values were obtained from plots constrained to a slope of 1.0. 
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Figure 4.3  Cumulative concentration-response curves for acetylcholine-induced contractions, expressed as a 
percentage of the maximum to acetylcholine in the first concentration-response curve, in the circular muscle of 
pig gastric fundus strips in the absence and presence of different concentrations of 4-DAMP (A) and p-F-HHSiD 
(B).  Inserts show the Schild plots of the respective antagonists.  The pA2 values and slopes are given in Table 
4.2.  Data points represent means ± s.e.mean of 8 independent experiments. 
 
muscle of the pig gastric fundus.  Because of the lack of selective muscarinic antagonists, a 
series of subtype-preferring antagonists are used to characterise pharmacologically the 
involvement of a particular muscarinic receptor.  The muscarinic antagonists used in this 
study to determine the profile of the pre- and postsynaptic muscarinic receptors of the circular 
muscle of the pig gastric fundus are the non-selective antagonist atropine, the M1-preferring 
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antagonist pirenzepine, the M2-preferring antagonists AF-DX 116 and methoctramine, the 
M3-preferring antagonists 4-DAMP and p-F-HHSiD and the M4-preferring antagonist MT-3. 
As described in the Results section, the postsynaptic muscarinic receptors are assessed 
when studying the influence of the muscarinic antagonists on acetylcholine-induced 
contractions.  The tissues are mounted in the direction of the circular muscle layer to measure 
these contractions and the short parts of longitudinal muscle in the tissues will not contribute 
to the contractions; this series of experiments thus evaluates the postsynaptic muscarinic 
receptors on the circular muscle cells of the pig gastric fundus.  The presynaptic muscarinic 
receptors are assessed when studying the influence of the muscarinic antagonists on 
electrically-induced tritium release; cholinergic neurones directed to the longitudinal muscle 
might contribute to the tritium release in this series, and interference of the muscarinic 
antagonists with presynaptic muscarinic receptors on these neurones might influence the 
results.  The release experiments were performed in the absence of the acetylcholinesterase 
inhibitor physostigmine.  We indeed previously demonstrated (Leclere & Lefebvre, 2001) that 
the Sn/S1 ratio for tritium is systematically similar to that for [3H]-acetylcholine, so it is not 
necessary to separate the radioactive components, which requires the presence of 
physostigmine.  Muscarinic antagonists can interfere with both pre- and postsynaptic 
muscarinic receptors when studied versus electrically-induced contractions, as illustrated by 
the results with atropine.  The pIC50 of atropine versus electrically-induced contractions was 
significantly lower than the pIC 50 versus acetylcholine-induced contractions; the stimulatory 
effect on acetylcholine release by antagonism of the presynaptic muscarinic receptors will 
indeed counteract the antagonistic effect versus acetylcholine at the postsynaptic level.  As the 
measured item is contraction, the presynaptic muscarinic receptors on the cholinergic 
neurones to the longitudinal muscle will not interfere in this assay. 
 
4.5.1. Characterisation of the postsynaptic muscarinic receptors 
 
The rank order of potencies (Table 4.1) and affinities (Table 4.2) at the postsynaptic 
level of the six investigated subtype-preferring antagonists is similar, and comparing these 
rank orders with the rank order of the binding constants for the five muscarinic receptor 
subtypes (Table 4.3) is consistent with the pharmacological profile of the M3 and M5 receptor 
subtypes.  However, analysis of the relationship of our potency and affinity values with 
literature data of binding affinity values for the muscarinic receptor subtypes shows that the 
best correlation coefficient (potency: M3: r = 0.977, P = 0.001; M5: r = 0.930, P = 0.007 and 
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affinity: M3: r = 0.977, P = 0.001; M5: r = 0.941, P = 0.005) was found for the M3 subtype.  
Our conclusion is similar to findings in gastrointestinal smooth muscle preparations (e.a. 
Lazareno & Roberts, 1989; Doods et al., 1994; Preiksaitis & Laurier, 1998; Shi & Sarna, 
1997, 1999) and in other tissues (see review Eglen et al., 1996), where the postsynaptic 
muscarinic receptors also belong to the M3 subtype.  The slope of the Schild plot for 
AF-DX 116 and especially for methoctramine was very small.  In the guinea-pig LMMP 
preparations, the slope for methoctramine versus acetylcholine-induced contractions was also 
significantly less than unity (Barocelli et al., 1994).  One possible explanation might be the 
antagonism of a heterogenous receptor population (Kenakin, 1993).  Indeed, many 
investigators demonstrated the presence of M2 receptors together with M3 receptors on 
smooth muscle via molecular and radioligand binding studies, or pharmacologically via  
indirect methods (see reviews Ehlert et al. , 1999; Eglen, 2001).  Although the majority of the 
muscular muscarinic receptors belong to the M2 subtype, muscarinic agonists mainly cause 
contraction via  stimulation of the M3 receptors.  Stimulation of M2 receptors inhibits adenylyl 
cyclase, and they will oppose the relaxations due to activation of adenylyl cyclase by e.g. 
stimulation of b-adrenoceptors (Ehlert et al., 1999; Eglen, 2001).  The M2 receptors might 
also have an important effect during inflammation (Shi & Sarna, 1997, 1999).  However, 
when using the method described by Hegde et al. (1997) to determine the presence of these 
M2 receptors, no evidence was found for the presence of M2 receptors on the pig gastric 
fundus (results not shown). 
 
Table 4.3  Affinity values (pKi) at muscarinic receptors from literature 
 
 M1 M2 M3 M4 M5 
Atropine 9.27 8.96 9.39 9.11 9.11 
Pirenzepine 7.96 6.24 6.82 7.11 6.73 
AF-DX 116 6.44 7.20 6.07 6.68 5.29 
Methoctramine 7.08 7.78 6.40 6.89 6.36 
4-DAMP 9.03 8.14 9.28 8.49 8.91 
p-F-HHSiD 7.30 6.41 7.56 7.21 6.73 
MT-3 6.78 < 6.3 6.3 8.33  
 
Affinity values (pK i) are the mean values which refer to radioligand binding studies at cortex (M1), heart (M2), 
submandibular and lacrimal gland (M3) and human cloned muscarinic receptors expressed in Chinese hamster 
ovary (CHO) cells (data from Lazareno & Roberts, 1989; Lazareno et al., 1990; Pedder et al., 1991; Doods et 
al., 1993; Esqueda et al., 1996; Hegde et al., 1997).  For MT-3, affinity values (pA2) refer to the effect of MT-3 
on acetylcholine stimulation of [35S]GTPgS binding to membranes of CHO cells expressing the cloned human 
M1 – M4 receptors (Olianas et al., 1999). 
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4.5.2. Characterisation of the presynaptic muscarinic receptors 
 
The results of the experiments performed to characterise the presynaptic muscarinic 
receptors do not allow to strongly support one particular subtype. 
The rank order of potencies of the muscarinic antagonists at the presynaptic level, as 
assessed via their influence on tritium release (Table 4.1) corresponds with the 
pharmacological profile of the M1 subtype (Table 4.3) and the correlation between the 
presynaptic pIC50 values (Table 4.1) with published binding affinity values for the M1 
receptor (Table 4.3) is significant (r = 0.941, P = 0.005), but other points argue against M1 
receptors.  First, the potency of pirenzepine was almost tenfold lower than expected at M1 
receptors (see Table 4.3).  Second, pirenzepine did not discriminate between the electrically- 
and acetylcholine-induced contractions, suggesting that the auto -receptor is not an M1 
receptor.  Nevertheless, the pIC50 value for pirenzepine obtained versus acetylcholine-induced 
contractions was significantly lower than that on tritium outflow.  This might be due to the 
presence of inhibitory M1 receptors on cholinergic neurones innervating the longitudinal 
smooth muscle of the pig gastric fundus and contributing to the higher potency of pirenzepine 
on tritium outflow.  Indeed, a different type of presynaptic muscarinic receptors has already 
been demonstrated on nerve endings in the circular versus longitudinal smooth muscle of the 
guinea-pig ileum (Soejima et al., 1993; Dietrich & Kilbinger, 1995).  Release experiments in 
circular muscle strips without longitudinal muscle layer and myenteric plexus, to avoid the 
possible interference from the cholinergic nerve endings in the longitudinal muscle, did not 
yield reproducible results.  Therefore, pirenzepine was tested in strips cut in the direction of 
the longitudinal muscle layer.  The pIC50 value of pirenzepine versus electrically -induced 
contractions was larger than those versus acetylcholine-induced contractions in these strips, 
suggesting that facilitatory M1 receptors are present on the cholinergic neurones innervating 
the longitudinal muscle.  We have thus no explanation for the results with pirenzepine in the 
circular muscle strips. 
When looking at the pIC50 values (Table 4.1), the M2 subtype preferring muscarinic 
antagonists AF-DX 116 and methoctramine were more potent in facilitating the evoked 
tritium release than in inhibiting the contractile response.  Also, electrically-evoked 
contractions were enhanced at the lowest concentrations, presumably due to facilitation of 
acetylcholine release.  These results would correlate with the presence of presynaptic M2 
receptors, but this possibility cannot be maintained.  Indeed 1) The rank order of the pIC50 
values versus electrically-induced tritium release did not correspond with that of an M2 
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receptor; and  2) When comparing the presynaptic pIC50 values with published pKi values for 
the M2 muscarinic subtype (r = 0.581, P = 0.227), no significant correlation was found. 
With regard to M4 receptors, a significant correlation was found between our 
presynaptic pIC 50 values and the pKi values from literature (r = 0.944, P = 0.005). However, it 
is not possible to define with certainty that the presynaptic muscarinic receptor belongs to the 
M4 subtype.  Indeed, the M4 antagonist MT-3 had no effect on the electrically -induced 
contractions and tritium release up to 10-8 M.  As the pKi value of MT-3 on M4 receptors is 
8.33 (Olianas et al., 1999), some effect of 10-8 M can be expected.  Indeed, D’agostino et al. 
(2000) demonstrated that in the human detrusor MT-3 increases [3H]-acetylcholine release by 
acting at the M4 receptor with a pIC50 value of 8.50, also illustrating that the substance 
penetrates in muscle strips.  Higher concentrations of MT-3 (3x10-8 – 10-7 M) even decreased 
the electrically-induced tritium release in our study.  This would correlate with the presence 
of facilitatory M4 receptors rather than inhibitory M4 receptors on the cholinergic neurones.  
However, one might then also expect a decrease in the electrically-induced tritium release at 
higher concentrations of atropine, pirenzepine, AF-DX 116 and 4-DAMP in view of their 
capacity at M4 receptors (see Table 4.3).  Another possibility is that MT-3, which is a toxin 
(Adem & Karlsson, 1997; Jerusalinsky et al., 2000), has a toxic effect at these concentrations.  
Remarkably, although the electrically-induced release decreased at these high concentrations 
of MT-3, the electrically-induced contractions tended to increase.  This is probably due to a 
postsynaptic effect of MT-3 whereby MT-3 interferes with the signal transduction of 
acetylcholine.  Indeed, MT-3 caused a leftward shift of the concentration-response curve to 
acetylcholine, while it did not influence the concentration-response curve to KCl.  
With regard to M3 receptors, the presynaptic pIC50 values of the antagonists used 
correlated closely with the average of the binding affinities for the M3 receptor (r = 0.965, P = 
0.002), suggesting the presence of presynaptic M3 receptors, inhibiting the release of 
acetylcholine.  This supports findings in the guinea-pig and canine LMMP preparations, 
where presynaptic M3 receptors were responsible for the inhibition of acetylcholine release 
(Soejima et al., 1993; Kostka et al., 1989).  However, it should be noted that a good 
correlation was also obtained with the average of binding affinity values for the cloned human 
M5 receptor (r = 0.945, P = 0.005).  This may not surprise given the fact that most antagonists 
discriminate poorly between M3 and M5 receptors.  It can also not be excluded that more than 
one subtype of muscarinic receptor is involved in the presynaptic inhibitory control of 
acetylcholine release. 
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In conclusion, the postsynaptic contractile muscarinic receptors in the circular muscle 
of the pig gastric fundus seem to belong to the M3 receptor subtype, while the presynaptic 
muscarinic receptor cannot be clearly defined. 
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CHAPTER  5 
PRESYNAPTIC MODULATION OF CHOLINERGIC 
NEUROTRANSMISSION IN THE HUMAN PROXIMAL STOMACH 
 
5.1.  Summary 
 
This study investigates whether the cholinergic neurones, innervating the human proximal 
stomach, can be modulated by nitric oxide (NO) or vasoactive intestinal polypeptide (VIP), or 
via presynaptic muscarinic, a2- or 5-hydroxytryptamine4 (5-HT4-) receptors.  Circular muscle 
strips, without mucosa, were incubated with [3H]-choline to incorporate [3H]-acetylcholine 
into the cholinergic transmitter stores.  The basal and electrically-induced release of tritium 
and [3H]-acetylcholine were analysed in a medium containing guanethidine (4x10-6 M), 
hemicholinium-3 (10-5 M), physostigmine (10-5 M) and atropine  (10-6 M).  Tissues were 
stimulated twice for 2 min (S 1 and S2: 40 V, 1 ms, 4 Hz) and drugs were added before S2.  The 
NO synthase inhibitor L-NG-nitroarginine methyl ester (3x10-4 M) and the NO donor sodium 
nitroprusside (10-5 M), as well as VIP (10-7 M) did not influence the basal release nor the 
electrically-evoked release.  The a2-adrenoceptor agonist UK-14,304 (10
-5 M) significantly 
inhibited the electrically -evoked release of [3H]-acetylcholine, and this was prevented by the 
a2-adrenoceptor antagonist rauwolscine (2x10
-6 M).  The 5-HT4-receptor agonist prucalopride 
(3x10-7 M) significantly enhanced the electrically-evoked release of [3H]-acetylcholine, and 
the 5-HT4-receptor antagonist SB204070 (10-9 M) prevented this.  When atropine (10-6 M) 
was omitted from the medium and added before the second stimulation, it significantly 
increased the release of [3H]-acetylcholine.  These results suggest that the release of 
acetylcholine from the cholinergic neurones, innervating the circular muscle in the human 
proximal stomach, can be inhibited via  presynaptic muscarinic auto-receptors and a2-
adrenoceptors, and stimulated via presynaptic 5-HT4-receptors.  No evidence for modulation 
by NO or VIP was obtained. 
 
5.2.  Introduction 
  
With regard to motility, the stomach can be divided into a proximal and a distal part.  
The proximal stomach consists of the fundus and the orad third of the corpus (Kelly, 1980).  It 
acts as a reservoir for solid and liquid food, and plays a major role in the gastric emptying of 
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liquids (see review Kelly, 1980).  During a meal, the proximal stomach relaxes with minimal 
increases in intragastric pressure, as inhibitory non-adrenergic non-cholinergic (NANC) 
neurones become activated (Abrahamsson, 1986).  Then, a tonic contraction of the proximal 
stomac h generates a gastroduodenal pressure gradient that has been shown to play an 
important role in liquid emptying from the stomach (Kelly, 1980; Valenzuela & Liu, 1982).  
In man, in vivo experiments demonstrated that atropine reduces proximal gastric emptyin g, 
while the muscarinic agonist bethanechol tended to stimulate proximal stomach contractility 
(Parkman et al., 1999), suggesting that proximal gastric tone in man appears to be maintained, 
at least in part, by cholinergic input.  In contrast, the proximal gastric relaxation during a 
meal, as mentioned above, depends on NANC neurones, of which the nitrergic neurones, 
releasing nitric oxide (NO), are the most important (Lefebvre, 1993; Tonini et al., 2000).  
Interaction between the nitrergic and cholinergic system might occur at the level of the 
stomach, as indirect evidence from functional experiments suggests that NO might inhibit the 
release of acetylcholine from intrinsic cholinergic nerve endings in rat, canine and rabbit 
gastric fundus (Lefebvre et al., 1992; Baccari et al., 1993; Paterson et al., 2000).  In 
experimental animals, but not in humans, it has been shown that the release of acetylcholine 
at the level of the stomach can be modulated by different types of presynaptic receptors.  
Stimulation of presynaptic a 2-adrenoceptors (Jansson & Lisander, 1969; Lefebvre et al., 
1984; MacDonald et al., 1990; Leclere & Lefebvre, 2001) and vasoactive intestinal 
polypeptide (VIP)-receptors (Milenov et al., 1991; Baccari et al., 1994) inhibits the release of 
acetylcholine, while activation of 5-hydroxytryptamine4 (5-HT4)-receptors increases its 
release (Amemiya et al. , 1996; Matsuyama et al. , 1996; Takada et al., 1999).  The possibility 
of auto-inhibition of acetylcholine release by stimulation of presynaptic muscarinic receptors 
has been demonstrated in the pig and guinea-pig stomach (Ogishima et al., 2000; Leclere & 
Lefebvre, 2001). 
 The aim of this study in the human proximal stomach was to measure acetylcholine 
release directly and to investigate possible presynaptic modulation of acetylcholine release by 
NO, and via presynaptic a 2-adrenoceptors and muscarinic, VIP - and 5-HT4-receptors. 
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5.3.  Methods 
 
5.3.1.  Tissue preparation  
 
With the approval of the local ethics committee, macroscopically normal segments of 
gastric fundus (n = 18) or corpus (n = 2) were obtained from 20 patients (16 men, mean age 
63 years (range 30 - 95)) undergoing surgery for oesophageal or gastric carcinoma.  
Experiments were carried out on isolated circular smooth muscle strips of the human gastric 
fundus or corpus.  As no differences between fundus and corpus were observed, the results 
are pooled.  As soon as possible, the stomach was incubated in physiological salt solution 
(PSS) and transported to the laboratory.  After the mucosa was removed, full thickness strips 
of 1 to 1.5 cm in length and 0.3 cm in width (weight: 65 ± 3 mg; n  = 99) were cut in the 
direction of the circular muscle.  All strips were used within 24 hours, except in one case 
when strips were used up to 36 hours after surgery.  Strips were mounted vertically between 
two platinum wire electrodes (40 x 0.5 mm) under a load of 2 g in 2 ml organ baths 
containing PSS (composition in mM: 112 NaCl, 4.7 KCl, 1.2 MgCl2, 1.2 KH2PO4, 2.5 CaCl2, 
11.5 glucose, 25 NaHCO3, 0.0015 choline and 0.057 ascorbic acid), maintained at 37°C and 
gassed with carbogen (95% O2 / 5% CO2). Guanethidine (4x10-6 M) was present in the 
medium throughout all experiments.  Electrical field stimulation (EFS) was applied by means 
of a Grass stimulator (S88, USA). 
 
5.3.2.  Experimental protocol 
 
Basically, the same method was used as described for the labelling of acetylcholine 
pools in pig gastric fundus (Leclere & Lefebvre, 2001).  Briefly, during 60 min, the tissues 
were superfused at a rate of 2 ml/min, using a peristaltic pump (Gilson Minipuls, France).  
During the last 20 min the strips were subjected to continuous EFS (40 V, 1 ms, 0.5 Hz).  
After this equilibration period, superfusion was stopped and the preparations were incubated 
for 30 min with [3H]-choline (5 µCi/ml) during which the tissues were stimulated electrically 
(40 V, 1 ms, 2 Hz) in order to label their cholinergic transmitter stores. 
After the labelling procedure, the strips were superfused (2 ml/min) for 90 min with 
PSS to remove loosely bound radioactivity.  From now on the PSS contained in addition 10-5 
M hemicholinium-3 to prevent the re-uptake of choline, 10-5 M physostigmine to prevent the 
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hydrolysis of acetylcholine and, except in one series of experiments, 10-6 M atropine to 
prevent the auto -inhibition of acetylcholine release. 
After the washout period, the strips were no longer superfused but the content of the 
organ bath (2 ml) was collected and replaced each 3 min.  A total of 35 samples was 
collected.  1 ml of the samples was mixed with 4 ml of the scintillator containing solution 
Ultima Gold (Canberra Packard, USA).  The strips were stimulated twice for 2 min (S1 and 
S2; 40 V, 1 ms, 4 Hz), at 13 min (S1, 5th sample), and 73 min (S2, 25th sample) after the end 
of the washout period.  Tetrodotoxin (TTX), calcium-free medium, L-NG-nitroarginine methyl 
ester (L-NAME), sodium nitroprusside (SNP), VIP and atropine were added 30 min (15th 
sample) before S2.  The a 2-adrenoceptor antagonist rauwolscine was added 30 min (15th 
sample) before S2 and the a2-adrenoceptor agonist, UK-14,304 was added 3 min (24th 
sample) before S2.  The 5-HT4-receptor antagonist, SB204070 was added 36 min (13th 
sample) before S2 and the 5-HT4-receptor agonist, prucalopride was added 15 min (20th 
sample) before S2.  The a2- and 5-HT4-receptor antagonists and agonists were either given to 
the same tissue, or to separate tissues.  Once added, drugs remained present until the end of 
the experiment.  At the end of the experiment, tissues were blotted and weighed. 
 
5.3.3.  Measurement of radioactivity and separation by HPLC of radioactive compounds 
 
Radioactivity of all samples was measured by liquid scintillation counting (Packard 
Tri-Carb 2100 TR, Canberra Packard, USA).  External standardization was used to correct for 
counting efficiency.  Electrical stimulation induced an increase in tritium overflow, not only 
in samples 5 (S1) and 25 (S2) but also in the five samples after that with stimulation.  The 
stimulation-induced increase in tritium overflow was calculated by subtracting basal tritium 
overflow.  Basal tritium overflow during the period of enhanced tritium overflow was 
calculated by fitting a regression line through the values of the four samples just before 
stimulation and the values of the four samples starting from the sixth sample after stimulation. 
The amount of [3H]-acetylcholine, [3H]-choline and [3H]-phosphorylcholine in the 
samples was analysed by reverse phase HPLC (Bischoff Chromatography, Germany; 
Hyperchrome-HPLC-column, 250 x 4.6 mm, prepacked with HYPERSIL – ODS 5.0 µm).  A 
0.1 M phosphate buffer (pH 4.7) was used, containing methanol (8 vol %) and 
tetramethylammonium (0.2 mM).  The flow was 0.5 ml/min and the effluent was collected in 
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one min fractions.  This is a suitable method to separate the different components as we have 
demonstrated previously (Leclere & Lefebvre, 2001). 
HPLC was performed on one sample before S1 and S2 (sample 3 before S1 and sample 
23 before S2), and on the sample during stimulation (sample 5 and 25).  100 µl of the sample 
was injected into the HPLC; 27 fractions were collected, and each fraction was mixed with 2 
ml of Ultima Gold.  Fractions 7 to 12 contained the peaks of [3H]-phosphorylcholine and 
[3H]-choline and were taken together to calculate the amount of [3H]-phosphorylcholine and 
[3H]-choline, as both peaks could not be separated completely with the phosphate buffer we 
used.  Fractions 14 to 25 were summed to calculate the amount of [3H]-acetylcholine.  The 
real amount of [3H]-phosphorylcholine plus [3H]-choline and of [3H]-acetylcholine was 
calculated by subtracting the background counting.  Background counting was calculated by 
fitting a regression line through the values of the first five fractions and fractions 26 and 27.  
Finally, the percentage of [3H]-acetylcholine in each sample was calculated. 
 
5.3.4.  Drugs and radiochemicals 
   
L-ascorbic acid, atropine sulphate, choline chloride, guanethidine sulphate, L-NG-
nitroarginine methyl ester, sodium nitroprusside and vasoactive intestinal polypeptide were 
obtained from Sigma (St. Louis, USA), hemicholinium-3-bromide from RBI (Natick, USA), 
methanol from Lab-Scan (Dublin, Ireland), [methyl-3H]-choline chloride (2775 GBq/mmol) 
from NEN (Boston, USA), physostigmine salicylate from Federa (Brussels, Belgium), 
prucalopride (gift from Janssen Research Foundation, Beerse, Belgium), rauwolscine 
hydrochloride from Carl Roth KG (Karlsruhe, Germany), SB204070 ((1-butyl-4-piperidinyl)-
methyl-8-amino-7-chloro1,4-benzodioxane-5-carboxylate HCl) (gift from SmithKline 
Beecham, Worthing, England), tetramethylammonium chloride from Merck-Schuchardt 
(Hohenbrunn, Germany), tetrodotoxin from Alomone Labs (Jerusalem, Israel) and UK-14,304 
tartrate (5-bromo-6-[-2-imidazolin-2-ylamino]-quinoxaline) (gift from Pfizer, Sandwich, 
England). 
Drugs were dissolved and diluted with distilled water.  Stock solutions of 10-3 M TTX, 
10-2 M prucalopride and 10-3 M SB204070 were kept frozen at –20°C.  Dilutions were made 
the day of the experiment.  
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5.3.5.  Data analysis 
 
The ratios S2/S1 for total radioactivity (TR) and for tritiated acetylcholine were 
calculated.  Experimental data are expressed as means ± s.e.mean and n  refers to the number 
of tissues.  Results were compared by the unpaired t-test or by ANOVA followed by a t-test 
corrected for multiple comparisons (Bonferroni procedure) when more than two responses 
had to be compared.  P values of less than 0.05 were considered statistically significant.  
 
5.4.  Results  
 
5.4.1.  Control experiments 
 
Tissues were electrically stimulated in PSS containing guanethidine (4x10-6 M), 
hemicholinium-3 (10-5 M), physostigmine (10-5 M) and atropine (10-6 M) at 40 V, 1 ms,  
4 Hz for 2 min after incubation with [3H]-choline for 30 min.  Field stimulation caused a 
clearcut increase in total radioactivity (TR) and 15 min were required after stimulation to re-
establish the basal release of tritium.  [3H]-Acetylcholine could be detected when HPLC was 
used to separate the different components present in the samples.  The mean amounts of TR, 
[3H]-choline plus [3H]-phosphorylcho line and [3H]-acetylcholine before and during 
stimulation, as well as the percentage of [3H]-acetylcholine released are given in Table 5.1.  
The S2/S1 ratios for TR and [
3H]-acetylcholine were respectively 0.72 ± 0.01 and 0.74 ± 0.02 
(n = 23). 
 
Table 5.1  Outflow of total radioactivity, [3H]-choline plus [3H]-phosphorylcholine and [3H]-acetylcholine from 
the circular muscle of human proximal stomach. 
 
 TR Ch. + Ph.-Ch. ACh % ACh 
Sample 3 46 500 ± 4 500 2 140 ± 200 380 ± 70 14 ± 2 
S1 1 556 700 ± 216 500*** 6 550 ± 690*** 28 640 ± 4 370*** 77 ± 2*** 
Sample 23 28 700 ± 2 300 1 480 ± 150 280 ± 60 16 ± 3 
S2 1 093 300 ± 145 600
### 3 080 ± 270### 19 080 ± 2 920### 83 ± 2### 
S2/S1 0.72 ± 0.01  0.74 ± 0.02  
 
Radioactivity is expressed as dpm per g tissue (TR: Total radioactivity) and dpm per g tissue for 100 µl injected 
in the HPLC (Ch. + Ph.-Ch.: [3H]-choline plus [3H]-phosphorylcholine; ACh: [3H]-acetylcholine).  TR for S1 and 
S2 represents the sum of radioactivity above baseline in respectively sample 5 and sample 25 and the following 
five samples, while [3H]-choline plus [3H]-phosphorylcholine and [3H]-acetylcholine for S1 and S2 represent the 
amount of these compounds detected by HPLC in 100 µl of respectively sample 5 and sample 25.  Results are 
given as mean ± s.e.mean, n = 23.  *** P < 0.001: Significantly different from values before S1 (sample 3).  
### P  
< 0.001: Significantly different from values before S2 (sample 23). 
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TTX (3x10-6 M; n = 3) or removal of extracellular calcium (n  = 3) did not influence 
basal release of TR, but they nearly abolished the electrically-evoked tritium release as 
compared with control (P < 0.001). In control tissues (n = 3), the S2/S1 ratios for release of TR 
and [3H]-acetylcholine were 0.71 ± 0.06 and 0.69 ± 0.03, respectively.  After superfusion with 
TTX or calcium-free medium, the S2/S1 ratios for TR were respectively 0.08 ± 0.04 and 0.05 
± 0.02, while those for [3H]-acetylcholine were respectively 0.01 ± 0.02 and 0.00 ± 0.02. 
 
5.4.2.  The effects of L-NG-nitroarginine methyl ester, sodium nitroprusside and VIP 
  
The NO synthase inhibitor L-NAME (3x10-4 M; n = 6) or the NO donor SNP (10-5 M; 
n = 5), when added 30 min before the second stimulation, had no influence on basal release of 
TR.  L-NAME or SNP had also no effect on the electrically-evoked increase of TR or [3H]-
acetylcholine released (Table 5.2).  Similarly, VIP (10-7 M; n = 5), added 30 min before S2, 
was without effect on the basal release of TR and on the electrically-evoked increase in 
release of TR or [3H]-acetylcholine (Table 5.2). 
 
5.4.3.  The effects of UK-14,304 and rauwolscine 
  
The a2-adrenoceptor antagonist rauwolscine (2x10-6 M; n = 9) did not alter the basal 
efflux of TR, nor had it any effect per se on the S2/S1 ratio for TR (S 2/S1 ratios for control and 
rauwolscine: 0.66 ± 0.04 and 0.66 ± 0.05, respectively, P > 0.05; n = 4). 
 
Table 5.2  Influence of a NOS inhibitor, a NO donor and VIP on the ratio (S2/S1) of the efflux of total 
radioactivity and [3H]-acetylcholine induced by two periods of stimulation. 
 
Drugs added before S 2 TR ACh n 
None 0.71 ± 0.03 0.77 ± 0.04 6 
L-NAME (3x10-4 M) 0.72 ± 0.03 0.74 ± 0.10 6 
None 0.70 ± 0.04 0.78 ± 0.04 5 
SNP (10-5 M) 0.69 ± 0.03 0.75 ± 0.05 5 
    
None 0.74 ± 0.03 0.76 ± 0.02 5 
VIP (10-7 M) 0.79 ± 0.02 0.81 ± 0.03 5 
 
After incubation with [3H]-choline and washout, tissues were stimulated twice (S1 and S2: 40 V, 1 ms, 4 Hz, 2 
min) and the content of the organ bath (2 ml) was collected every 3 min.  The electrically-evoked efflux by S2 is 
expressed as a ratio of that by S1.  HPLC was performed to calculate the S2/S1 ratio for [
3H]-acetylcholine.  L-
NG-nitroarginine methyl ester (L-NAME), sodium nitroprusside (SNP) or vasoactive intestinal polypeptide (VIP) 
were added 30 min before S2.  TR: total radioactivity; ACh: [
3H]-acetylcholine.  Mean ± s.e.mean.  n refers to 
number of tissues used. 
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Figure 5.1  Effects of UK-14,304 and UK-14,304 in the presence of rauwolscine on the electrically-evoked 
release of total radioactivity (TR) from preparations of human proximal stomach pre-incubated with [3H]-
choline.  Tissues were stimulated twice (S1 and S2: 40 V, 1 ms, 4 Hz, 2 min), and the content of the organ bath (2 
ml) was collected in 3 min samples for TR.  A.  TR outflow of control experiments (n = 6).  B.  Release of TR 
when UK-14,304 (10-5 M) was added 3 min before S2 (n = 6).  C.  Release of TR when rauwolscine (2x10
-6 M) 
was added 30 min and UK-14,304 (10-5 M) 3 min before S2 (n = 5).  The results are given as mean ± s.e.mean. 
 
The selective a2-adrenoceptor agonist UK-14,304 (10-5 M), added 3 min before the 
second stimulation period, did not alter the basal efflux of TR (n = 6).  However,  
UK-14,304 significantly reduced the amount of TR and [3H]-acetylcholine released upon 
electrical stimulation.  In control tissues, the S2/S1 ratios for release of TR and [3H]-
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acetylcholine were 0.72 ± 0.02 and 0.70 ± 0.03 respectively (Figure 5.1A), while in the 
presence of UK-14,304 the ratios were 0.33 ± 0.03 and 0.31 ± 0.04 (P  < 0.001; n = 6; Figure 
5.1B).  Rauwolscine prevented the inhibition of the electrically-evoked release of TR and 
[3H]-acetylcholine by UK-14,304 (S 2/S1 ratios for TR and [3H]-acetylcholine in the presence 
of rauwolscine: 0.67 ± 0.06 and 0.58 ± 0.04 respectively, P > 0.05 compared with control, n  = 
5; Figure 5.1C). 
 
5.4.4.   The effects of prucalopride and SB204070 
  
The 5-HT4-receptor antagonist SB204070 (10-9 M; n  = 8) did not alter the basal release 
of TR, nor did SB204070 influence the S2/S1 ratio for TR versus control (0.64 ± 0.06 and 0.66 
± 0.04, respectively, P  > 0.05; n = 4). 
The selective 5-HT4-receptor agonist prucalopride (3x10-7 M) did not alter the basal 
efflux of TR.  However, prucalopride significantly enhanced the amount of TR (P < 0.001) 
and [3H]-acetylcholine (P  < 0.01) released upon electrical stimulation (n  = 6; Figure 5.2).  
When SB204070 was added before prucalopride, it completely prevented the increase of the 
electrically-evoked release of TR and [3H]-acetylcholine by prucalopride (P  > 0.05; n = 4; 
Figure 5.2). 
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Figure 5.2  Effects of prucalopride (pruca) and prucalopride in the presence of SB204070 (SB) on the 
electrically-evoked release of total radioactivity (TR) and [3H]-acetylcholine from preparations of human 
proximal stomach pre-incubated with [3H]-choline.  Tissues were stimulated twice (S1 and S2: 40 V, 1 ms, 4 Hz, 
2 min); SB204070 (10-9 M) was added 36 min and prucalopride (3x10-7 M) 15 min before S2.  The electrically-
evoked efflux by S2 is expressed as a ratio of that by S1.  HPLC was performed to calculate the S2/S1 ratio for 
[3H]-acetylcholine.  Each column represents the mean ± s.e.mean.  ** P < 0.01; *** P < 0.001: Significantly 
different from control.  Numbers above the columns refer to number of tissues used. 
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5.4.5.  The effect of atropine 
 
 Until now, all experiments were performed in the presence of the muscarinic 
antagonist atropine.  To study whether the released acetylcholine is able to influence its own 
release, a series of experiments was done in the absence of atropine.  In the absence of 
atropine, the mean basal release of TR before S1 (sample 3) was 54 200 ± 14 600 dpm per g 
tissue (n  = 6), which is not significantly different from the basal release in the presence of 
atropine.  However, the mean increase in TR released during the first stimulation was 563 600 
± 153 400 dpm per g tissue, a significant decrease in comparison to tissues stimulated in the 
presence of atropine (1 556 700 ± 216 500 dpm per g tissue, see Table 5.1, P < 0.05), 
suggesting that acetylcholine inhibits its own release.  This was confirmed by the observation 
that atropine (10-6 M), added 30 min before S2, significantly increased the S2/S1 ratios for both 
TR and [3H]-acetylcholine released upon electrical stimulation, without having an effect on 
basal release.  In control tissues, the S2/S1 ratios for release of TR and [3H]-acetylcholine were 
0.82 ± 0.05 (n = 6) and 0.92 ± 0.04 (n  = 5) respectively, while the ratios were 2.03 ± 0.22 (P < 
0.001; n = 6) and 2.70 ± 0.52 (P < 0.01; n = 5) when atropine was added between S1 and S2. 
 
5.5.  Discussion 
 
 This study investigated whether the release of acetylcholine in the human proximal 
stomach can be influenced by NO or VIP, or via  presynaptic muscarinic, a2- or 5-HT4-
receptors, as assessed by direct measurement of [3H]-acetylcholine release.  Experiments were 
conducted on preparations which had been incubated with [3H]-choline to incorporate [3H]-
acetylcholine into the cholinergic transmitter stores. 
 
5.5.1.  Control experiments 
 
 Incubation of the human proximal stomach with [3H]-choline resulted in the synthesis 
of [3H]-acetylcholine, that was released during field stimulation.  The field-stimulated release 
of TR and [3H]-acetylcholine was prevented by TTX or by the removal of extracellular 
calcium, indicating a neuronal release dependent upon respectively, the opening of sodium 
channels, and the presence of calcium in the external medium.  Basal release of TR was not 
influenced in the presence of TTX or the absence of extracellular calcium, indicating a low 
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degree of spontaneous activity of the cholinergic neurones during rest.  This  implies a low 
exchange of newly synthesised [3H]-acetylcholine against unlabelled acetylcholine, 
suggesting that electrical stimulation during labelling is necessary, as it is in the rat myenteric 
plexus and the pig gastric fundus (Wessler & Werhand, 1990; Leclere & Lefebvre, 2001).  
Electrical stimulation not only caused an increase in the release of [3H]-acetylcholine, 
but also a moderate increase in the outflow of [3H]-phosphorylcholine and [3H]-choline.  Our 
results are in contrast with results in the guinea-pig and rat myenteric plexus, where electrical 
field stimulation only caused an increase in [3H]-acetylcholine release (Wessler & Werhand, 
1990; Hebeib & Kilbinger, 1996), but are in agreement with results in the canine ileum, pig 
gastric fundus and rat and guinea-pig trachea (Wessler et al., 1990, 1991; Hryhorenko et al. , 
1994; Leclere & Lefebvre, 2001).  As the S2/S1 ratio for [3H]-acetylcholine was 
systematically similar to that for TR, it will no longer be necessary to separate all radioactive 
components in future experiments with this tissue as the results of TR reflect those of [3H]-
acetylcholine. 
 
5.5.2.  Presynaptic modulation of acetylcholine release 
 
5.5.2.a.  Acetylcholine 
 
 In this type of experiments, the presence of an acetylcholinesterase inhibitor 
(physostigmine) is required to be able to determine the amount of [3H]-acetylcholine released.  
Our previous experiments in the pig gastric fundus illustrated that the process of auto-
inhibition of acetylcholine release via stimulation of presynaptic muscarinic auto-receptors on 
the cholinergic neurones is increased in the presence of physostigmine.  This auto-inhibition 
was prevented by adding atropine together with physostigmine (Leclere & Lefebvre, 2001), 
and this condition was also used in the actual human proximal stomach experiments.  The 
presence of inhibitory presynaptic muscarinic auto-receptors in the human proximal stomach 
was confirmed in the experiments in the absence of atropine in the basal medium since: (1) 
when only physostigmine was present, about three times less tritium was liberated during 
electrical stimulation; (2) the ratio S2/S1 for TR and [3H]-acetylcholine was significantly 
increased when atropine was added before S2 compared to control strips in the presence of 
physostigmine alone.  The presence of presynaptic muscarinic auto -receptors on the 
cholinergic neurones of human proximal stomach is in agreement with the general concept 
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that presynaptic muscarinic receptors inhibit the release of acetylcholine from peripheral ends 
of parasympathetic nerve fibres in tissues of different species (see review Starke et al., 1989). 
 
5.5.2.b.  NO and VIP  
 
 In several species and tissues it has been demonstrated that NO can act presynaptically 
on cholinergic neurones to enhance the basal release of acetylcholine and to inhibit the 
electrically-evoked release of acetylcholine (Kilbinger, 1996).  Functional experiments in the 
human gastric fundus led to the proposal that endogenous NO might tonically inhibit the 
release of acetylcholine (Tonini et al., 2000).  From functional studies, however, it is not 
possible to determine with certainty the site(s) of action of NO (presynaptic inhibition of 
acetylcholine release versus postsynaptic functional antagonism).  For this reason, the effects 
of a NO synthase inhibitor and a NO donor on [3H]-acetylcholine release in the human 
proximal stomach were determined.  Blockade of NO synthase, or addition of SNP did not 
significantly affect the basal release of TR or the electrically-evoked overflow of TR and 
[3H]-acetylcholine, suggesting that NO does not modulate acetylcholine release in the human 
proximal stomach.  This is in agreement with the findings in other species and tis sues where 
NO donors and NO synthase inhibitors do not modify [3H]-acetylcholine release in either 
tracheal or intestinal preparations (Brave et al., 1991; Ward et al., 1993, 1996; Milenov & 
Kalfin, 1996; Rae et al., 1998; Leclere & Lefebvre, 2001).  Still, as the strips are cut in the 
direction of the circular muscle layer, it cannot be excluded that longitudinally directed 
interneurones and/or sensory neurones are not fully assessed; modulation of acetylcholine 
released by NO might still be present at this level. 
 As VIP is co-localised with NO in the majority of the myenteric neurones in the 
human gastric fundus, and VIP is released during electrical field stimulation (Tonini et al., 
2000), the effect of VIP on the electrically-evoked release of acetylcholine was investigated.  
The concept that VIP can inhibit cholinergic neurotransmission via a presynaptic mechanism 
has indeed been proposed for gastrointestinal and respiratory tissue (Hakoda & Ito, 1990; 
Milenov et al., 1991; Baccari et al. , 1994).  VIP did not significantly affect the basal release 
of TR or electrically-evoked overflow of TR and [3H]-acetylcholine, suggesting that VIP does 
not modulate [3H]-acetylcholine release in human proximal stomach.  This is in agreement 
with observations in various gastrointestinal and respiratory tissues (Lefebvre et al., 1992; 
Ward et al., 1993; Sekizawa et al.1993), although modulation of acetylcholine released by 
VIP might still be present at the level of the longitudinally directed interneurones and/or 
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sensory neurones.  Indeed, it has been demonstrated that PACAP and VIP can stimulate the 
spontaneous and inhibit the electrically -evoked release of [3H]-acetylcholine of guinea-pig 
longitudinal muscle myenteric plexus preparations (Katsoulis et al., 1993). 
 
5.5.2.c.  Presynaptic a2-adrenoceptors 
 
 It has already been shown that presynaptic inhibitory a2-adrenoceptors are present on 
cholinergic neurones in various gastrointestinal and other tissues (see introduction; for review 
De Ponti et al., 1996).  In the actual study, the a 2-adrenoceptor agonist UK-14,304 
significantly reduced the stimulation-induced efflux of TR and [3H]-acetylcholine in the 
human proximal stomach, as it did in guinea-pig ileum and pig gastric fundus (Funk et al., 
1995; Leclere & Lefebvre, 2001). The incubation period of 3 min for UK-14,304 is sufficient 
as increasing this period to 30 min did not increase the inhibitory effect of UK-14,304 (results 
not shown).  The inhibition of the stimulated overflow produced by UK-14,304 was 
antagonised by rauwolscine, a selective a2-adrenoceptor antagonist (Weitzell et al., 1979), 
indicating that cholinergic nerves of the human proximal stomach are endowed with a2-
adrenoceptors, causing inhibition of acetylcholine release.  This corresponds with the general 
idea that endogenous noradrenaline is able to inhibit non-sphincteric muscle in the 
gastrointestinal tract by inhibition of acetylcholine release from the cholinergic motor 
neurones via  presynaptic a2-adrenoceptors (McIntyre & Thompson, 1992).  Whether 
endogenous noradrenaline is able to influence acetylcholine release in the human proximal 
stomach within the experimental conditions was not assessed, as guanethidine was 
continuously present in the PSS, preventing the release of endogenous noradrenaline.  
 
5.5.2.d.  Presynaptic 5-HT4-receptors 
 
 Stimulation of gastrointestinal 5-HT4-receptors induces contraction or relaxation 
depending on the tissue and species studied.  Contractile responses are generally ascribed to 
5-HT4-receptors localized on cholinergic neurones, facilitating acetylcholine release (see e.g. 
Elswood et al., 1991; Kilbinger & Wolf, 1992; Briejer & Schuurkes, 1996) while the relaxant 
responses are due to 5-HT4-receptors localized on smooth muscle (see e.g. Tam et al., 1995; 
Prins et al., 2000).  In the stomach, facilitatory 5-HT4-receptors on cholinergic neurones are 
present in the guinea-pig (Buchheit & Buhl, 1994; Matsuyama et al., 1996) and rat (Amemiya 
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et al., 1996).  Whereas nervous 5-HT4-receptors seem present in the rat gastric fundus 
(Amemiya et al., 1996), a recent study in the guinea-pig stomach suggested a regional 
distribution of the nervous 5-HT4-receptors, being present in the corpus and antrum but absent 
in the fundus (Takada et al., 1999).  In this study, we assessed the possible presence of 
facilitatory 5-HT4-receptors on the cholinergic nerves by use of the selective 5-HT4-receptor 
agonist prucalopride (Briejer et al., 1998).  Prucalopride significantly increased the 
stimulation-induced efflux of TR and [3H]-acetylcholine in the human proximal stomach.  
This increase was completely antagonised by SB204070, a selective 5-HT4-receptor 
antagonist (Wardle et al., 1994).  This indicates that cholinergic nerves of the human 
proximal stomach are endowed with 5-HT4-receptors stimulating acetylcholine release.  A 
stimulatory effect of gastroprokinetic agents such as cisapride can thus also be expected at the 
level of the human proximal stomach.  As SB204070 did not influence the S2/S1 ratio for TR, 
it is unlikely that electrical stimulation causes the release of endogenous 5-HT which might 
act on 5-HT4-receptors to enhance [3H]-acetylcholine release. 
 
 In conclusion, the data provided by this study indicate that measurement of tritium 
release after incubation with [3H]-choline can be used to reflect endogenous acetylcholine 
release in response to cholinergic neuron stimulation in the human proximal stomach.  The 
results indicated the presence of presynaptic inhibitory a2-adrenoceptors and muscarinic auto-
receptors, and excitatory 5-HT4-receptors.  No evidence for the modulation of acetylcholine 
release by NO or VIP was obtained. 
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CHAPTER  6 
5-HT4-RECEPTORS LOCATED ON CHOLINERGIC NERVES AS 
WELL AS ON SMOOTH MUSCLE CELLS INVOLVED IN 
CONTRACTILITY OF HUMAN COLON CIRCULAR MUSCLE 
 
6.1.  Summary 
 
5-HT4-receptor agonists promote colonic propulsion. The alteration of circular muscle (CM) 
motility underlying this involves inhibition of contractility via smooth muscle 5-HT4-
receptors and proximal colonic motility stimulation, the mechanism of the latter not having 
been characterised. To identify and characterise a 5-HT4-receptor-mediated stimulation of 
human colon CM contractile activity, 5-HT4-receptor ligands were tested on electrical field 
stimulation (EFS)-induced contractions of human colonic muscle strips cut in the circular 
direction (called ‘whole tissue’ strips). Additionally, after incubation of tissues with [3H]-
choline these compounds were tested on EFS-induced release of tritium in whole tissue strips 
and in ‘isolated’ CM strips, obtained by superficial cutting in the circular muscle layer. 
Tetrodotoxin (TTX) and atropine blocked EFS-induced contractions of whole tissue CM 
strips. Prucalopride (3x10-7 M) evoked a heterogenous response on EFS-induced contraction, 
ranging from inhibition (most frequently observed) to enhancement.  In the release 
experiments, EFS-induced tritium efflux was blocked by TTX.  Prucalopride increased EFS-
induced tritium and [3H]-acetylcholine efflux in whole tissue as well as in isolated CM strips. 
All effects of prucalopride were antagonised by the selective 5-HT4-receptor antagonist 
GR113808. The results obtained indicate the presence of 5-HT4-receptors on cholinergic 
nerves within the CM of human colon. 
 
6.2.  Introduction 
 
5-HT4-receptors have been described to be abundantly expressed in the gastrointestinal 
tract, mediating various aspects of gut motor function (Hegde & Eglen, 1996).  Although 
most pharmacological studies were performed with intact rodents or rodent isolated tissues, 
dogs and humans are endowed with these receptors as well.  This was demonstrated in recent 
in vivo and in vitro studies.  In humans, 5-HT4-receptor agonists have been demonstrated to 
stimulate whole gut transit, as well as colonic transit (Emmanuel et al., 1998; Bouras et al., 
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1999).  Colonic contractility patterns were influenced by the 5-HT4-receptor agonist 
prucalopride in conscious dogs, equipped with circularly orientated force transducers on the 
various regions of large intestine (Briejer et al., 2001b) and the change of colonic motility 
was often associated with increased stool frequency.  Prucalopride stimulated proximal, and 
inhibited distal colonic motility, and reduced the time to the first giant migrating contraction 
(GMC).  GMCs are held responsible for mass movements over longer distances of large 
intestine (Karaus & Sarna, 1987).  We have attempted to establish correlates of these in vivo 
actions by means of isolated tissue studies. 
In the longitudinal muscle layer of both canine large intestine (from ascending to 
descending colon) and human large intestine (from ascending colon to rectum), 5-HT4-
receptors on cholinergic nerves mediate facilitation of cholinergic neurotransmission resulting 
in enhanced longitudinal muscle contractility (Prins et al., 2000a).  In canine large intestine 
circular muscle (CM), smooth muscle 5-HT4-receptors mediate relaxation, a phenomenon that 
gradually increases in efficiency going from the ascending colon to the rectum (Prins et al., 
1999).  In human large intestine CM, 5-HT4-receptors located on smooth muscle mediate 
relaxation, irrespective of the region observed (Prins et al., 2000b).  This inhibitory action on 
circular muscle tone demonstrated  in vitro may explain the distally increasing circular muscle 
inhibition observed with prucalopride in dog large intestine in vivo (Briejer et al., 2001b).  
Although the effects of 5-HT4-receptor agonists on human colonic motility in vivo have not 
been documented, it can be anticipated from the inhibitory 5-HT4-receptors on colon CM that 
also in humans, activation of 5-HT4-receptors will be associated with reduction of large 
intestine luminal resistance.  However, the stimulation of human colonic transit by 5-HT4-
receptor agonists cannot be triggered by inhibition of circular muscle activity alone.  It 
remains thus to be investigated what mechanism underlies the 5-HT4-receptor-mediated 
stimulation of colonic motility in the circular muscle.  We hypothesised that in human colon 
circular muscle, in addition to the presence of inhibitory smooth muscle 5-HT4-receptors, 
excitatory 5-HT4-receptors are present on cholinergic neurones.   
We set out to investigate this via  two experimental approaches.  First, in classical 
organ bath experiments we tested the effect of a 5-HT4-receptor agonist and antagonist on 
electrical field stimulation (EFS)-induced contractions of strips from human large intestinal 
circular muscle.  Second, we assessed the effect of these ligands on EFS-triggered release of 
tritiated acetylcholine from those muscle strips. 
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6.3.  Methods 
 
6.3.1.  Tissue preparation  
 
With the approval of the local ethics committee, human large intestine specimens (6 
ascending colon, 2 transverse colon, 1 descending colon and 11 sigmoid colon) were obtained 
during colectomy surgery for colonic cancer.  
 
6.3.1.a.  Dissection and preparation of muscle strips 
 
The segments were cut open along the longitudinal axis.  Luminal contents were 
rinsed out with Krebs-Henseleit solution (composition in mM: glucose 11.1, CaCl2 2.51, 
NaHCO3 25, MgSO4 1.18, KH2PO4 1.18, KCl 4.69 and NaCl 118) and the mucosa and 
adhering mesentery were removed.  The tissue was stored in fresh solution at 4 °C to be used 
the next day. 
There were two ways of dissection of CM strips.  The first one was obtained by 
cutting through the entire wall in the circular direction.  This conventional dissection method 
yielded CM strips that contained circular muscle, some longitudinal muscle, and the 
intermediate myenteric plexus.  These strips were called ‘whole tissue’ CM strips and were 
used for both organ bath experiments and release experiments.  Using a light microscope, the 
other type of CM strips was obtained by superficial cutting in the circular muscle layer with a 
pair of curved scissors.  This provided CM strips that did not contain longitudinal muscle and 
they were called for future reference ‘isolated’ CM strips.  Isolated CM strips were used for 
release experiments only.  This dissection procedure was performed to evaluate the possible 
contribution of excitatory 5-HT4-receptors on cholinergic neurones in the longitudinal muscle 
layer (Prins et al., 2000a).  We were aided in this dissection procedure by the use of 
intertaenial tissue of human specimens, in which the longitudinal muscle layer is clearly less 
pronounced. 
 
6.3.2.  Contractility study 
 
 Only ‘whole tissue’ muscle strips (measuring about 2-3 cm in length and 2-3 mm in 
width) were used to study contractility as isolated CM strips only showed very weak 
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contractions to electrical stimulation.  The strips were anchored to organ bath hooks between 
platinum-wire electrodes (40 mm length, 0.5 mm width) and suspended in a classical organ 
bath set-up for isotonic measurement (2g load).  The 20 ml organ baths were filled with 
Krebs-Henseleit solution, kept at 37 °C and gassed with carbogen (95% O2, 5% CO2).  
Electrical field stimulation (EFS) was applied using stimulation equipment made at the 
Janssen Research Foundation. 
 
6.3.2.a.  Experimental protocol of contractility study 
 
After a 30 min period of stabilisation, the strips were contracted with carbachol (10-5 M) 
to test their viability and responsiveness.  After wash-out, NG-nitro-L-arginine (L-NNA; 10-4 
M) was added to the organ bath solution in order to prevent relaxation due to EFS-induced 
release of nitric oxide.  After 30 min of incubation, the muscle strips were electrically 
stimulated (initial parameters: 1 ms pulses in trains of 10 s, at an interval of 3 min, 20 V at 12 
Hz).  Each pulse train resulted in a contraction, and after 4-5 consecutive pulse trains, 
contractions were reproducible.  The voltage was then reduced until reproducible contractions 
with an amplitude approximating 30-50% of the contraction observed at 20 V was obtained.  
Stimulation at this voltage was continued for at least 15 min, followed by addition of the 
selective 5-HT4 receptor antagonist, GR113808 or solvent, which, in turn, was left to incubate 
for 15 min, while EFS was continued.  Then, the selective 5-HT4-receptor agonist, 
prucalopride was added to the organ bath solution under continued EFS and the response was 
followed for another 15 min.  
 
6.3.3.  Release study 
 
The muscle strips (whole tissue or isolated CM strips) were transported in ice-chilled 
Krebs-Henseleit solution to the laboratory where the release study was conducted.  Upon 
receipt, the Krebs-Henseleit solution was replaced by physiological salt solution (PSS; 
composition in mM: glucose 11.5, CaCl2 2.5, NaHCO3 25, MgCl2 1.2, KH2PO4 1.2, KCl 4.7, 
NaCl 112, choline 0.0015 and ascorbic acid 0.057).  The human colon tissue preparations 
weighed 24.13 ± 2.81 (whole tissue CM; n  = 34) and 7.32 ± 0.80 (isolated CM; n = 149) mg, 
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respectively.  Whole tissue preparations used for release experiments were 1 cm in length and 
3 mm in width, while measures of isolated CM preparations were more variable: 3-6 mm in 
length and 2-3 mm in width.  A first series of experiments with single isolated CM strips 
revealed that the amount of total radioactivity (TR) released was too small to allow separation 
of the different components by HPLC.  Therefore, a second series of experiments was 
performed whereby four isolated CM strips were mounted in one organ bath.  As no 
differences between the different regions of the human colon were observed, the results were 
pooled.  All human strips were used within 24 hours after surgery.  Strips were mounted 
vertically without load between 2 platinum wire electrodes (40 x 0.5 mm) in 2 ml organ baths 
containing PSS, maintained at 37°C and gassed with carbogen (95% O2 / 5% CO2).  
Guanethidine (4x10-6 M) was present in the medium throughout all experiments to avoid 
noradrenergic influences. EFS was applied by means of a Grass stimulator (S88, USA).  
 
6.3.3.a.  Experimental protocol of release study 
 
Basically, the same method was used as described for the labelling of acetylcholine 
pools in pig gastric fundus (Leclere & Lefebvre, 2001).  Briefly, using a peristaltic pump 
(Gilson Minipuls, France), the tissues were superfused at a rate of 2 ml/min during 60 min, 
and continuous EFS (40 V, 1 ms, 0.5 Hz) was applied the last 20 min.  After this equilibration 
period, superfusion was stopped and the preparations were incubated for 30 min with [3H]-
choline (5 µCi/ml) during which the tissues were stimulated electrically (40 V, 1 ms, 2 Hz) in 
order to label their cholinergic transmitter stores.  
After the labelling procedure, the strips were superfused (2 ml/min) for 60 min with 
PSS to remove loosely bound radioactivity. From now on the PSS contained hemicholinium-3 
(10-5 M) to prevent the re-uptake of choline, physostigmine (10-5 M) to prevent the hydrolysis 
of acetylcholine and atropine (10-6 M) to prevent the auto-inhibition of acetylcholine release. 
After the washout period, the strips were no longer superfused but the content of the 
organ bath, filled with 1 ml, was collected at 3 min intervals.  A total of 35 samples was 
collected.  0.5 ml of the samples was mixed with 2 ml of the scintillator containing solution 
Ultima Gold (Canberra Packard, USA).  The strips were stimulated twice for 2 min (S1 and 
S2; 15 V, 1 ms, 4 Hz), at 13 min (S1, 5th sample), and 73 min (S 2, 25th sample) after the end of 
the washout period.  Tetrodotoxin (TTX), calcium free medium and w -conotoxin-GVIA were 
added 30 min (15th sample) before S2, GR113808 was added 36 min (13th sample) before S2 
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and prucalopride was added 15 min (20th sample) before S2, and they remained present until 
the end of the experiment.  At the end of the experiment, tissues were blotted and weighed. 
 
6.3.3.b.  Measurement of radioactivity and separation by HPLC of radioactive compounds 
 
Radioactivity of all samples was measured by liquid scintillation counting (Packard Tri-
Carb 2100 TR, Canberra Packard, USA).  External standardization was used to correct for 
counting efficiency.  Electrical stimulation induced an increase in tritium overflow, not only 
in samples 5 (S 1) and 25 (S 2) but also in the two till four following samples.  The stimulation-
induced increase in tritium overflow was calculated by subtracting basal tritium overflow.  
Basal tritium overflow during the period of enhanced tritium overflow was calculated by 
fitting a regression line through the values of the three samples just before stimulation and the 
values of the three samples starting from where overflow had returned to basal values after 
stimulation. 
The amount of [3H]-acetylcholine, [3H]-choline and [3H]-phosphorylcholine in the 
samples was analysed by reverse phase HPLC (Bischoff Chromatography, Germany; 
Hyperchrome-HPLC-column, 250 x 4.6 mm, prepacked with HYPERSIL – ODS 5.0 µm).  A 
0.1 M phosphate buffer (pH 4.7) was used, containing methanol (8 vol %) and 
tetramethylammonium (2x10-4 M).  The flow was 0.5 ml/min and the effluent was collected in 
one min fractions.  This is a suitable method to separate the different components as 
demonstrated previously (Leclere & Lefebvre, 2001). 
HPLC was performed on one sample before S1 and S2 (sample 3 and sample 23, 
respectively), and on the sample during stimulation (sample 5 and 25).  100 µl of the sample 
was injected into the HPLC; 27 fractions were collected, and each fraction was mixed with 2 
ml of Ultima Gold.  Fractions 7 to 12 contained the peaks of [3H]-phosphorylcholine and 
[3H]-choline and were taken together to calculate the amount of [3H]-phosphorylcholine and 
[3H]-choline.  Fractions 14 to 25 were summed to calculate the amount of [3H]-acetylcholine 
(see Figure 6.2B and C).  The absolute amount of [3H]-phosphorylcholine plus [3H]-choline 
and of [3H]-acetylcholine was calculated by subtracting the background counting.  
Background counting was calculated by fitting a regression line through the values of the first 
5 fractions and fractions 26 and 27.  Finally, the percentage of [3H]-acetylcholine in each 
sample was calculated. 
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6.3.4.  Data analysis 
 
6.3.4.a.  Contractility study 
 
For each individual (whole) muscle strip, the average contraction to five EFS pulse 
trains before addition of treatment or solvent was taken as 100% (called the initial value) and 
all contractions of this strip were related to this initial value. Repeated measures over time 
were analysed using PROC MIXED (SAS v PC 6.12) for data with an unbalanced covariance 
structure. 
 
6.3.4.b.  Release study 
 
The ratios S2/S1 for TR and for tritiated acetylcholine were calculated. Results were 
compared by a paired or unpaired t-test, where appropriate. In the case where more than two 
responses were assessed, ANOVA was performed, followed by a post-hoc t-test corrected for 
multiple comparisons (Bonferroni procedure).  
 
For both types of study, experimental data are expressed as means ± s.e.mean., n  
referring to the number of tissues obtained from different human specimens. P values of less 
than 0.05 were considered significant. 
 
6.3.5.  Dru gs used 
 
The following compounds were used in the contractility study (with their 
pharmaceutical names and respective suppliers given in parentheses): [1-[2-
[(methylsulphonyl)amino]ethyl]-4-piperidinyl] methyl 1-methyl-1H-indole-3-carboxylate 
(GR113808), 4-amino-5-chloro-2,3-dihydro-N-(1-[3-methoxypropyl]-4-piperidinyl)-7-benzo-
furancarboxamide HCl (prucalopride; R093877) (Janssen Research Foundation, Belgium), 
atropine sulphate, carbachol, NG-nitro-L-arginine (Janssen Chimica, Belgium), TTX (Serva, 
Germany). All compounds were dissolved in 0.9% NaCl solution, except for GR113808, 
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which was dissolved in 0.9% NaCl acidified with tartaric acid in the stock solution. Solutions 
were prepared freshly on the day of the experiment and all dilutions were made using 0.9% 
NaCl solution. The solvents did not affect EFS-induced contractions.  
In the release study, L-ascorbic acid, atropine sulphate, choline chloride and 
guanethidine sulphate were obtained from Sigma (St. Louis, USA), hemicholinium-3-bromide 
from RBI (Natick, USA), methanol from Lab-Scan (Dublin, Ireland), [methyl-3H]-choline 
chloride (2775 GBq/mmol) from NEN (Boston, USA), physostigmine salicylate from Federa 
(Brussels, Belgium), prucalopride, and GR113808 from Janssen Research Foundation 
(Beerse, Belgium), tetramethylammonium chloride from Merck-Schuchardt (Hohenbrunn, 
Germany), and TTX and w -conotoxin-GVIA from Alomone Labs (Jerusalem, Israel).  The 
calcium free medium was prepared by replacing 2.5 mM CaCl2 by 2.5 mM MgCl2 in the PSS. 
Drugs were dissolved and diluted with deionized water.  Stock solutions of TTX (10-3 M), 
prucalopride (10-2 M) and GR113808 (10-2 M) were kept frozen at –20°C.  Dilutions were 
made on the day of the experiment. 
 
6.4.  Results  
 
6.4.1.  Contractility study 
 
The human large intestinal (whole tissue) circular muscle strips were spontaneously 
active after they had been mounted in the organ baths. After wash-out of the contraction to 
carbachol (10-5 M), that induced a stable contraction in all preparations, the strips returned to 
baseline, and spontaneous activity was reduced. Spontaneous contractility was further reduced 
during EFS (to constitute roughly 5% of maximal contraction to EFS). 
TTX (3x10-7 M) and atropine (10-6 M) blocked the contractions elicited by EFS in every 
preparation. The effect of prucalopride (3x10-7 M) on EFS-evoked contractions of human 
large intestinal preparations was variable. Prucalopride stimulated EFS-induced contractions 
in one specimen (by 26%), inhibited them in four out of eight preparations (inhibition ranging 
from 22-100%), and was without effect in three preparations (Figure 6.1A). On average, 
prucalopride (3x10-7 M) tended to inhibit EFS-induced contractions, albeit this effect was not 
significant (71 ± 15% versus initial value, n = 8, P > 0.05). In all human muscle strips, 
GR113808 (10-7 M) prevented any effect of prucalopride (111 ± 8 % versus initial value, n = 
8, P > 0.05, Figure 6.1B). 
 141
-30 -15 0 15
0
25
50
75
100
125
150
Individual results
T
S
S
S
A
S
T
A
Prucalopride 0.3 µM
Time (min)
C
on
tr
ac
tio
n 
(%
 o
f i
ni
tia
l v
al
ue
)
A
-30 -15 0 15
Solvent
GR113808 0.1 µM
Mean results (n = 8)
Prucalopride 0.3 µM
B
Time (min)  
Figure 6.1  Effect of prucalopride on EFS-evoked contractions of human large intestine circular muscle. All 
experiments were carried out in the presence of L-NNA (10-4 M).  The left panel shows individual data points of 
the effect of prucalopride, that are connected by a within-specimen solid line. The origin of the tissues in the 
large intestine is indicated : A, ascending colon, T, transverse colon, S, sigmoid colon. The right panel shows 
mean contraction ± s.e.mean. (n = 8), calculated as percentage of the mean contraction to five EFS pulse trains 
immediately prior to any addition of compound (initial value). The response to prucalopride after addition of 
solvent or GR113808 is shown. 
 
6.4.2.  Release study 
 
6.4.2.a.  Whole tissue of human colon 
 
In human tissues, field stimulation caused a clear-cut increase in total radioactivity 
(TR) and 9-12 min were required after stimulation to re-establish the basal release of tritium 
(Figure 6.2A). The mean amount of TR in samples 3 and 23 (pre stimulation), and in the 
samples with increased release due to stimulation  (S1 and S2), is given in Table 6.1. This 
yielded a S2/S1 ratio for TR of 0.67 ± 0.02 (n = 8).  [
3H]-Acetylcholine could be detected 
when HPLC was used to separate the different components present in the samples.  In basal 
conditions, TR contained more [3H]-phosphorylcholine plus [3H]-choline then [3H]-
acetylcholine.  Stimulation induced a pronounced increase in the release of [3H]-
acetylcholine, although there was also a two- to threefold increase in the release of [3H]-
phosphorylcholine and [3H]-choline during stimulation (Figure 6.2B and C).  The mean 
amounts of [3H]-choline plus [3H]-phosphorylcholine, and [3H]-acetylcholine before and 
during stimulation, as well as the percentage of [3H]-acetylcholine released are given in Table 
6.1.  The S 2/S1 ratio for [
3H]-acetylcholine was 0.71 ± 0.06 (n  = 7). 
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Figure 6.2  Influence of electrical field stimulation on the release of total radioactivity (TR) and [3H]-
acetylcholine from control whole tissue strips of human colon.  (A) TR outflow from human colon whole tissue 
preparations pre-incubated with [3H]-choline.  The abscissa starts at the end of the washout period.  Tissues were 
stimulated twice (S1 and S2: 15 V, 1 ms, 4 Hz, 2 min), and the superfusate (1 ml) was collected in 3 min 
fractions.  (B)  HPLC-separation of the radioactive outflow before (sample 3) and during (sample 5) S1.  Arrows 
indicate the peaks for [3H]-phosphorylcholine, [3H]-choline and [3H]-acetylcholine.  (C)  HPLC-separation of the 
radioactive outflow before (sample 23) and during (sample 25) S2.  100 µl of the samples were injected into the 
HPLC, and every min 500 µl was collected.  Results are given as mean ± s.e.mean (panel A, n = 8; panels B and 
C, n = 7). 
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Table 6.1  Outflow of total radioactivity, [3H]-phosphorylcholine plus [3H]-choline and [3H]-acetylcholine for 
control whole tissue (WT) and isolated (ISO) circular muscle strips of human colon (4 isolated circular muscle 
strips were mounted in one organ bath for each experiment). 
 
  TR Ph.-Ch. + Ch. ACh % ACh 
Sample 3 58 280 ± 9 830 37 440 ± 4 190 6 180 ± 4 400 9 ± 5 
S1 698 840 ± 196 510 100 180 ± 14 400*** 178 360 ± 33 250*** 63 ± 4*** 
Sample 23 35 760 ± 7 140 19 910 ± 4 600 3 690 ± 3 020 7 ± 4 
S2 466 090 ± 132 530 41 180 ± 4 050## 125 370 ± 23 260### 72 ± 4### 
S2/S1 0.67 ± 0.02  0.71 ± 0.06  
WT 
n 8 7 7 7 
Sample 3 75 200 ± 7 640 69 060 ± 12 480 2 920 ± 1 590 5 ± 2 
S1 850 950 ± 181 690 232 520 ± 69 680* 32 086 ± 57 690** 59 ± 5*** 
Sample 23 48 040 ± 6 930 41 480 ± 6 280 3 850 ± 2 060 7 ± 3 
S2 509 340 ± 95 460 89 330 ± 21 460# 202 760 ± 38 710## 68 ± 5### 
S2/S1 0.63 ± 0.03  0.63 ± 0.03  
ISO 
n 6 6 6 6 
 
S1 and S2 for total radioactivity (TR) are the sum of respectively sample 5 and sample 25 and the following 
samples (see text), while S1 and S2 for [
3H]-phosphorylcholine plus [3H]-choline (Ph.-Ch. + Ch.) and [3H]-
acetylcholine (ACh) are respectively samples 5 and 25.  Radioactivity is expressed as dpm per g tissue.  * P  < 
0.05, ** P  < 0.01, *** P < 0.001: Significantly different from values before S1 (sample 3).  
# P < 0.05, ## P  < 
0.01, ### P < 0.001: Significantly different from values before S2 (sample 23).  Results are given as mean ± 
s.e.mean. 
 
TTX (3x10-6 M; n = 5), w -conotoxin-GVIA (10-6 M; n  = 1) or removal of extracellular 
calcium (n = 2) did not influence basal release of TR.  TTX nearly abolished the electrically-
evoked tritium release as compared with control.  In control tissues (n = 5), the S2/S1 ratio for 
release of TR was 0.70 ± 0.02.  The S2/S1 ratio for TR after superfusion with TTX was 0.08 ± 
0.01 (P < 0.001).  The S2/S1 ratio for TR in the presence of w -conotoxin was 0.16 (n  = 1), 
while the ratio was 0.67 for control tissue.  In the absence of calcium (n = 2), the S2/S1 ratio 
for TR was 0.05 and 0.13 , while this was 0.65 and 0.67 in control tissues. 
Prucalopride (3x10-7 M) did not alter the basal efflux of TR.  However, prucalopride 
increased the electrically evoked release of TR and [3H]-acetylcholine; the mean increase in 
electrically evoked release of [3H]-acetylcholine by prucalopride was significant (Figure 
6.3A). The 5-HT4-receptor antagonist GR113808 (10
-7 M) did not alter the basal release of 
TR (n = 8), nor did it influence the S2/S1 ratio for TR (S2/S1 ratio for control: 0.69 ± 0.05, n  = 
4, and for GR113808: 0.66 ± 0.03, n = 4, P > 0.05) and for [3H]-acetylcholine (S 2/S1 ratio for 
control: 0.75 ± 0.01, n = 3, and for GR113808: 0.78 ± 0.05, n = 3, P  > 0.05).  When added 
before prucalopride, GR113808 prevented the increase of the electrically evoked release of 
TR and reduced that of [3H]-acetylcholine (n = 4) by prucalopride (Figure 6.3A). 
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Figure 6.3  Effects of prucalopride (pruca) and prucalopride in the presence of GR113808 (GR) on the 
electrically evoked release of total radioactivity (TR) and [3H]-acetylcholine from preparations of (A) human 
colon whole tissue preparations and (B) human colon isolated circular muscle preparations pre-incubated with 
[3H]-choline (in B, 4 isolated circular muscle strips were mounted together in one organ bath for each 
experiment).  Tissues were stimulated twice (S1 and S2: 15 V, 1 ms, 4 Hz, 2 min); GR113808 (10
-7 M) was added 
36 min and prucalopride (3x10-7 M) 15 min before S2.  The electrically evoked efflux by S2 is expressed as a 
ratio of that by S1.  Each column represents the mean ± s.e.mean.  *, ** P < 0.05, 0.01: Significantly different 
from control.  # P  < 0.05: Significantly different from pruca.  Numbers above the columns refer to the number of 
experiments. 
 
6.4.2.b.  Isolated circular smooth muscle of human colon 
 
Electrical stimulation induced an increase in tritium overflow in isolated human colon 
CM, and 6-12 min were required after stimulation to re-establish the basal release of tritium.  
The S2/S1 ratio for TR was 0.53 ± 0.03 (n = 11).  However, the amount of TR released by the 
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very small isolated CM strips was very low, and reached the detection limit of the HPLC; a 
reliable separation by HPLC of the different components present in the samples was therefore 
not feasible. 
TTX (3x10-6 M; n = 4), w -conotoxin-GVIA (10-6 M; n  = 1) or removal of extracellular 
calcium (n = 2) did not influence basal release of TR.  TTX nearly abolished the electrically-
evoked tritium release as compared with control in three out of four experiments (S2/S1 ratios 
for release of TR: control, 0.55 ± 0.03 versus TTX, 0.13 ± 0.03; n = 3; P < 0.001).  In one 
experiment, the electrically evoked tritium release was not abolished by TTX (S2/S1 ratios for 
release of TR: control, 0.53 versus TTX, 0.51), but in the whole tissue preparation of the same 
patient, TTX abolished the electrically -evoked tritium release (S 2/S1 ratios for release of TR: 
control, 0.65 versus TTX, 0.09).  The S2/S1 ratio for TR in the presence of w -conotoxin was 
0.15 (n = 1), while the ratio was 0.49 for control tissue.  After superfusion with calcium free 
medium (n  = 2), the S2/S1 ratio for TR was 0.24 and 0.10, while this was 0.59 and 0.49 in 
control tissues. 
Prucalopride (3x10-7 M) did not alter the basal efflux of TR.  However, prucalopride 
significantly enhanced the amount of TR (S2/S1 ratio for TR: control, 0.54 ± 0.03 versus 
prucalopride, 0.77 ± 0.05; P < 0.001; n = 9).  GR113808 (10-7 M) did not alter the basal 
release of TR (n = 7).  When added before prucalopride, GR113808 antagonised the increase 
of the electrically evoked release of TR by prucalopride (S2/S1 ratio for TR: 0.62 ± 0.02; n  = 
7). 
In order to be able to measure [3H]-acetylcholine by HPLC, an additional series of 
experiments was performed where four isolated CM strips were mounted together in one 
organ bath.  This allowed to separate the different components by HPLC, as enough 
radioactivity was released.  
In basal conditions, released radioactivity contained only a small fraction of [3H]-
acetylcholine.  Stimulation induced a significant increase in the release of [3H]-acetylcholine, 
although there was some increase in the release of [3H]-phosphorylcholine and [3H]-choline 
during stimulation.  The mean amounts of TR, [3H]-choline plus [3H]-phosphorylcholine and 
[3H]-acetylcholine before and during stimulation, as well as the percentage of [3H]-
acetylcholine released are given in Table 6.1.  The S2/S1 ratios were 0.63 ± 0.03 for both TR 
and [3H]-acetylcholine (n = 6). 
TTX (3x10-6 M; n = 5) did not influence basal release of TR.  However, TTX nearly 
abolished the electrically-evoked tritium release as compared with control (the S2/S1 ratios for 
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release of TR and [3H]-acetylcholine for control tissues were respectively 0.58 ± 0.03 and 
0.69 ± 0.06, while the ratios for TTX were respectively 0.15 ± 0.03 and 0.03 ± 0.01; P < 
0.001; n = 5). 
Prucalopride (3x10-7 M) did not alter the basal efflux of TR.  However, prucalopride 
significantly enhanced the amount of TR and [3H]-acetylcholine (P < 0.01; n = 5; Figure 
6.3B).  GR113808 (10-7 M; n  = 7), added before prucalopride, had no effect on basal release, 
however, it completely antagonised the increase by prucalopride of the electrically evoked 
release of TR (Figure 6.3B).  It also reduced the increase by prucalopride of the electrically 
evoked release of [3H]-acetylcholine; although the S2/S1 ratio for [3H]-acetylcholine in the 
presence of GR113808 and prucalopride was not significantly different from that in the 
presence of prucalopride alone, it was also not significantly different from the S2/S1 ratio in 
control tissues. 
 
6.5.  Discussion 
 
The data presented here suggest that the human colon circular muscle is endowed with 
5-HT4-receptors located on cholinergic nerves, mediating facilitation of cholinergic 
neurotransmission resulting in enhanced contraction. Colonic circular muscle may be the first 
single muscle layer expressing both an inhibitory smooth muscle and an excitatory neuronal 
5-HT4-receptor component.  
Stimulation-induced contractions and release of TR and [3H]-acetylcholine in colon 
tissues were reduced by TTX and calcium free medium (the latter only tested in the release 
study). This indicates a neuronal release dependent upon the opening of sodium channels, and 
the presence of calcium in the external medium, respectively. The blockade of EFS-induced 
contractions by atropine in all whole tissue muscle strips, suggested that these nerves are 
cholinergic in origin. Calcium enters the cholinergic nerves via  N-type calcium channels as w -
conotoxin-GVIA abolished the electrically evoked release of TR.  [3H]-Choline and [3H]-
phosphorylcholine may be released by leakage from the nerve terminals in basal conditions; 
they indeed formed the major part of basally released radioactivity, and this was not 
influenced in the presence of TTX and w -conotoxin.  TTX abolished stimulation-induced 
increase of [3H]-acetylcholine, while stimulation-induced increase of TR was clearly reduced 
but not abolished.  This supports the full neuronal release of acetylcholine, but suggests that 
stimulation induces some non-neuronal release of [3H]-choline and [3H]-phosphorylcholine.  
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Prucalopride has been shown to be a selective 5-HT4-receptor agonist in isolated tissues 
of rodents (Briejer et al., 2001a), dogs (Prins et al., 1999) as well as humans (Prins et al., 
2000b). At 3x10-7 M, prucalopride stimulates 5-HT4-receptors on cholinergic nerves in canine 
ascending and descending colon and human large intestine longitudinal muscle (Prins et al., 
2000a). Here, this concentration of prucalopride enhanced contractions due to EFS in some 
human colonic muscle strips, an effect that was absent in the presence of the selective 5-HT4-
receptor antagonist GR113808 (10-7 M) (Gale et al., 1994). The competitive nature of the 
5-HT4-receptor antagonism produced by GR113808 has been confirmed in studies with 
canine and human gastrointestinal preparations (pKB 9.1 (Prins et al., 1999); pKB 9.4 (Prins et 
al., 2000b)), showing that 10-7 M would induce over a 2-log unit shift of the curve to a 5-HT4-
receptor agonist. Prucalopride at 3x10-7 M induces an approximate EC50-EC90 response via  
5-HT4-receptors as determined in various bioassays of rodent (Briejer et al., 2001a), dog 
(Prins et al., 1999) and human gastrointestinal tissue (Prins et al., 2000b). Hence, GR113808 
(10-7 M) is expected to block a 5-HT4-receptor-mediated response to prucalopride (3x10-7 M). 
In this manner, it is conceivable that the enhancement of EFS-induced circular muscle 
contraction after prucalopride may be due to activation of 5-HT4-receptors triggering a 
cholinergic pathway. This was strongly corroborated by the prucalopride-evoked systematic  
increase in TR and [3H]-acetylcholine efflux from whole tissue CM, an effect that was 
prevented by GR113808. Still, the whole tissue CM strips contain a small amount of 
longitudinally directed muscle, where 5-HT4-receptors are present on the cholinergic nerves 
(Prins et al., 2000a) and that might contribute to the acetylcholine release detected in the 
whole tissue preparations. However, also in isolated CM strips, only containing circular 
muscle and nerve endings between the muscle fibers, prucalopride stimulated TR and [3H]-
acetylcholine release and this effect was antagonised by GR113808, although to a smaller 
extent in the case of [3H]-acetylcholine.  It is unlikely that prucalopride acts on another (5-
HT-)receptor as it possesses high selectivity for 5-HT4-receptors and was not used in a 
supramaximal concentration (Briejer et al., 2001a). Hence, in human colon CM, excitatory 
5-HT4-receptors are presumably located on cholinergic nerves within the circular muscle wall.  
As GR113808 did not influence the S2/S1 ratio for TR and [3H]-acetylcholine, it is unlikely 
that electrical stimulation causes the release of endogenous 5-HT which might act on 5-HT4-
receptors to enhance [3H]-acetylcholine release. 
The question can then be raised why the corresponding functional response, i.e. 
increased contraction after cholinergic nerve stimulation in the presence of the 5-HT4-receptor 
agonist, is not systematically observed in the contractility study as prucalopride even reduced 
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the EFS-induced contractions in some strips. This is explained by the presence of inhibitory 
smooth muscle 5-HT4-receptors in human colonic circular muscle, for which a number of 
reports have provided compelling evidence (Prins et al., 2000b, Meulemans et al., 1995, Tam 
et al., 1994, McLean et al., 1996). Inducing contractions by EFS does not prevent 
prucalopride from activating these smooth muscle receptors, irrespective of prucalopride 
stimulating neuronal receptors as well. Hence, functional antagonism of the EFS-induced 
contraction is expected due to activation of the inhibitory smooth muscle 5-HT4-receptors. In 
view of the above, across-specimen variation in the expression of both functional responses 
(inhibition versus stimulation of contractility) may explain the heterogenous nature of the 
prucalopride-induced response in the contractility study.  It is unlikely that the region 
determines the EFS-induced response to prucalopride, as in one specimen of transverse colon, 
EFS-induced contractions were enhanced by prucalopride, while in another specimen these 
contractions were inhibited.  Nevertheless, the outcome of this study is ultimately novel, as 
the colon circular muscle may represent the very first tissue entity in which both locations and 
functions of 5-HT4-receptors have been detected. 
The mechanisms underlying the triggering and propulsion of giant contractions over 
longer distances of large intestine are as yet unknown, but the outcome of the current study 
may provide the first evidence to explain the prucalopride-induced occurrence of GMCs in 
conscious dogs (Briejer et al., 2001b). The blockade of colonic motility and GMCs by the 
non-selective muscarinic cholinoceptor antagonist atropine and the selective M3 cholinoceptor 
antagonist zamifenacin (Prins et al., 2001) indicates that these phenomena are highly 
dependent on the presence of cholinergic tone mediated via mainly M3 cholinoceptors. It is 
thus conceivable that the outflow of acetylcholine from cholinergic neurones that fire in a 
GMC, is enhanced in the presence of a selective 5-HT4-receptor agonist. In cases where 
cholinergic drive underlying GMCs may be low (in some forms of constipation (Sarna et al. , 
2000)), or not yet maximal (normal subjects), one may expect higher GMC frequency and 
amplitude after 5-HT4-receptor activation. Possibly the well-co-ordinated interplay between 
constant muscle activity inhibition via smooth muscle 5-HT4-receptor activation, alternated 
by short-lasting high-amplitude contractions due to activated 5-HT4-receptors on excitatory 
cholinergic nerves facilitates propulsion of large bowel contents. These combined smooth 
muscle inhibitory and cholinergic facilitatory activities may be the main mechanism by which 
5-HT4-receptor agonists are potent and efficacious stimulators of co-ordinated colonic 
motility and stool frequency.  
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In conclusion, this study illustrates the presence of 5-HT4 receptors on cholinergic 
nerves within the circular muscle of the human colon. 
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CHAPTER  7 
GENERAL DISCUSSION 
 
Cholinergic neurones are important in the regulation of GI motility.  The released 
acetylcholine acts on muscular muscarinic receptors, causing contraction of the muscle.  
Other neurotransmitters can interfere with acetylcholine at the postsynaptic level whereby the 
cholinergic contraction will be modulated, and/or presynaptically whereby the release of 
acetylcholine will be enhanced or inhibited.  The purpose of this thesis was to investigate the 
modulation of cholinergic neurotransmission at the post- and presynaptic level in stomach and 
colon.  Contraction and release experiments were performed.  Even when the contraction is 
induced by electrical stimulation of the cholinergic neurones and release of acetylcholine, a 
change in contraction does not necessarily reflect a change in acetylcholine release.  In release 
experiments, tissues are incubated with [3H]-choline in order to label the vesicles with [3H]-
acetylcholine, that will be released upon electrical stimulation.  The radioactivity released can 
be measured and HPLC of the samples allows to determine the amount of [3H]-acetylcholine.  
The presynaptic effect of substances can then be assessed directly.  Experiments were 
performed on whole tissue strips, cut in the direction of the circular muscle, from pig and 
human gastric fundus, and human colon.  For human colon, also strips that only contained 
circular muscle were studied. 
 
7.1. Interaction of the nitrergic and cholinergic innervation of the gastric 
fundus 
 
The study focused on the interaction between acetylcholine and NO, as the latter is the 
principle NANC inhibitory neurotransmitter.  During the course of the contraction 
experiments, the basal tone of the circular muscle strips of pig gastric fundus tended to 
increase, a phenomenon also described by other authors (Mandrek and Kreis, 1992; Lefebvre 
et al., 1995).  During the experiments to characterise the muscarinic receptors, it was shown 
that indomethacin, a cyclo-oxygenase inhibitor preventing the synthesis of prostanoids, 
prevented the increase in basal tone, suggesting that the progressive synthesis of prostanoids 
is responsible for the increase in basal tone.  The acetylcholinesterase inhibitor physostigmine 
induced contraction in pig gastric fundus, suggesting that there is some acetylcholine release 
under basal conditions.  When the different components in samples released under basal 
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conditions were separated by HPLC in the release experiments, small amounts of [3H]-
acetylcholine were detected, confirming that some acetylcholine is released under basal 
conditions.  The release is probably due to leakage out of the cholinergic neurones and not to 
action potential propagation as tetrodotoxin did not influence basal [3H]-acetylcholine release 
of the strips.  The acetylcholine released apparently does not contribute to the basal tone as 
atropine did not lower the tone of the tissues.  NO is also released under basal conditions as 
the NOS inhibitor L-NAME induced contraction.  Tetrodotoxin did not influence basal tone 
suggesting that NO is released from the nitrergic neurones without action potential 
propagation. 
Electrically-induced responses (relaxations or contractions) in pig gastric fundus strips 
were blocked by tetrodotoxin, illustrating the neuronal origin of the responses, except for 
contractions at higher frequencies of stimulation.  These remaining contractions are probably 
due to direct smooth muscle cell activation.  The nicotinic receptor blocker hexamethonium 
did not affect the responses to electrical stimulation, indicating that postganglionic neurones 
are activated.  Electrical stimulation of pig gastric fundus strips induced relaxations at low 
frequencies, and contractions at higher frequencies.  The NOS inhibitor L-NAME and the 
acetylcholinesterase inhibitor physostigmine reversed the electrically-induced relaxations into 
contractions while they enhanced the contractions; the muscarinic receptor antagonist atropine 
blocked the contractions, and relaxations occurred at all frequencies in the absence of L-
NAME.  These results suggest that both NO and acetylcholine are released at all stimulation 
frequencies, but the nitrergic contribution is dominant at the lower while the cholinergic 
contribution is dominant at the higher stimulation frequencies, corresponding to what has 
been observed in the opossum lower oesophageal sphincter and human gastric fundus (Cellek 
& Moncada, 1997; Tonini et al., 2000).  When released together, NO and acetylcholine can 
certainly be expected to functionally antagonise each other at the postsynaptic level.  
However, in guinea-pig (Wiklund et al., 1993; Kilbinger & Wolf, 1994; Hebeib & Kilbinger, 
1996, 1998), canine (Hryhorenko et al., 1994) and mouse (Mang et al., 2000) ileum, as well 
as in rat trachea (Sekizawa et al., 1993), it has been shown that NO is also able to modulate 
cholinergic responses by presynaptic inhibition of acetylcholine release.  To study whether 
NO might interfere with acetylcholine release in pig gastric fundus, we investigated the 
influence of the NO donor SNP on contractions to either electrical stimulation causing the 
release of endogenous acetylcholine, or exogenously applied acetylcholine.  This was done in 
the presence of L-NAME to exclude a possible inhibitory effect of endogenously released NO 
on acetylcholine release.  If NO inhibits acetylcholine release, it can be expected that SNP 
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inhibits contractions to electrical stimulation more than those to exogenous acetylcholine.  
The effect of SNP on contractions induced by electrical stimulation or exogenous 
acetylcholine was always similar, suggesting that the interaction between NO and 
acetylcholine in the pig gastric fundus occurs only at the postsynaptic level.  This corresponds 
with results obtained in guinea-pig gastric fundus (Milenov & Kalfin, 1996), opossum lower 
oesophageal sphincter (Cellek & Moncada, 1997), guinea-pig trachea (Brave et al., 1991) and 
human airways (Ward et al., 1993).  However, it is not possible to determine with certainty 
the site(s) of action of NO (presynaptic inhibition of acetylcholine release versus postsynaptic 
functional antagonism of acetylcholine) from functional experiments.  For this reason, the 
effect of NO on [3H]-acetylcholine release from cholinergic nerve endings in the pig gastric 
fundus was studied.  Neither L-NAME nor NO donors interfered with [3H]-acetylcholine 
release.  No evidence for presynaptic modulation of acetylcholine release by NO was thus 
obtained supporting our suggestion from the contraction experiments that NO and 
acetylcholine antagonise each other only at the postsynaptic level.  In human gastric fundus, it 
had been shown that electrical stimulation induced the release of acetylcholine and NO, and 
functional antagonism between NO and acetylcholine was suggested on the basis of 
functional results (Tonini et al., 2000).  As it was our goal to compare the results obtained in 
pig and human gastric fundus, the effect of L-NAME and SNP on [3H]-acetylcholine release 
was also measured in human gastric fundus.  Neither L-NAME nor SNP influenced [3H]-
acetylcholine release, illustrating that also in human gastric fundus NO only functionally 
antagonises acetylcholine at the postsynaptic level.  
 
7.2.  Characterisation of pre- and postsynaptic muscarinic receptors 
 
Stimulation-induced cholinergic contractions were blocked by atropine in the pig 
gastric fundus, indicating that the released acetylcholine activates muscular muscarinic 
receptors.  Pharmacological studies in many tissues found evidence that M3 receptors are 
involved in the contraction of  smooth muscle cells.  However, radioligand binding studies 
demonstrated a high predominance of M2 receptors, whereby e.g. in human stomach 79% of 
the muscular muscarinic receptors belong to the M2 subtype, and the remaining 21% are M3 
receptors (Bellido et al., 1995).  Although M3 receptors mediate muscle contraction in the GI 
tract, a role for M2 receptors, in terms of modulation of cyclic AMP driven relaxation, is 
evident under specialized experimental conditions.  Indeed, when the M3 receptors are 
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blocked, and guanylyl cyclase is activated, then acetylcholine can contract the tissues via  
stimulation of muscular M2 receptors (see reviews Eglen et al., 1996; Caulfield & Birdsall, 
1998).  To characterise pharmacologically the muscarinic receptor subtype, one needs to test a 
series of subtype-preferring muscarinic antagonists because of the lack of selective muscarinic 
receptor antagonists.  By comparing the influence of these muscarinic receptor antagonists on 
contractions to exogenously applied acetylcholine, it is possible to characterise the 
postsynaptic muscarinic receptor subtype.  The rank order of the potencies as well as the 
affinity constants of the muscarinic antagonists suggested that the postsynaptic muscarinic 
receptors in pig gastric fundus, responsible for the contraction of the circular muscle, belong 
to the M3 subtype.  This is in agreement with observations in other tissues (see e.g. Dietrich & 
Kilbinger, 1995; Shi & Sarna, 1997; Preiksaitis & Laurier, 1998).  However, we did not find 
any evidence for the presence of postsynaptic M2 receptors, although a binding study in pig 
gastric fundus suggested that two different muscular muscarinic receptors are present, one of 
them most likely belonging to the M2 subtype (Herawi et al., 1988). 
In many tissues, acetylcholine interferes with its own release, mostly inhibiting the 
release of acetylcholine, although a facilitatory effect has also been observed (see reviews 
Stärke et al., 1989; Grimm et al., 1994).  Atropine, added before the second stimulation in our 
release experiments, increased electrically-induced [3H]-acetylcholine release in pig and 
human gastric fundus, suggesting the presence of inhibitory presynaptic muscarinic 
autoreceptors on cholinergic nerve endings innervating the circular muscle layer of pig and 
human gastric fundus.  An attempt was made to characterise pharmacologically the inhibitory 
presynaptic muscarinic receptors on the cholinergic neurones of the pig gastric fundus by 
comparing the effect of a series of subtype-preferring muscarinic receptor antagonists on 
electrically-induced contractions and acetylcholine release; this was not done for human 
gastric fundus due to the limited number of stomachs available.  AF-DX 116 and 
methoctramine, two M2 subtype preferring muscarinic antagonists, increased the electrically-
induced contractions at the lowest concentrations tested, and they were more potent in 
facilitating the evoked tritium release (a presynaptic effect) than in inhibiting the contractile 
response (a postsynaptic effect).  These results suggest the presence of a presynaptic 
inhibitory M2 receptor.  However, the pIC 50 values for the presynaptic effect of the 
antagonists on tritium release did not correlate with published pKi values for the muscarinic 
antagonists at the M2 receptor subtype, excluding that the presynaptic inhibitory muscarinic 
receptors belong to the M2 subtype.  A significant correlation was found between the 
presynaptic pIC50 values for the tested antagonists and the pKi values for M4 receptors from 
 156
literature, but results with the selective M4 receptor antagonist MT-3 did not allow to 
conclude to the presence of presynaptic M4 receptors.  Indeed, MT-3 had no effect on 
electrically-induced contractions and tritium release in concentrations up to 10-8 M, where an 
effect of MT-3 can be expected as the pKi value of MT-3 on M4 receptors is between 8.9 - 8.3 
(Adem & Karlsson, 1997; Olianas et al., 1999; Jerusalinsky et al., 2000).  A similar and 
significant correlation was obtained between the presynaptic pIC50 values for the antagonists 
tested, and binding affinities at M1, M3 and M5 receptors from literature, making it impossible 
to classify the presynaptic inhibitory muscarinic receptor as one of these muscarinic receptor 
subtypes.  An explanation for these results might be the presence of more than one type of 
muscarinic receptor on the cholinergic nerve endings, inhibiting or even stimulating 
acetylcholine release.  In the guinea-pig LMMP preparation, two types of presynaptic 
muscarinic receptors were identified, an inhibitory M3 and a facilitatory M1 receptor (Soejima 
et al., 1993).  In canine LMMP preparations, the presence of presynaptic M3 receptors was 
demonstrated, but the presence of another presynaptic muscarinic subtype could not be 
excluded (Kostka et al. , 1989). 
 
7.3  Presynaptic modulation of acetylcholine release in the gastric fundus 
 
Throughout the GI tract, nitrergic neurones often contain VIP besides of nNOS 
(Furness et al. , 1992; Lefebvre et al., 1995).  This is also the case in human gastric fundus, 
where VIP desensitisation reduced L-NNA-resistant relaxations induced by electrical 
stimulation at higher frequencies, suggesting that VIP is released (Tonini et al., 2000).  In 
rabbit stomach, electrically-induced cholinergic contractions were inhibited by VIP (Baccari 
et al. , 1994); the authors suggested that VIP might inhibit the release of acetylcholine, 
although this type of contraction studies cannot exclude that VIP only antagonises 
acetylcholine at the postsynaptic level.  In guinea-pig stomach, VIP inhibits electric ally-
induced [3H]-acetylcholine release (Milenov et al., 1991) while in LMMP preparations of 
guinea-pig ileum, VIP and PACAP increased basal and inhibited electrically -induced [3H]-
acetylcholine release from cholinergic nerve endings (Katsoulis et al. , 1993).  Also in ferret 
trachea, VIP inhibited [3H]-acetylcholine release from cholinergic neurones regulating mucus 
secretion (Liu et al., 1999).  In human proximal stomach, we did not obtain evidence that VIP 
inhibits electrically-induced [3H]-acetylcholine release, suggesting that VIP and acetylcholine 
only functionally antagonise each other when released simultaneously.  This is in agreement 
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with observations in rat gastric fundus and trachea, and human airway (Lefebvre et al., 1992; 
Sekizawa et al. , 1993; Ward et al., 1993).  
Noradrenaline is able to inhibit non-sphincteric muscle in the GI tract by inhibition of 
acetylcholine release from the cholinergic motor neurones via presynaptic a2-adrenoceptors 
(see reviews McIntyre & Thompson, 1992; De Ponti et al., 1996).  In pig gastric fundus, 
noradrenaline and adrenaline have been shown to produce concentration-dependent 
contractions due to activation of postsynaptic a-adrenoceptors (Mandrek & Kreis, 1992).  A 
possible inhibitory effect of a-adrenoceptor agonists on electrically -induced cholinergic 
contractions in contraction experiments might thus be masked by the contractile effect per se 
of these substances.  In preliminary experiments (data not shown), we observed that addition 
of the a2-adrenoceptor agonist UK-14,304 induced contractions of circular smooth muscle 
strips in the pig gastric fundus, suggesting that a2-adrenoceptors are present on the circular 
smooth muscle cells of pig gastric fundus.  We thus investigated the effect of UK-14,304 on 
the electrically-induced release of [3H]-acetylcholine.  UK-14,304 inhibited the electrically-
evoked [3H]-acetylcholine release in pig gastric fundus, an effect that was prevented by the 
a2-adrenoceptor antagonist rauwolscine.  Also in human gastric fundus, the electrically-
induced [3H]-acetylcholine release was inhibited by stimulation of a2-adrenoceptors, the 
degree of inhibition being even larger than in pig gastric fundus.  Thus, presynaptic inhibitory 
a2-adrenoceptors are present on the cholinergic nerve endings innervating the circular muscle 
layer of pig and human gastric fundus, corresponding with results obtained in other parts of 
the GI tract (McIntyre & Thompson, 1992; De Ponti et al. , 1996). 
Stimulation of 5-HT4-receptors induces contraction or relaxation dep ending on the 
tissue and species studied.  Relaxant 5-HT4-receptors are localized on smooth muscle cells 
(see e.g. Tuladhar et al., 1996; Prins et al. , 2000b), while contractile responses are ascribed to 
5-HT4-receptors localized on cholinergic neurones, facilitating acetylcholine release (see e.g. 
Elswood et al., 1991; Kilbinger & Wolf, 1992).  In rat gastric fundus, facilitatory 5-HT4-
receptors have been suggested to be present on cholinergic neurones, increasing electrically-
evoked cholinergic contractio ns (Amemiya et al., 1996).  Matsuyama and colleagues (1996) 
demonstrated that 5-HT4-receptor agonists enhanced electrically-induced cholinergic 
contractions and [3H]-acetylcholine release in strips from all regions of guinea-pig stomach.  
In a more recent study by Takada and colleagues (1999), a regional distribution of facilitatory 
5-HT4-receptors on cholinergic neurones innervating the guinea-pig stomach was suggested 
whereby neuronal 5-HT4-receptors seem to be present in the corpus and antrum but absent in 
 158
the fundus.  In human, the 5-HT4-receptor agonist cisapride increased solid and liquid gastric 
emptying in vivo  (Johnson, 1989).  Prucalopride, another 5-HT4-receptor agonist, had no 
effect on gastric emptying in healthy humans (Bouras et al., 1999), but it accelerated gastric 
emptying in patients with constipation (Bouras et al. , 2001).  In vitro, prucalopride enhanced 
electrically-induced contractions of circular muscle strips of human stomach (Ver Donck et 
al., 1999), but the precise mechanism of this stimulatory effect was not investigated.  Our aim 
was to study the mechanism of the stimulatory effect of prucalopride in human gastric fundus.  
We observed in our study a stimulatory effect of prucalopride on electrically-induced [3H]-
acetylcholine release in human gastric fundus.  This effect was prevented by the 5-HT4-
receptor antagonist SB204070, strengthening the idea that facilitatory 5-HT4-receptors are 
also present on the cholinergic nerve endings innervating the circular muscle layer of human 
gastric fundus.  Stimulation of these receptors by 5-HT4-receptor agonists will contribute to 
the stimulatory effect of these agents on gastric emptying. 
 
An integrative scheme of our results on modulation of cholinergic neurotransmission 
in the gastric fundus, discussed in 7.1, 7.2 and 7.3, is shown in Figure 7.1.  Selective a2-
adrenoceptor agonists and 5-HT4-receptor agonists might be used to inhibit respectively 
stimulate cholinergic neurotransmission in the proximal stomach as required.  The similarity 
of the results in the pig and human gastric fundus illustrates that the pig is a good model to 
study the regulation of human gastric motility. 
 
7.4.  Presynaptic modulation of acetylcholine release via 5-HT4-receptors in 
the human colon 
 
In vivo studies in humans demonstrated that prucalopride stimulates colonic transit 
(Emmanuel et al., 1998; Bouras, 1999, 2001).  In dog, prucalopride stimulated proximal, and 
inhibited distal colonic motility, and reduced the time to the first GMC (Briejer et al., 2001).  
In vitro experiments demonstrated that in the longitudinal muscle layer of both canine large 
intestine (from ascending to descending colon) and human large intestine (from ascending 
colon to rectum), 5-HT4-receptors on cholinergic neurones mediate facilitation of cholinergic 
neurotransmission resulting in enhanced longitudinal muscle contractility (Prins et al., 2000a) 
(Figure 7.2).  This correlates with facilitatory 5-HT4-receptors on cholinergic neurones in 
LMMP preparations of guinea-pig proximal colon (Elswood et al., 1991; Briejer & 
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Figure 7.1  Integrative scheme summarising our results on modulation of cholinergic neurotransmission in the 
gastric fundus.  Acetylcholine (ACh) is released and interacts with postsynaptic M3 receptors to induce 
contraction.  It can exert negative feedback on its release via presynaptic muscarinic receptors; the latter cannot 
be pharmacologically characterised within the M1-M5 classification.  Nitric oxide (NO) and vasoactive intestinal 
polypeptide (VIP), released from non-adrenergic non-cholinergic (NANC) neurones functionally antagonise 
acetylcholine at the smooth muscle cells.  The release of acetylcholine can be stimulated via presynaptic 5-HT4-
receptors (5-HT4) and inhibited via presynaptic a2-adrenoceptors (a2). 
 
Schuurkes, 1996).    In canine large intestine circular muscle, smooth muscle 5-HT4-receptors 
mediate relaxation, a phenomenon that gradually increases in efficiency going from the 
ascending colon to the rectum (Prins et al., 1999).  In human large intestine circular muscle, 
5-HT4-receptors located on smooth muscle mediate relaxation, with a similar efficiency 
throughout the large intestine (Tam et al., 1994; Prins et al., 2000b) (Figure 7.2).  This 
inhibitory action on circular muscle tone demonstrated  in vitro may explain the distally 
increasing circular muscle inhibition observed with prucalopride in dog large intestine in vivo 
(Briejer et al., 2001).  The stimulatory effect of prucalopride on human colonic transit can 
very probably not only be explained by interaction with the relaxant 5-HT4-receptors on the 
circular smooth muscle cells and the 5-HT4-receptors on the cholinergic nerve endings 
innervating the longitudinal muscle layer.  Indeed, although the circular muscle relaxation 
might induce a decrease in lu minal resistance towards transit, it is unlikely that the three 
bands of longitudinal muscle can provide sufficient contractile force to promote transit.  
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However, a coordinated mechanism whereby the circular muscle first relaxes and then is 
activated via its cholinergic innervation might explain the effect of prucalopride on colonic 
transit.  For this reason, the presence of 5-HT4-receptors on the cholinergic neurones 
innervating the circular muscle layer was investigated. 
Therefore, the effect of prucalopride on electrically-induced [3H]-acetylcholine release 
was studied.  In whole tissue strips, cut in the direction of the circular muscle, prucalopride 
increased electrically-induced [3H]-acetylcholine release and this effect was antagonised by 
the 5-HT4-receptor antagonist GR113808.  However, whole tissue circular muscle strips 
contain some longitudinal muscle material.  This means that the cholinergic nerve endings 
innervating the longitudinal muscle layer can contribute to some extent to the amount of  
[3H]-acetylcholine detected.  As facilitatory 5-HT4-receptors have been described on the 
cholinergic nerve endings innervating the longitudinal muscle layer in the human colon (Prins 
et al., 2000a), the effect of prucalopride on the electrically -induced [3H]-acetylcholine release 
 
 
Figure 7.2  Schematic representation of the locations of 5-HT4-receptors in human colon.  Muscular 5-HT4-
receptors (#) are present on the smooth muscle cells of the circular muscle layer, causing relaxation (Prins et al., 
2000b).  Neuronal 5-HT4-receptors (*) are shown to facilitate acetylcholine release from cholinergic nerve 
endings innervating the longitudinal (Prins et al., 2000a) and circular (this thesis) muscle layer. 
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in the whole tissue strips might be due to activation of these 5-HT4-receptors.  For this reason, 
strips only containing part of the circular muscle layer and its nerve endings were prepared.  
Prucalopride enhanced the electrically-induced [3H]-acetylcholine release in these isolated 
circular muscle strips.  This effect was antagonised by the 5-HT4-receptor antagonist 
GR113808.  Our results thus clearly demonstrate that 5-HT4-receptors are present on the 
cholinergic nerve endings innervating the circular muscle layer in the human colon (Figure 
7.2).  Contractio n experiments with isolated circular muscle strips were not feasible because 
of very weak contractile responses to electrical stimulation.  When the influence of 
prucalopride was studied on electrically-induced cholinergic contractions in whole tissue 
strips cut in the circular direction, its effect on these electrically -induced cholinergic 
contractions varied from potentiation to inhibition.  Any kind of effect of prucalopride was 
antagonised by GR113808, indicating that the action of prucalopride was due to activation of 
5-HT4-receptors.  In one tissue, prucalopride enhanced the electrically-induced contractions, 
supporting the results from our release study that facilitatory 5-HT4-receptors are present on 
the cholinergic neurones innervating the circular muscle layer.  However, in four tissues, 
prucalopride inhibited the electrically-evoked contractions, probably via  activation of the 
relaxant 5-HT4-receptors on the circular muscle cells and functional antagonism of 
acetylcholine released.  In three other tissues, prucalopride had no effect on electrically-
induced contractions.  The influence of prucalopride on electrically-induced cholinergic 
contractions in whole tissue strips is the balance of the activation of the inhibitory 5-HT4-
receptors on the circular smooth muscle cells and that of the stimulatory 5-HT4-receptors on 
the cholinergic nerve endings towards the circular muscle.  The variability of effect of 
prucalopride might be explained by the varying density of neuronal versus muscular 5-HT4-
receptors across specimens. 
 
Figure 7.2 gives a schematic representation of the locations of 5-HT4-receptors in 
human colon.  Muscular 5-HT4-receptors can be found on circular smooth muscle cells (Prins 
et al., 2000b).  Facilitatory 5-HT4-receptors are present on cholinergic nerve endings 
innervating the longitudinal (Prins et al., 2000a) and circular (this thesis) muscle layer.  The 
effect of prucalopride on human colonic transit might be due to the coordinated stimulation of 
inhibitory 5-HT4-receptors on the circular muscle cells and facilitatory neuronal 5-HT4-
receptors on cholinergic neurones innervating the circular muscle, whereby the circular 
muscle of the colon first relaxes and then is activated via  its cholinergic innervation.  The 
relaxation of the colon allows an easy propagation of the faecal contents by the contraction. 
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SUMMARY 
 
Gastrointestinal (GI) motility is under neuronal and hormonal control.  The 
acetylcholine-releasing cholinergic neurones are the most important among the neurones that 
release a contractile neurotransmitter; in contrast, nitric oxide (NO) is the most important  
relaxant neurotransmitter.  Studies in the peripheral and central nervous system demonstrated 
that the release of acetylcholine from cholinergic nerve endings can be modified via  
presynaptic auto- and heteroreceptors, whereby the release of acetylcholine can be increased 
or inhibited.  In the GI tract, there is some evidence that NO modifies the release of 
acetylcholine presynaptically, while other authors argue against a modulatory role for NO at 
the presynaptic level and suggest that NO only functionally antagonises acetylcholine.  The 
sympathetic nervous system, releasing noradrenaline, is known to modulate acetylcholine 
release in non-sphincteric regions of the GI tract.  5-HT4-receptors, stimulating acetylcholine 
release, have been demonstrated on cholinergic nerve endings in the GI tract, although also 
relaxant 5-HT4-receptors located on smooth muscle cells have been described.  To investigate 
the presynaptic regulation of acetylcholine release, a technique measuring acetylcholine 
release directly must be applied. 
The aim of this thesis was to study the presynaptic regulation of acetylcholine release 
in the porcine and human gastric fundus.  In human colon, the presence of 5-HT4-receptors on 
the cholinergic nerve endings innervating the circular muscle layer was investigated. 
The first study investigated the functional interaction between the cholinergic and 
nitrergic innervation in circular muscle strips of the pig gastric fundus (Chapter 2).  Both 
cholinergic and nitrergic neurones are stimulated during electrical stimulation; the nitrergic 
contribution is dominant at lower and the cholinergic contribution at higher stimulation 
frequencies.  The results suggest that the interaction between NO and acetylcholine lies at the 
postsynaptic level but a presynaptic effect of NO on acetylcholine release could not be fully 
excluded. 
A method was therefore introduced to measure acetylcholine release from the 
cholinergic nerve endings after incubation of the tissue with [3H]-choline (Chapter 3).  
Electrical stimulation of circular muscle strips of the pig gastric fundus activated cholinergic 
neurones causing the release of [3H]-acetylcholine, although stimulation also induced some 
[3H]-phosphorylcholine and [3H]-choline release.  Neither the NO synthase inhibitor L-NG-
nitro-arginine methyl ester (L-NAME) nor the NO donors sodium nitroprusside (SNP) and 3-
 169
morpholino-sydnonimine (SIN-1) had any effect on [3H]-acetylcholine release, suggesting 
that NO does not interfere with the release of [3H]-acetylcholine from cholinergic neurones 
innervating the circular muscle layer of pig gastric fundus.  The a2-adrenoceptor agonist UK-
14,304 inhibited the electrically-induced [3H]-acetylcholine release, an effect prevented by the 
a2-adrenoceptor antagonist rauwolscine, suggesting that inhibitory a2-adrenoceptors are 
present on the cholinergic neurones.  The non-selective muscarinic antagonist atropine 
increased stimulation-induced [3H]-acetylcholine release, suggesting the presence of 
inhibitory muscarinic autoreceptors  on the cholinergic neurones. 
An attempt was made to characterize pharmacologically the presynaptic muscarinic 
receptors on the cholinergic nerve endings in pig gastric fundus by using a series of subtype-
preferring muscarinic antagonists (Chapter 4).  However, we were not able to classify the 
presynaptic muscarinic receptor, although the presynaptic presence of the M2 subtype could 
be excluded.  A second goal was the pharmacological characterization of the postsynaptic 
muscarinic receptors.  Acetylcholine, released upon stimulation, is responsible for the 
contraction of the tissue after activation of muscular M3 receptors; no evidence for the 
occurrence of another muscular muscarinic receptor was found. 
Also in human gastric fundus, [3H]-acetylcholine release from cholinergic neurones 
innervating the circular muscle layer was measured (Chapter 5).  The increase in 
radioactivity during stimulation was again mainly due to [3H]-acetylcholine but to some 
extent also to [3H]-phosphorylcholine and [3H]-choline.  In human gastric fundus, neither NO 
nor VIP inhibited the electrically-induced [3H]-acetylcholine release, indicating that these two 
neurotransmitters only functionally antagonise acetylcholine.  UK-14,304 inhibited 
electrically-induced [3H]-acetylcholine release, an effect prevented by the a 2-adrenoceptor 
antagonist rauwolscine, suggesting the presence of presynaptic inhibitory a 2-adrenoceptors on 
the cholinergic nerve endings.  Atropine increased the electrically-induced [3H]-acetylcholine 
release, indicative for the presence of presynaptic inhibitory autoreceptors.  The 5-HT4-
receptor agonist prucalopride stimulated the electrically-induced [3H]-acetylcholine release, 
an effect that was prevented by the 5-HT4-receptor antagonist SB204070, suggesting the 
presence of facilitatory 5-HT4-receptors on the cholinergic nerve endings innervating the 
circular muscle layer. 
As the stimulatory effect of 5-HT4-receptor agonists on colonic transit in vivo cannot 
be fully explained by interaction with the 5-HT4-receptors that were described in the human 
colon in vitro, we studied whether 5-HT4-receptors are present on the cholinergic nerve 
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endings innervating the circular muscle layer in the human colon (Chapter 6).  When the 
effect of prucalopride was measured on electrically-induced [3H]-acetylcholine release in 
tissues cut in the direction of the circular muscle layer (these contain besides of circular 
muscle also some longitudinal muscle material and the myenteric plexus; whole tissue), as 
well as in strips containing only isolated circular muscle with its nerve endings, we observed 
that prucalopride enhanced electrically -induced [3H]-acetylcholine release; the 5-HT4-receptor 
antagonist GR113808 antagonised this effect, supportive of the presence of stimulatory 5-
HT4-receptors on cholinergic nerve endings innervating the circular muscle layer in human 
colon.  When the influence of prucalopride was studied on electrically-induced cholinergic 
contractions in whole tissue strips, they were either potentiated, not influenced or even 
inhibited.  This can probably be ascribed by a variable balance between the stimulatory 5-
HT4-receptors on the cholinergic neurones, described in this thesis, and the inhibitory 5-HT4-
receptors on the smooth muscle cells in the human colon, described before. 
 
In conclusion, our results show that the pig gastric fundus is a good model to study the 
human gastric fundus.  Both NO and VIP only postsynaptically antagonise acetylcholine at 
this level of the GI tract.  The cholinergic neurones from porcine and human gastric fundus 
contain presynaptic inhibitory muscarinic autoreceptors and a2-adrenoceptors.  Presynaptic 
stimulatory 5-HT4-receptors are present on cholinergic nerve endings innervating the circular 
muscle layer of human gastric fundus as well as of human colon. 
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SAMENVATTING 
 
Gastro-intestinale (GI) motiliteit staat onder neuronale en hormonale controle.  De 
cholinerge zenuwcellen, die acetylcholine vrijstellen, zijn de belangrijkste zenuwcellen die 
een contractiele neurotransmitter vrijstellen; daartegenover staat stikstofmonoxide (NO) als 
belangrijkste relaxerende neurotransmitter.  Studies, uitgevoerd in het perifere en centrale 
zenuwstelsel, toonden aan dat de vrijstelling van acetylcholine uit cholinerge zenuwuiteinden 
beïnvloed kan worden via  presynaptische auto- en heteroreceptoren, waarbij de vrijstelling 
van acetylcholine gestimuleerd of verminderd kan worden.  Sommige resultaten suggereren 
dat NO de vrijstelling van acetylcholine presynaptisch kan beïnvloeden in het GI kanaal; 
andere auteurs argumenteren dat NO geen regulerende rol vervult op het presynaptische 
niveau en suggereren dat NO acetylcholine enkel functioneel tegenwerkt.  Van het 
sympathische zenuwstelsel, dat noradrenaline vrijstelt, is geweten dat het de vrijstelling van 
acetylcholine kan beïnvloeden in de sphinctervrije zones van het GI kanaal.  5-HT4-receptoren 
die de vrijstelling van acetylcholine stimuleren, zijn aangetoond op de cholinerge 
zenuwuiteinden in het GI kanaal, hoewel er ook relaxerende 5-HT4-receptoren op gladde 
spiercellen beschreven zijn.  Ten einde de presynaptische regeling van de vrijstelling van 
acetylcholine te onderzoeken, moet een techniek worden toegepast die de vrijstelling van 
acetylcholine rechtstreeks meet. 
Het doel van deze thesis bestond uit het bestuderen van de presynaptische regeling van 
de vrijstelling van acetylcholine in de maagfundus van het varken en de mens.  In menselijk 
colon werd de aanwezigheid van 5-HT4-receptoren op cholinerge zenuwuiteinden naar de 
circulaire spierlaag onderzocht. 
De eerste studie onderzocht de functionele interactie tussen de cholinerge en nitrerge 
bezenuwing van circulaire spierstrips van de maagfundus van het varken (Hoofdstuk 2).  
Zowel cholinerge als nitrerge zenuwcellen worden geactiveerd tijdens elektrische stimulatie; 
de nitrerge bijdrage is de belangrijkste tijdens lagere and de cholinerge tijdens hogere 
stimulatie-frequenties.  De resultaten suggereren dat de interactie tussen NO en acetylcholine 
op het postsynaptische niveau gelegen is maar een presynaptisch effect van NO op de 
vrijstelling van acetylcholine kon niet worden uitgesloten. 
Daarom werd een methode geïntroduceerd om de vrijstelling van acetylcholine van 
cholinerge zenuwuiteinden te meten na incubatie van de weefsels met [3H]-choline 
(Hoofdstuk 3).  Elektrische stimulatie van de circulaire spierstrips van de maagfundus van 
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het varken stimuleerde cholinerge zenuwcellen met als gevolg de vrijstelling van [3H]-
acetylcholine, hoewel stimulatie ook enige vrijstelling van [3H]-phosphorylcholine en [3H]-
choline uitlokte.  Noch de NO-synthase-inhibitor L-NG-nitro-arginine methyl ester (L-
NAME) noch de NO-donoren natriumnitroprusside (SNP) en 3-morfolino-sydnonimine (SIN-
1) beïnvloedden de vrijstelling van [3H]-acetylcholine, wat suggereert dat NO niet interfereert 
met de vrijstelling van acetylcholine uit cholinerge zenuwuiteinden die de circulaire spierlaag 
van de maagfundus van het varken bezenuwen.  De a2-adrenoceptor agonist UK-14,304 
verminderde de elektrisch geïnduceerde [3H]-acetylcholine vrijstelling, een effect dat 
voorkomen werd door de a 2-adrenoceptor antagonist rauwolscine, wat suggereert dat 
remmende a 2-adrenoceptoren aanwezig zijn op de cholinerge zenuwuiteinden.  De niet-
selectieve muscarine-antagonist atropine veroorzaakte een toename van de elektrisch 
geïnduceerde vrijstelling van [3H]-acetylcholine wat suggereert dat remmende muscarine-
autoreceptoren aanwezig zijn op de cholinerge zenuwcellen. 
Een poging werd ondernomen om farmacologisch de presynaptische muscarine-
receptoren op de cholinerge zenuwuiteinden in de maagfundus van het varken te 
karakteriseren door gebruik te maken van een reeks muscarine-antagonisten met een 
specificiteit voor een bepaald subtype (Hoofdstuk 4).  We waren niet in staat om de 
presynaptische muscarinereceptor te bepalen, hoewel de presynaptische aanwezigheid van het 
M2 subtype uitgesloten kon worden.  Een tweede doelstelling was het farmacologisch typeren 
van de postsynaptische muscarinereceptoren.  Acetylcholine, vrijgesteld tijdens stimulatie, is 
verantwoordelijk voor de contractie van het weefsel na activatie van M3 receptoren gelegen 
op de spiercellen; er werd geen evidentie voor de aanwezigheid van een andere muscarine-
receptor op de spiercellen gevonden. 
Ook in de maagfundus van de mens werd de vrijstelling van [3H]-acetylcholine uit 
cholinerge zenuwcellen die de circulaire spierlaag bezenuwen gemeten (Hoofdstuk 5).  De 
toename van de radioactiviteit tijdens stimulatie was opnieuw vooral het gevolg van [3H]-
acetylcholine maar in bepaalde mate ook van [3H]-phosphorylcholine en [3H]-choline.  In de 
maagfundus van de mens verminderde noch NO noch VIP de elektrisch geïnduceerde 
vrijstelling van [3H]-acetylcholine wat aantoont dat deze twee neurotransmitters acetylcholine 
enkel functioneel tegenwerken.  UK-14,304 verminderde de elektrisch geïnduceerde 
vrijstelling van [3H]-acetylcholine, een effect dat voorkomen werd door de a 2-adrenoceptor 
antagonist rauwolscine, wat suggereert dat presynaptische remmende a 2-adrenoceptoren 
aanwezig zijn op de cholinerge zenuwuiteinden.  Atropine deed de elektrisch geïnduceerde 
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vrijstelling van [3H]-acetylcholine toenemen, wat de aanwezigheid van presynaptische 
remmende autoreceptoren aantoont.  De 5-HT4-receptor agonist prucalopride stimuleerde de 
elektrisch geïnduceerde vrijstelling van [3H]-acetylcholine, een effect dat door de 5-HT4-
receptor antagonist SB204070 voorkomen werd, wat suggereert dat stimulerende 5-HT4-
receptoren aanwezig zijn op de cholinerge zenuwuiteinden die de circulaire spierlaag 
bezenuwen. 
Vermits het stimulerend in vivo effect van 5-HT4-receptor agonisten op de doorgang in 
het colon niet volledig verklaard kan worden door een interactie met de 5-HT4-receptoren 
beschreven in het menselijk colon in vitro, hebben we de aanwezigheid van 5-HT4-receptoren 
op de cholinerge zenuwuiteinden naar de circulaire spierlaag van het menselijk colon 
functioneel onderzocht (Hoofdstuk 6).  Wanneer het effect van prucalopride op de elektrisch 
geïnduceerde vrijstelling van [3H]-acetylcholine gemeten werd in weefsels gesneden in de 
richting van de circulaire spierlaag (deze bevatten naast circulaire spiermateriaal ook enig 
longitudinaal spiermateriaal en de myenterische plexus; “volledig” weefsel), als ook van 
strips enkel bestaande uit geïsoleerde circulaire spieren en hun zenuwuiteinden, stelden we 
vast dat prucalopride de elektrisch geïnduceerde vrijstelling van [3H]-acetylcholine doet 
toenemen; de 5-HT4-receptor antagonist GR113808 neutraliseerde dit effect, wat 
overeenstemt met de aanwezigheid van stimulerende 5-HT4-receptoren op de cholinerge 
zenuwuiteinden naar de circulaire spierlaag in het menselijke colon.  Wanneer de invloed van 
prucalopride op elektrisch geïnduceerde cholinerge contracties in “volledig” weefsel strips 
onderzocht werd, waren de contracties ofwel toegenomen, niet beïnvloed of zelfs verminderd.  
Een wisselend evenwicht tussen de stimulerende 5-HT4-receptoren op de cholinerge zenuwen, 
beschreven in deze thesis, en de remmende 5-HT4-receptoren op de gladde spiercellen in het 
menselijk colon, eerder beschreven, is waarschijnlijk de verklaring. 
 
In het algemeen tonen onze resultaten aan dat de maagfundus van het varken een goed 
model is om de maagfundus van de mens te bestuderen.  Zowel NO als VIP werken 
acetylcholine enkel postsynaptisch tegen op dit niveau van het GI kanaal.  De cholinerge 
zenuwcellen van de maagfundus van het varken en de mens bevatten presynaptische 
remmende muscarine-autoreceptoren en a2-adrenoceptoren.  Presynaptische stimulerende 
5-HT4-receptoren zijn aanwezig op de cholinerge zenuwuiteinden naar de circulaire spierlaag 
van de maagfundus alsook van het colon van de mens. 
 
 
